

Table of Contents

Supplementary Table 1. Studies reporting HCV Ab prevalence in blood donors in Middle East and North Africa.....	1
Supplementary Table 2. Studies reporting HCV Ab prevalence in the general populations in Middle East and North Africa	15
Supplementary Table 3. Studies reporting HCV viremic rate in blood donors and the general population in countries of the Middle East and North Africa.....	31
References	33

Table S1. Studies reporting HCV Ab prevalence in blood donors in the Middle East and North Africa.

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Afghanistan					
Dupire, 1999 ⁽¹⁾	1995-1996	CS	Conv	1,081	0.28
Khan, 2011 ⁽²⁾	1996-1996	CS	Conv	5,309	0.11
Khan, 2011 ⁽²⁾	1997-1997	CS	Conv	3,942	0.25
Khan, 2011 ⁽²⁾	1998-1998	CS	Conv	4,221	0.38
Khan, 2011 ⁽²⁾	1999-1999	CS	Conv	7,964	0.16
Central Blood Bank, 2015 ⁽³⁾	2000-2000	CS	Conv	3,136	0.00
Central Blood Bank, 2015 ⁽³⁾	2001-2001	CS	Conv	9,974	0.02
Khan, 2011 ⁽²⁾	2002-2002	CS	Conv	581	0.00
Khan, 2011 ⁽²⁾	2002-2002	CS	Conv	964	0.00
Central Blood Bank, 2015 ⁽³⁾	2002-2002	CS	Conv	11,276	0.61
Khan, 2011 ⁽²⁾	2003-2003	CS	Conv	4,714	0.00
Khan, 2011 ⁽²⁾	2003-2003	CS	Conv	3,629	1.57
Central Blood Bank, 2015 ⁽³⁾	2003-2003	CS	Conv	18,673	0.92
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	232	0.00
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	2,147	0.05
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	1,264	0.08
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	2,890	0.10
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	256	0.39

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	888	0.56
Khan, 2011 ⁽²⁾	2004-2004	CS	Conv	3,525	2.55
Central Blood Bank, 2015 ⁽³⁾	2004-2004	CS	Conv	26,318	1.09
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	1,867	0.11
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	1,190	0.59
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	2,185	1.05
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	826	1.94
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	168	4.76
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	2,145	6.90
Khan, 2011 ⁽²⁾	2005-2005	CS	Conv	584	7.19
Central Blood Bank, 2015 ⁽³⁾	2005-2005	CS	Conv	30,351	1.48
Central Blood Bank, 2015 ⁽³⁾	2006-2006	CS	Conv	37,024	2.01
Central Blood Bank, 2015 ⁽³⁾	2007-2007	CS	Conv	39,402	1.83
Central Blood Bank, 2015 ⁽³⁾	2008-2008	CS	Conv	43,769	1.49
Afghanistan National AIDS Control Program, 2010 ⁽⁴⁾	2008-2009	CS	Conv	19,875	3.00
Central Blood Bank, 2015 ⁽³⁾	2009-2009	CS	Conv	36,447	1.23

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Central Blood Bank, 2015 ⁽³⁾	2010-2010	CS	Conv	52,698	1.12
Central Blood Bank, 2015 ⁽³⁾	2011-2011	CS	Conv	74,820	0.82
Central Blood Bank, 2015 ⁽³⁾	2012-2012	CS	Conv	70,820	0.85
Central Blood Bank, 2015 ⁽³⁾	2013-2013	CS	Conv	83,802	0.64
Central Blood Bank, 2015 ⁽³⁾	2014-2014	CS	Conv	95,940	0.57
Central Blood Bank, 2015 ⁽³⁾	2015-2015	CS	Conv	30,510	0.38
Algeria					
Ayed, 1995 ⁽⁵⁾	1992-1993	CS	Conv	905	0.11
Ayed, 1995 ⁽⁵⁾	1992-1993	CS	Conv	207	0.48
Bouali, 2013 ⁽⁶⁾	2009-2012	CS	Conv	100,310	0.27
Djibouti					
Dray, 2005 ⁽⁷⁾	1998-2000	NS	Conv	8,057	0.26
Dray-Spira, 2004 ⁽⁸⁾	1998-2000	NS	Conv	9,006	0.30
Egypt					
el Gohary, 1995 ⁽⁹⁾	1990-1992	CS	Conv	271	14.39
el Gohary, 1995 ⁽⁹⁾	1990-1992	CS	Conv	1,187	14.49
el Gohary, 1995 ⁽⁹⁾	1990-1992	CS	Conv	148	15.54
Quinti, 1995 ⁽¹⁰⁾	1992-1994	CS	Conv	283	20.85
Abdelaal, 1994 ⁽¹¹⁾	1992-1992	CS	Conv	49	24.49

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	30	0.00
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	58	3.45
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	136	11.03
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	56	16.07
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	30	16.67
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	29	17.24
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	28	17.86
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	349	19.48
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	129	19.38
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	29	20.69
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	193	22.28
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	30	23.33
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional	139	24.46

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	99	24.24
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	136	23.53
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	134	26.87
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	181	28.18
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	130	29.23
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	136	31.62
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	169	33.14
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	135	32.59
Al Omar, 1996 ⁽¹³⁾	1993-1994	CS	Conv	420	34.05
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	154	37.01
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	89	38.20
Arthur, 1997 ⁽¹²⁾	1993-1993	CS	Proportional sampling	45	37.78
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	1,609	16.47
El Damaty, 2007	1996-1997	CS	Multi-stage	525	15.05

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
(15)			cluster sampling		
El Damaty, 2007 (15)	1996-1997	CS	Multi-stage cluster sampling	336	15.48
Tanaka, 2004 ⁽¹⁶⁾	1999-1999	CS	Conv	750	4.00
Tanaka, 2004 ⁽¹⁶⁾	1999-1999	CS	Conv	1,050	6.00
El Damaty, 2007 (15)	1999-2000	Retrospective cohort	Conv	476	6.93
El Damaty, 2007 (15)	1999-2000	Retrospective cohort	Conv	2,369	7.77
Tanaka, 2004 ⁽¹⁶⁾	1999-1999	CS	Conv	833	12.00
Tanaka, 2004 ⁽¹⁶⁾	1999-1999	CS	Conv	975	12.72
Khattab, 2010 ⁽¹⁷⁾	2000-2008	Retrospective cohort	Conv	29,649	3.00
Eissa, 2007 ⁽¹⁸⁾	2000-2005	CS	Conv	99,757	4.04
Eissa, 2007 ⁽¹⁸⁾	2000-2005	CS	Conv	46,747	6.88
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	1,977	7.44
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	7,405	9.37
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	6,981	9.58
Khattab, 2010 ⁽¹⁷⁾	2000-2008	Retrospective cohort	Conv	182,123	10.00
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	8,674	10.20
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	7,536	10.63
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	613	10.60
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	110	10.91

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	296	11.15
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	704	12.36
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	6,865	13.15
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	631	13.95
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	598	14.55
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	6,156	14.77
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	686	16.76
Ismail, 2009 ⁽¹⁹⁾	2000-2007	CS	Conv	6,686	17.78
El-Gilany, 2006 ⁽²⁰⁾	2002-2003	Retrospective cohort	Conv	807	2.48
El-Gilany, 2006 ⁽²⁰⁾	2002-2003	Retrospective cohort	Conv	1,350	2.81
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	14,941	4.48
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	14,412	4.60
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	20,726	4.60
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	23,352	4.60
El-Zayadi, 2008 ⁽²²⁾	2005-2005	CS	Conv	636	4.72
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	17,843	5.30
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	35,835	5.50
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	37,661	5.60
Eita, 2009 ⁽²¹⁾	2005-2008	CS	Conv	22,165	5.80
El-Zayadi, 2008 ⁽²²⁾	2005-2005	CS	Conv	124	6.45
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	23,885	1.50

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
		cohort			
Rushdy, 2009 ⁽²⁴⁾	2006-2007	CS	Conv	1,995	1.70
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	31,582	2.49
		cohort			
Rushdy, 2009 ⁽²⁴⁾	2006-2007	CS	Conv	7,155	2.92
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	29,158	3.18
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	35,873	3.47
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	25,257	3.80
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	40,165	4.00
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	34,972	4.29
		cohort			
Ashour, 2009 ⁽²⁵⁾	2006-2008	CS	Conv	515,758	4.83
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	20,960	4.86
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	19,878	5.52
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	15,979	7.22
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	16,425	8.86
		cohort			
Hussein, 2014 ⁽²³⁾	2006-2012	Retrospective	Conv	14,628	8.92
		cohort			

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Wasfi, 2011 ⁽²⁶⁾	2007-2008	CS	Conv	3,420	3.48
Elkareh, 2009 ⁽²⁷⁾	2008-2008	Retrospective cohort	Conv	3,569	6.33
Elkareh, 2009 ⁽²⁷⁾	2008-2008	Retrospective cohort	Conv	414	8.70
Elkareh, 2009 ⁽²⁷⁾	2008-2008	Retrospective cohort	Conv	4,709	12.70
Elkareh, 2009 ⁽²⁷⁾	2008-2008	Retrospective cohort	Conv	8,705	14.59
Abdel Messih, 2014 ⁽²⁸⁾	2010-2011	CS	Conv	2,101	0.71
Hamed, 2012 ⁽²⁹⁾	2010-2011	CS	Conv	7,340	2.33
Abdel Messih, 2014 ⁽²⁸⁾	2010-2011	CS	Conv	15,017	4.28
El-Shanshory, 2013 ⁽³⁰⁾	2010-2011	CC	Conv	3,756	17.55
Teruya, 2011 ⁽³¹⁾	NS	CS	Conv	3,425	1.61
Maha, 2012 ⁽³²⁾	2011-2011	Retrospective cohort	Conv	10,598	4.89
Maha, 2012 ⁽³²⁾	2011-2011	Retrospective cohort	Conv	4,626	8.73
Badr, 2013 ⁽³³⁾	2012-2012	CS	Conv	5,145	4.94
Badr, 2013 ⁽³³⁾	2012-2012	CS	Conv	2,847	8.08
Badr, 2015 ⁽³⁴⁾	2013-2014	CS	Conv	33,921	0.18
Agha, 2006 ⁽³⁵⁾	NS	CS	Conv	2,400	8.00

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
el-Zayadi, 1997 ⁽³⁶⁾	NS	CC	Conv	180	9.44
Darwish, 1992 ⁽³⁷⁾	NS	CS	Conv	90	14.44
Awadalla, 2011 (38)	NS	CS	Conv	825	15.03
El-Zayadi, 1998 (39)	NS	CS	Conv	75	16.00
el-Zayadi, 1997 ⁽³⁶⁾	NS	CC	Conv	320	16.25
Attia, 1996 ⁽⁴⁰⁾	NS	CS	Conv	82	17.07
Al-Knawy, 1995 (41)	NS	Retrospective cohort	Conv	204	21.08
Attia, 1996 ⁽⁴⁰⁾	NS	CS	Conv	156	21.79
Hashish, 2005 ⁽⁴²⁾	NS	CS	Conv	95	23.16
Hagag, 1998 ⁽⁴³⁾	NS	CS	SRS	398	23.62
Awadalla, 2011 (38)	NS	CS	Conv	175	25.14
Hagag, 1998 ⁽⁴³⁾	NS	CS	SRS	59	25.42
Bassily, 1995 ⁽⁴⁴⁾	NS	CC	Conv	188	26.60
Attia, 1996 ⁽⁴⁰⁾	NS	CS	Conv	74	27.03
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	114	27.19
Iran					
Alavian, 2002 ⁽⁴⁶⁾	1996-1998	CC	Conv	319,375	0.09
Afzali, 2003 ⁽⁴⁷⁾	NS	CS	Conv	6,669	0.37
Ansar, 2002 ⁽⁴⁸⁾	1997-1998	CS	SRS	5,976	0.03
Afzali, 2003 ⁽⁴⁷⁾	NS	CS	Conv	6,750	0.64
Mansour-	1998-2003	CS	Conv	221,508	0.32

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Ghanaei, 2007 ⁽⁴⁹⁾					
Afzali, 2003 ⁽⁴⁷⁾	NS	CS	Conv	6,922	0.59
Ghavanini, 2000 ⁽⁵⁰⁾	NS	CS	Conv	7,879	0.60
Hajiani, 2006 ⁽⁵¹⁾	1998-2003	CC	Conv	360	1.11
Afzali, 2003 ⁽⁴⁷⁾	NS	CS	Conv	6,986	1.56
Tahereh, 2005 ⁽⁵²⁾	2000-2002	CS	SRS	39,598	0.25
Afzali, 2003 ⁽⁴⁷⁾	NS	CS	Conv	8,683	1.46
Rahnama, 2005 ⁽⁵³⁾	2000-2001	CC	SRS	140	2.14
Rahbar, 2004 ⁽⁵⁴⁾	NS	CC	Conv	60,892	0.10
Emam, 2006 ⁽⁵⁵⁾	2001-2003	CS	Conv	3,000	0.30
Pourshams, 2005 ⁽⁵⁶⁾	NS	CS	SRS	1,465	0.41
Moniri, 2004 ⁽⁵⁷⁾	2001-2002	CS	Conv	600	0.50
Pourshams, 2005 ⁽⁵⁶⁾	NS	CS	SRS	494	0.61
Afzali, 2003 ⁽⁴⁷⁾	NS	CS	Conv	7,721	1.71
Farahzadeh, 2005 ⁽⁵⁸⁾	2001-2002	CC	Conv	96	3.13
Masaeli, 2006 ⁽⁵⁹⁾	2002-2003	CS	Conv	29,458	0.24
Salehi, 2011 ⁽⁶⁰⁾	2002-2006	CS	Conv	4,808	0.27
Aghanjanipoor, 2006 ⁽⁶¹⁾	NS	CS	Conv	16,576	0.48
Barhaghtalab, 2008 ⁽⁶²⁾	2002-2007	CS	Conv	25,491	0.55
Mahmoudian,	2003-2004	CS	Conv	1,489,935	0.07

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
2006 ⁽⁶³⁾					
Delavari, 2004 ⁽⁶⁴⁾	NS	CS	Conv	2,921	0.10
Taheri, 2008 ⁽⁶⁵⁾	2003-2005	CS	Conv	49,820	0.18
Kazeminejad, 2005 ⁽⁶⁶⁾	NS	CS	Conv	38,920	0.19
Habibzadeh, 2005 ⁽⁶⁷⁾	NS	CS	Conv	441	0.23
Delavari, 2004 ⁽⁶⁴⁾	NS	CS	Conv	12,331	0.46
Kasraian, 2010 ⁽⁶⁸⁾	NS	CS	Conv	1,694	0.47
Doosti, 2009 ⁽⁶⁹⁾	2003-2004	CS	Conv	11,200	0.59
Kasraian, 2010 ⁽⁶⁸⁾	NS	CS	Conv	239	0.84
Karim, 2008 ⁽⁷⁰⁾	2003-2005	CC	Conv	125	2.40
Hosseien, 2009 ⁽⁷¹⁾	NS	CS	Conv	329,516	2.82
Gachkar, 2005 ⁽⁷²⁾	NS	CS	Conv	399	0.00
Metanet, 2006 ⁽⁷³⁾	NS	CC	Conv	1,399	0.07
Shahshahani, 2013 ⁽⁷⁴⁾	2004-2010	CS	Conv	10,190	0.09
Shahshahani, 2013 ⁽⁷⁴⁾	2004-2010	CS	Conv	244,570	0.09
Kafi-abad, 2009 ⁽⁷⁵⁾	NS	CS	Conv	1,494,282	0.13
Karimi, 2008 ⁽⁷⁶⁾	2004-2006	CS	Conv	35,124	0.21
Maneshi, 2010 ⁽⁷⁷⁾	2004-2008	CS	Conv	51,884	0.34
Rezazadeh, 2006 ⁽⁷⁸⁾	2004-2005	CS	Conv	18,306	0.43
Tajbakhsh, 2007	NS	CS	Conv	1,870	0.53

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
(79)					
Tajbakhsh, 2007	NS	CS	Conv	9,602	0.61
(79)					
Ghaderi, 2007 ⁽⁸⁰⁾	2004-2006	CC	Conv	150	0.67
Hosseien, 2009 ⁽⁷¹⁾	NS	CS	Conv	329,961	1.49
Farshadpour, 2016 ⁽⁸¹⁾	2004-2014	CS	Conv	274,556	0.10
Farshadpour, 2016 ⁽⁸¹⁾	2004-2014	CS	Conv	18,898	0.05
Assarehzadegan, 2008 ⁽⁸²⁾	NS	CS	Conv	400	0.00
Zanjani, 2013 ⁽⁸³⁾	2005-2006	CS	Conv	3,211	0.06
Zanjani, 2013 ⁽⁸³⁾	2005-2006	CS	Conv	26,505	0.12
Kafi-abad, 2009	NS	CS	Conv	1,603,149	0.14
(75)					
Hosseini, 2007 ⁽⁸⁴⁾	NS	NS	NS	19,627	0.24
Mohammadali, 2014 ⁽⁸⁵⁾	2005-2011	CS	Conv	2,031,451	0.39
Khedmat, 2007 ⁽⁸⁶⁾	2005-2006	CS	SRS	1,014	2.07
Hosseien, 2009 ⁽⁷¹⁾	NS	CS	Conv	345,412	2.08
Ghafouri, 2011 ⁽⁸⁷⁾	2006-2009	CS	Conv	95,538	0.01
Kafi-abad, 2009	NS	CS	Conv	1,667,412	0.13
(75)					
Esmaili, 2009 ⁽⁸⁸⁾	2006-2007	CS	Conv	20,294	0.21
Kafi-abad, 2009	NS	CS	Conv	1,735,008	0.12
(75)					

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Kasraian, 2008 ⁽⁸⁹⁾	2007-2008	CC	Conv	93,987	0.22
Farshadpour, 2010 ⁽⁹⁰⁾	2007-2007	CS	Conv	2,376	2.31
Khodabandehloo, 2013 ⁽⁹¹⁾	2008-2011	CS	Conv	124,704	0.03
Sofian, 2010 ⁽⁹²⁾	NS	CS	SRS	531	0.19
Keshvari, 2015 ⁽⁹³⁾	NS	CS	Conv	296,567	0.14
Bozorgi, 2012 ⁽⁹⁴⁾	NS	CS	Conv	20,591	0.17
Seyed-Askari, 2015 ⁽⁹⁵⁾	2009-2013	CS	Conv	360,722	0.08
EMRO, 2011 ⁽⁹⁶⁾	NS	CS	NS	1,986,992	0.06
Rezaie, 2016 ⁽⁹⁷⁾	2011-2015	CS	Conv	42,253	0.06
Samadi, 2014 ⁽⁹⁸⁾	NS	CS	Conv	2,108	0.00
Keshvari, 2015 ⁽⁹³⁾	NS	CS	Conv	282,010	0.07
Amini, 2005 ⁽⁹⁹⁾	NS	CS	Conv	100	0.00
Mogaddam, 2010 ⁽¹⁰⁰⁾	NS	CC	NS	60	0.00
Iraq					
Hassan, 2008 ⁽¹⁰¹⁾	1996-1997	Retrospective cohort	Conv	7,707	0.22
Hassan, 2008 ⁽¹⁰¹⁾	1997-1998	Retrospective cohort	Conv	3,621	0.50
Hassan, 2008 ⁽¹⁰¹⁾	1998-1999	Retrospective cohort	Conv	4,825	0.08
Abdul-Aziz, 2001	1999-2001	CS	Conv	3,934	0.20

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
(102)					
Abdul-Aziz, 2001	1999-2001	CS	Conv	16,174	0.96
(102)					
Hassan, 2008 ⁽¹⁰¹⁾	1999-2000	Retrospective cohort	Conv	8,500	0.08
Hassan, 2008 ⁽¹⁰¹⁾	2000-2001	Retrospective cohort	Conv	9,148	0.03
Hassan, 2008 ⁽¹⁰¹⁾	2001-2002	Retrospective cohort	Conv	8,189	0.16
Chiad, 2009 ⁽¹⁰³⁾	2003-2004	CS	Conv	32	0.00
Chiad, 2009 ⁽¹⁰³⁾	2003-2004	CS	Conv	968	1.03
Al-Doori, 2006	2004-2005	CS	Conv	193	0.00
(104)					
Al-Doori, 2006	2004-2005	CS	Conv	781	0.26
(104)					
Al-Doori, 2006	2004-2005	CS	Conv	574	0.52
(104)					
Al-Doori, 2006	2004-2005	CS	Conv	368	0.82
(104)					
Al-Doori, 2006	2004-2005	CS	Conv	62	1.61
(104)					
Aljooani, 2012 ⁽¹⁰⁵⁾	2005-2007	CS	Conv	123	2.44
Aljooani, 2012 ⁽¹⁰⁵⁾	2005-2007	CS	Conv	158	2.53
Aljooani, 2012 ⁽¹⁰⁵⁾	2005-2007	CS	Conv	149	3.36
Abdullah, 2012	2005-2007	CS	Conv	100	1.00
(106)					

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Ataallah, 2011 ⁽¹⁰⁷⁾	2006-2006	CS	Conv	137,486	0.15
Ataallah, 2011 ⁽¹⁰⁷⁾	2006-2006	CS	Conv	4,086	0.39
Hussein, 2010 ⁽¹⁰⁸⁾	2006-2006	Retrospective cohort	Conv	204	0.00
Hussein, 2010 ⁽¹⁰⁸⁾	2006-2006	Retrospective cohort	Conv	14,229	0.11
Al-Kamil, 2011 ⁽¹⁰⁹⁾	2006-2008	Retrospective cohort	Conv	160,758	0.08
Al-Kamil, 2011 ⁽¹⁰⁹⁾	2006-2008	Retrospective cohort	Conv	1,229	0.08
Ataallah, 2011 ⁽¹⁰⁷⁾	2007-2007	CS	Conv	113,543	0.19
Ataallah, 2011 ⁽¹⁰⁷⁾	2007-2007	CS	Conv	3,683	0.30
Ali, 2009 ⁽¹¹⁰⁾	2007-2008	CS	Conv	600	1.67
Al Juboury, 2010 ⁽¹¹¹⁾	2007-2008	CS	Conv	23,122	0.49
Al Juboury, 2010 ⁽¹¹¹⁾	2007-2008	CS	Conv	214	1.40
Hussein, 2010 ⁽¹⁰⁸⁾	2007-2007	Retrospective cohort	Conv	144	0.00
Hussein, 2010 ⁽¹⁰⁸⁾	2007-2007	Retrospective cohort	Conv	16,997	0.10
Salih, 2007 ⁽¹¹²⁾	2007-2007	CS	Conv	95	2.11
Ataallah, 2011 ⁽¹⁰⁷⁾	2008-2008	CS	Conv	109,983	0.18
Ataallah, 2011 ⁽¹⁰⁷⁾	2008-2008	CS	Conv	3,368	0.42
Amin, 2012 ⁽¹¹³⁾	2008-2009	CS	Conv	35,114	0.07

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Amin, 2012 ⁽¹¹³⁾	2008-2009	CS	Conv	426	0.70
Hamim, 2012 ⁽¹¹⁴⁾	2008-2008	CS	Conv	388,985	0.42
Hussain, 2010 ⁽¹¹⁵⁾	2008-2009	CS	Conv	117	0.85
Strak, 2014 ⁽¹¹⁶⁾	2008-2009	CS	SRS	2,070	0.14
Ataallah, 2011 ⁽¹⁰⁷⁾	2009-2009	CS	Conv	120,458	0.22
Ataallah, 2011 ⁽¹⁰⁷⁾	2009-2009	CS	Conv	3,041	0.36
Noaman, 2012 ⁽¹¹⁷⁾	2009-2010	CS	Conv	93	1.08
Hamim, 2012 ⁽¹¹⁴⁾	2009-2009	CS	Conv	482,988	0.33
Al-Duliami, 2012 ⁽¹¹⁸⁾	2010-2011	CS	SRS	90	0.00
Tawfeeq, 2013 ⁽¹¹⁹⁾	2011-2012	CS	Conv	15,560	0.29
Obied, 2014 ⁽¹²⁰⁾	2012-2013	CS	Conv	5,179	0.39
Al-Rubaye, 2015 ⁽¹²¹⁾	2013-2013	CS	Conv	69,658	0.12
Al-Rubaye,2015 ⁽¹²¹⁾	2013-2013	CS	Conv	257	0.00
Khalid, 2012 ⁽¹²²⁾	NS	CS	Conv	100	2.00
Saadoon, 2012 ⁽¹²³⁾	NS	CS	Conv	1,128	0.62
Jassim, 2011 ⁽¹²⁴⁾	NS	CS	Conv	98	0.00
Jassim, 2011 ⁽¹²⁴⁾	NS	CS	Conv	72	0.00
Albaitushi, 2011 ⁽¹²⁵⁾	NS	CS	Conv	27	3.70
Toffik, 2006 ⁽¹²⁶⁾	NS	CS	Conv	200	0.50
Jordan					
Jbara, 2006 ⁽¹²⁷⁾	2003-2005	CS	Conv	370	0.54

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Jbara, 2006 ⁽¹²⁷⁾	2003-2005	CS	Conv	8,380	0.80
Rashdan, 2008 ⁽¹²⁸⁾	2004-2006	CS	Conv	13,666	0.20
Rashdan, 2008 ⁽¹²⁸⁾	2004-2006	CS	Conv	570	0.35
Al-Gani, 2011 ⁽¹²⁹⁾	2006-2009	CS	Conv	7,800	0.83
Al-Gani, 2011 ⁽¹²⁹⁾	2006-2009	CS	Conv	390	2.05
Al Abbadi, 2014 (130)	2009-2009	CS	Conv	28,315	0.16
Souan, 2016 ⁽¹³¹⁾	2009-2010	CS	Conv	10,101	0.20
Al Abbadi, 2014 (130)	2010-2010	CS	Conv	31,543	0.18
Souan, 2016 ⁽¹³¹⁾	2010-2011	CS	Conv	12,694	0.20
Al Abbadi, 2014 (130)	2011-2011	CS	Conv	34,412	0.13
Souan, 2016 ⁽¹³¹⁾	2011-2012	CS	Conv	13,387	0.13
Souan, 2016 ⁽¹³¹⁾	2012-2013	CS	Conv	14,256	0.20
Souan, 2016 ⁽¹³¹⁾	2013-2014	CS	Conv	12,495	0.11
Kuwait					
Ameen, 2005 ⁽¹³²⁾	NS	CS	Conv	8,561	0.78
Ameen, 2005 ⁽¹³²⁾	NS	CS	Conv	4,237	5.43
Lebanon					
Irani-Hakime, 2006 ⁽¹³³⁾	1997-2003	CS	Conv	14,990	0.37
Irani-Hakime, 2006 ⁽¹³³⁾	1997-2003	CS	Conv	1,094	0.82
Tamim, 2001 ⁽¹³⁴⁾	1998-2000	CS	Conv	349	0.00
Tamim, 2001 ⁽¹³⁴⁾	1998-2000	CS	Conv	4,679	0.32

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Tamim, 2001 ⁽¹³⁴⁾	1998-2000	CS	Conv	88	3.41
Irani-Hakime, 2001 ⁽¹³⁵⁾	1999-1999	CC	Conv	256	0.00
Irani-Hakime, 2001 ⁽¹³⁵⁾	1999-1999	CC	Conv	337	0.30
Ramia, 2005 ⁽¹³⁶⁾	2002-2003	CS	SRS	56	0.00
Araj, 1995 ⁽¹³⁷⁾	NS	CS	SRS	4,179	0.12
Naman, 1996 ⁽¹³⁸⁾	NS	CS	NS	7,771	0.41
Ramia, 2003 ⁽¹³⁹⁾	NS	CS	SRS	500	0.20
Salem, 2003 ⁽¹⁴⁰⁾	NS	CS	SRS	150	0.00
Libya					
Saleh, 1994 ⁽¹⁴¹⁾	1992-1992	CS	Conv	76	6.58
Daw, 2002 ⁽¹⁴²⁾	1999-2001	CS	Conv	1,200	1.17
Daw, 2016 ⁽¹⁴³⁾	2008-2008	CS	Conv	35,859	2.61
Daw, 2016 ⁽¹⁴³⁾	2009-2009	CS	Conv	65,330	2.62
Daw, 2016 ⁽¹⁴³⁾	2010-2010	CS	Conv	254,177	1.56
Daw, 2016 ⁽¹⁴³⁾	2011-2011	CS	Conv	173,873	1.76
Daw, 2016 ⁽¹⁴³⁾	2012-2012	CS	Conv	260,139	1.72
Daw, 2016 ⁽¹⁴³⁾	2013-2013	CS	Conv	218,836	1.71
Elzouki, 1995 ⁽¹⁴⁴⁾	NS	CS	Conv	86	1.16
Mauritania					
Lo, 1999 ⁽¹⁴⁵⁾	1998-1998	CS	Conv	349	1.15
Morocco					
Lahlou Amine, 2010 ⁽¹⁴⁶⁾	2002-2005	CS	Conv	3,600	0.33

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Aqodad, 2011 ⁽¹⁴⁷⁾	2006-2007	CS	Conv	777	0.77
Baha, 2013 ⁽¹⁴⁸⁾	2008-2008	CS	Conv	52,279	0.57
Zohoun, 2011 ⁽¹⁴⁹⁾	2008-2009	CS	Conv	19,801	0.23
Baha, 2013 ⁽¹⁴⁸⁾	2009-2009	CS	Conv	55,496	0.64
Baha, 2013 ⁽¹⁴⁸⁾	2010-2010	CS	Conv	61,830	0.65
Doblali, 2014 ⁽¹⁵⁰⁾	2010-2012	CS	Conv	29,530	0.18
Uwingabiye, 2016 (151)	2010-2010	CS	Conv	8,245	0.35
Uwingabiye, 2016 (151)	2011-2011	CS	Conv	8,232	0.21
Uwingabiye, 2016 (151)	2012-2012	CS	Conv	9,184	0.19
Laouina, 2016 ⁽¹⁵²⁾	2015-2015	CS	Conv	57,711	0.40
Benjelloun, 1996 (153)	NS	CS	Conv	1,000	1.10
Laouina, 2012 ⁽¹⁵⁴⁾	NS	CS	SRS	10,423	0.69
Laouina, 2012 ⁽¹⁵⁴⁾	NS	CS	SRS	3,648	0.90
WHO Regional Office for the Eastern Mediterranean, 2011 ⁽⁹⁶⁾	NS	CS	Conv	132,197	0.16
Oman					
Al Dhahry, 1993 (155)	NS	CS	Conv	564	0.89

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Al Dhahry, 2003 (156)	NS	CS	Conv	668	0.90
Al Dhahry, 2003 (156)	NS	CS	Conv	2,596	1.31
Al Dhahry, 2003 (156)	NS	CS	Conv	3,584	1.42
Al Dhahry, 2003 (156)	NS	CS	Conv	2,033	1.13
Al Dhahry, 2003 (156)	NS	CS	Conv	2,330	0.86
Al Dhahry, 2003 (156)	NS	CS	Conv	2,637	0.95
Al Dhahry, 2003 (156)	NS	CS	Conv	2,638	0.99
Al Dhahry, 2003 (156)	NS	CS	Conv	2,817	0.71
Al Dhahry, 2003 (156)	NS	CS	Conv	2,996	0.63
Al Dhahry, 2003 (156)	NS	CS	Conv	3,290	0.70
Al Dhahry, 2003 (156)	NS	CS	Conv	4,423	0.57
Schuster, 2009 ⁽¹⁵⁷⁾	2006-2008	CS	Conv	6,725	0.45
Ashraf, 2010 ⁽¹⁵⁸⁾	NS	CS	Conv	3,587	0.67
EMRO, 2011 ⁽⁹⁶⁾	NS	CS	Conv	47,413	0.50

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Pathare, 2012 ⁽¹⁵⁹⁾	NS	CS	Conv	6,146	0.39
Alnaqy, 2006 ⁽¹⁶⁰⁾	NS	CS	Conv	600	1.50
Pakistan					
Kakepoto, 1996 ⁽¹⁶¹⁾	1989-1994	CS	Conv	14,933	1.19
Kakepoto, 1996 ⁽¹⁶¹⁾	1989-1994	CS	Conv	1,772	1.19
Mujeeb, 2000 ⁽¹⁶²⁾	1996-1997	CS	Conv	612	0.49
Khattak, 2002 ⁽¹⁶³⁾	1996-2000	CS	Conv	14,513	3.49
Khattak, 2002 ⁽¹⁶³⁾	1996-2000	CS	Conv	19,711	4.26
Khattak, 2002 ⁽¹⁶³⁾	1996-2000	CS	Conv	21,047	4.14
Khattak, 2002 ⁽¹⁶³⁾	1996-2000	CS	Conv	24,573	4.07
Khattak, 2002 ⁽¹⁶³⁾	1996-2000	CS	Conv	24,014	4.26
Qureshi, 2002 ⁽¹⁶⁴⁾	1996-1999	CS	Conv	401	4.49
Mujeeb, 2000 ⁽¹⁶⁵⁾	1997-1998	CS	Conv	754	2.52
Mujeeb, 2000 ⁽¹⁶⁵⁾	1997-1998	CS	Conv	1,005	1.09
Mujeeb, 2000 ⁽¹⁶⁵⁾	1997-1998	CS	Conv	3,331	2.70
Mujeeb, 2000 ⁽¹⁶⁵⁾	1997-1998	CS	Conv	1,445	1.38
Mujeeb, 2000 ⁽¹⁶⁵⁾	1997-1998	CS	Conv	512	5.27
Mujeeb, 2006 ⁽¹⁶⁶⁾	2000-2000	CS	Conv	7,168	3.60
Mujeeb, 2006 ⁽¹⁶⁶⁾	2000-2000	CS	Conv	157	3.18
Mumtaz, 2002 ⁽¹⁶⁷⁾	2001-2002	CS	Conv	563	6.22
Asif, 2004 ⁽¹⁶⁸⁾	2002-2003	CS	Conv	3,187	5.15
Asif, 2004 ⁽¹⁶⁸⁾	2002-2003	CS	Conv	243	2.47
Bhatti, 2007 ⁽¹⁶⁹⁾	2003-2005	CS	Conv	94,177	4.16

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Ahmad, 2007 ⁽¹⁷⁰⁾	2004-2004	CS	SRS	300	20.67
Bhatti, 2007 ⁽¹⁶⁹⁾	2004-2004	CS	Conv	966	3.83
Sultan, 2007 ⁽¹⁷¹⁾	2004-2005	CS	Conv	970	1.24
Sultan, 2007 ⁽¹⁷¹⁾	2004-2005	CS	Conv	11,396	3.30
Sultan, 2007 ⁽¹⁷¹⁾	2004-2005	CS	Conv	1,522	6.31
Mujeeb, 2008 ⁽¹⁷²⁾	2004-2007	CS	Conv	5,345	7.52
Mujeeb, 2008 ⁽¹⁷²⁾	2004-2004	CS	Conv	1,339	7.17
Irfan, 2013 ⁽¹⁷³⁾	2004-2010	CS	Conv	108,598	2.70
Abbas, 2009 ⁽¹⁷⁴⁾	2005-2008	Retrospective cohort	Conv	804	15.05
Karim, 2017 ⁽¹⁷⁵⁾	2005-2016	CS	Conv	262,819	1.78
Mujeeb, 2008 ⁽¹⁷²⁾	2007-2007	CS	Conv	1,333	8.78
Bangash, 2009 ⁽¹⁷⁶⁾	2007-2007	CS	Conv	1,300	1.62
Bangash, 2009 ⁽¹⁷⁷⁾	2007-2008	CS	Conv	10,343	0.48
Shah, 2010 ⁽¹⁷⁸⁾	2007-2008	CS	Conv	32,042	1.57
Borhany, 2011 ⁽¹⁷⁹⁾	2007-2009	CS	Conv	5,717	1.91
Qadeer, 2013 ⁽¹⁸⁰⁾	2007-2012	CS	Conv	5,000	4.12
Hussain, 2009 ⁽¹⁸¹⁾	2008-2008	CS	Conv	98,012	5.76
Jadoon, 2010 ⁽¹⁸²⁾	2008-2008	CS	Conv	550	8.18
Safi, 2011 ⁽¹⁸³⁾	2008-2009	CS	Conv	62,251	2.61
Attaullah, 2012 ⁽¹⁸⁴⁾	2008-2011	Retrospective cohort	Conv	127,828	2.46
Khan, 2011 ⁽¹⁸⁵⁾	2009-2009	CS	Conv	7,148	1.89
Khan, 2012 ⁽¹⁸⁶⁾	2009-2012	CS	Conv	6,513	1.14
Ansari, 2012 ⁽¹⁸⁷⁾	2010-2010	CS	Conv	5,517	1.98

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Bhutta, 2012 ⁽¹⁸⁸⁾	2010-2010	CS	Conv	100	12.00
Waheed, 2012 ⁽¹⁸⁹⁾	2010-2011	Retrospective cohort	Conv	10,145	8.34
Ijaz, 2012 ⁽¹⁹⁰⁾	2011-2012	CS	Conv	3,652	12.35
Khan, 2013 ⁽¹⁹¹⁾	2011-2011	CS	Conv	356	20.79
Moiz, 2014 ⁽¹⁹²⁾	2011-2012	CS	Conv	40,110	1.73
Moiz, 2014 ⁽¹⁹²⁾	2011-2012	CS	Conv	2,720	0.55
Sultan, 2016 ⁽¹⁹³⁾	2011-2014	CC	Conv	200	3.00
Ahmad, 2017 ⁽¹⁹⁴⁾	2011-2015	CS	Conv	79,774	1.76
Niazi, 2015 ⁽¹⁹⁵⁾	2012-2013	CS	Conv	56,772	1.84
Niazi, 2016 ⁽¹⁹⁶⁾	2012-2015	CS	Conv	170,519	0.01
Butt, 2013 ⁽¹⁹⁷⁾	2013-2013	CS	Conv	833	1.92
Parveen, 2014 ⁽¹⁹⁸⁾	2013-2013	CS	Conv	6,216	2.20
Parveen, 2014 ⁽¹⁹⁸⁾	2013-2013	CS	Conv	4,450	3.91
Nepal, 2016 ⁽¹⁹⁹⁾	2013-2014	CS	Conv	6,996	3.04
Ata, 2017 ⁽²⁰⁰⁾	2013-2016	CS	Conv	34,496	1.38
Noorulamin, 2016 ⁽²⁰¹⁾	2014-2015	CS	Conv	6,053	1.72
Saeed, 2017 ⁽²⁰²⁾	2014-2015	CS	Conv	18,274	2.63
Karim, 2016 ⁽²⁰³⁾	2015-2015	CS	Conv	5,318	1.13
Ghanghro, 2016 ⁽²⁰⁴⁾	2015-	CS	Conv	656	12.20
Waheed, 2017 ⁽²⁰⁵⁾	2016-2016	CS	Conv	71,795	1.65
Amin, 2017 ⁽²⁰⁶⁾	2017-2017	CS	Conv	190	3.16
Akram, 2017 ⁽²⁰⁷⁾	2017-2017	CS	Conv	1,084	5.17

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Khattak, 2008 ⁽²⁰⁸⁾	NS	CS	Conv	1,131	4.07
Jadoon, 2010 ⁽²⁰⁹⁾	NS	CC	Conv	10,000	4.90
Zaffar, 2013 ⁽²¹⁰⁾	NS	Retrospective cohort	Conv	246,611	2.92
Sheikh, 2015 ⁽²¹¹⁾	NS	Coh	Conv	300	4.33
Kanwal, 2016 ⁽²¹²⁾	NS	CC	Conv	100	3.00
Arshad, 2016 ⁽²¹³⁾	NS	CS	Conv	16,557	1.85
Arshad, 2016 ⁽²¹³⁾	NS	CS	Conv	45	2.22
Wazeer, 2017 ⁽²¹⁴⁾	NS	CS	Conv	10,460	4.77
Palestine					
Novack, 2007 ⁽²¹⁵⁾	1999-2002	CS	NS	2,784	3.95
Palestinian Health Information Center, 2004 ⁽²¹⁶⁾	2003-2003	CS	Conv	21,219	0.30
Palestinian Health Information Center, 2004 ⁽²¹⁶⁾	2003-2003	CS	Conv	23,771	0.30
Palestinian Health Information Center, 2004 ⁽²¹⁶⁾	2005-2005	CS	Conv	21,804	0.10
Palestinian Health Information Center, 2006 ⁽²¹⁷⁾	2005-2005	CS	Conv	23,225	0.20

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Information Center, 2006 ⁽²¹⁷⁾					
Palestinian Health Information Center, 2007	2006-2006	CS	Conv	2,116	0.00
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	3,428	0.03
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	4,231	0.05
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	4,712	0.11
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	2,189	0.23
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	26,506	0.26

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	1,113	0.27
Palestinian Health Information Center, 2007 ⁽²¹⁸⁾	2006-2006	CS	Conv	8,856	0.27
Palestinian Health Information Center, 2008 ⁽²¹⁹⁾	2007-2007	CS	Conv	543	0.00
Palestinian Health Information Center, 2008 ⁽²¹⁹⁾	2007-2007	CS	Conv	871	0.00
Palestinian Health Information Center, 2008 ⁽²¹⁹⁾	2007-2007	CS	Conv	2,734	0.04
Palestinian Health Information Center, 2008 ⁽²¹⁹⁾	2007-2007	CS	Conv	3,819	0.10
Palestinian	2007-2007	CS	Conv	834	0.12

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Health Information Center, 2008 ⁽²¹⁹⁾					
Palestinian	2007-2007	CS	Conv	3,849	0.13
Health Information Center, 2008 ⁽²¹⁹⁾					
Palestinian	2007-2007	CS	Conv	11,639	0.14
Health Information Center, 2008 ⁽²¹⁹⁾					
Palestinian	2007-2007	CS	Conv	1,981	0.20
Health Information Center, 2008 ⁽²¹⁹⁾					
Palestinian	2007-2007	CS	Conv	3,930	0.25
Health Information Center, 2008 ⁽²¹⁹⁾					
Palestinian	2007-2007	CS	Conv	4,669	0.28
Health Information Center, 2008 ⁽²¹⁹⁾					
Palestinian	2007-2007	CS	Conv	2,054	0.29
Health Information					

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Center, 2008 ⁽²¹⁹⁾					
Palestinian Health Information	2007-2007	CS	Conv	7,072	0.37
Center, 2008 ⁽²¹⁹⁾					
Palestinian Health Information	2007-2007	CS	Conv	4,223	0.73
Center, 2008 ⁽²¹⁹⁾					
Palestinian Health Information	2007-2007	CS	Conv	887	1.13
Center, 2008 ⁽²¹⁹⁾					
Palestinian Health Information	2009-2009	CS	Conv	3,198	0.00
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	608	0.00
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	1,259	0.00
Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	217	0.00

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Health Information Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	3,792	0.05
Health Information Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	2,120	0.09
Health Information Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	6,111	0.13
Health Information Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	3,667	0.16
Health Information Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	11,820	0.17
Health Information Center, 2010 ⁽²²⁰⁾					
Palestinian	2009-2009	CS	Conv	919	0.22
Health Information					

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	4,422	0.32
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	3,730	0.35
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	2,199	0.45
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	2,112	0.57
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	792	0.76
Center, 2010 ⁽²²⁰⁾					
Palestinian Health Information	2009-2009	CS	Conv	1,035	1.26
Center, 2010 ⁽²²⁰⁾					
MENA	2011-2011	CS	Conv	63,477	0.18

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
HIV/AIDS					
Synthesis Project, 2011 ⁽⁹⁶⁾					
Palestinian Health Information Center, 2014 ⁽²²¹⁾	2013-2013	CS	Conv	4,383	0.00
Palestinian Health Information Center, 2014 ⁽²²¹⁾	2013-2013	CS	Conv	2,690	0.07
Palestinian Health Information Center, 2014 ⁽²²¹⁾	2013-2013	CS	Conv	3,486	0.09
Palestinian Health Information Center, 2014 ⁽²²¹⁾	2013-2013	CS	Conv	5,983	0.17
Palestinian Health Information Center, 2014 ⁽²²¹⁾	2013-2013	CS	Conv	978	0.72
Palestinian Health Information Center, 2014 ⁽²²¹⁾	2013-2013	CS	Conv	2,051	0.73

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Center, 2014 ⁽²²¹⁾					
Palestinian Health Information	2013-2013	CS	Conv	9,643	0.31
Center, 2014 ⁽²²¹⁾					
Palestinian Health Information	2014-2014	CS	Conv	3,812	0.10
Center, 2015 ⁽²²²⁾					
Palestinian Health Information	2014-2014	CS	Conv	5,162	0.14
Center, 2015 ⁽²²²⁾					
Palestinian Health Information	2014-2014	CS	Conv	6,230	0.24
Center, 2015 ⁽²²²⁾					
Palestinian Health Information	2014-2014	CS	Conv	10,614	0.24
Center, 2015 ⁽²²²⁾					
Palestinian Health Information	2014-2014	CS	Conv	3,269	0.28
Center, 2015 ⁽²²²⁾					
Palestinian	2014-2014	CS	Conv	992	0.30

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Health Information Center, 2015 ⁽²²²⁾					
Palestinian	2014-2014	CS	Conv	3,227	0.43
Health Information Center, 2015 ⁽²²²⁾					
Shemer-Avni, 1998 ⁽²²³⁾	NS	CS	Conv	1,509	2.25
Qatar					
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	28,622	0.53
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	6,235	11.23
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	6,227	1.65
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	3,307	0.60
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	5,145	0.29
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	1,831	0.27
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	9,083	0.32
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	2,246	0.45
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	4,532	0.29
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	2,283	0.39
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	8,919	0.46
Fawzi, 2007 ⁽²²⁴⁾	1994-2001	CS	Conv	49,868	1.89
Saudi Arabia					
Al Karawi, 1992 ⁽²²⁵⁾	1989-1990	CS	Conv	4,818	1.49
Bahakim, 2001 ⁽²²⁶⁾	1990-1990	CS	SRS	500	5.60

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Fathalla, 1994 ⁽²²⁷⁾	1991-1992	CS	Conv	8,934	1.66
Abdelaal, 1994 ⁽¹¹⁾	NS	CS	SRS	363	0.55
Abdelaal, 1994 ⁽¹¹⁾	NS	CS	SRS	165	4.24
Abdelaal, 1994 ⁽¹¹⁾	NS	CS	SRS	49	24.49
Abdelaal, 1994 ⁽¹¹⁾	NS	CS	SRS	38	0.00
Abdelaal, 1994 ⁽¹¹⁾	NS	CS	SRS	57	1.75
Al Sohaibani, 1995 ⁽²²⁸⁾	1992-1994	CS	Conv	292	1.71
Tamimi, 2004 ⁽²²⁹⁾	1992-1995	CS	Conv	7,013	1.03
Altamimi, 1998 ⁽²³⁰⁾	NS	CS	Conv	2,286	0.48
Al Omar, 1996 ⁽¹³⁾	1993-1994	CS	Conv	3,190	1.22
Altamimi, 1998 ⁽²³⁰⁾	NS	CS	Conv	2,549	0.98
Kashgari, 1997 ⁽²³¹⁾	NS	CS	SRS	332	0.60
Ankra-Badu, 2001 ⁽²³²⁾	NS	CS	Conv	3,461	2.17
Altamimi, 1998 ⁽²³⁰⁾	NS	CS	Conv	2,178	1.65
Abdelaal, 1998 ⁽²³³⁾	NS	CS	Conv	593	1.69
Arif, 1998 ⁽²³⁴⁾	1995-1996	CS	Conv	8,478	1.62
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	8,003	1.35
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	1,609	16.47

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	288	2.43
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	52	1.92
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	28	0.00
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	128	1.56
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	391	1.79
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	406	2.46
Mehdi, 2000 ⁽¹⁴⁾	1995-1997	CS	Conv	102	2.94
Ankra-Badu, 2001 (232)	NS	CS	Conv	3,001	2.50
Tamimi, 2004 ⁽²²⁹⁾	1995-2002	CS	Conv	63,368	0.58
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	393,327	0.32
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	2,866,113	0.32
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	356,250	0.21
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	1,824,952	0.19
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	55,725	0.18
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	1,483,258	0.14
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	4,538,346	0.09
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	890,625	0.09
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	288,321	0.08
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	575,000	0.07
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	1,283,251	0.06
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	205,882	0.05
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	1,297,311	0.04
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	940,217	0.04
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	113,393	0.03

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	487,778	0.03
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	270,808	0.03
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	883,186	0.03
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	280,727	0.02
Madani, 2007 ⁽²³⁵⁾	1995-2005	CS	Conv	1,030,159	0.02
Ankra-Badu, 2001 ⁽²³²⁾	NS	CS	Conv	3,724	1.99
Bashawri, 2002 ⁽²³⁶⁾	NS	CS	Conv	3,724	1.85
Mehdi, 2006 ⁽²³⁷⁾	1996-2004	CC	Conv	11,035	2.90
Mitwalli, 2000 ⁽²³⁸⁾	NS	CC	SRS	100	2.00
Ankra-Badu, 2001 ⁽²³²⁾	NS	CS	Conv	3,307	1.63
Bashawri, 2002 ⁽²³⁶⁾	NS	CS	Conv	3,307	1.48
Ankra-Badu, 2001 ⁽²³²⁾	NS	CS	Conv	3,379	1.45
Bashawri, 2002 ⁽²³⁶⁾	NS	CS	Conv	3,379	1.24
Bashawri, 2004 ⁽²³⁹⁾	1998-2001	CS	Conv	10,778	0.98
Bashawri, 2004 ⁽²³⁹⁾	1998-2001	CS	Conv	2,665	3.30
Bashawri, 2004 ⁽²³⁹⁾	1998-2001	CS	Conv	119	0.84

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Bashawri, 2004 (239)	1998-2001	CS	Conv	397	14.61
Bashawri, 2004 (239)	1998-2001	CS	Conv	157	1.27
Bashawri, 2004 (239)	1998-2001	CS	Conv	406	1.23
Bashawri, 2004 (239)	1998-2001	CS	Conv	227	0.44
Bashawri, 2004 (239)	1998-2001	CS	Conv	208	3.85
Bashawri, 2004 (239)	1998-2001	CS	Conv	318	1.57
Bashawri, 2004 (239)	1998-2001	CS	Conv	294	1.02
Bashawri, 2004 (239)	1998-2001	CS	Conv	307	1.63
Al-Bahrani, 2001 (240)	NS	CS	Conv	5,937	0.67
Al-Bahrani, 2001 (240)	NS	CS	Conv	933	3.43
Bashawri, 2002 (236)	NS	CS	Conv	3,414	1.58
Bashawri, 2002 (236)	NS	CS	Conv	3,618	1.52
El Hazmi, 2004	2000-2002	CS	Conv	482	8.09

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
(241) El Hazmi, 2004	2000-2002	CS	Conv	594	0.67
(241) El Hazmi, 2004	2000-2002	CS	Conv	588	0.34
(241) El Hazmi, 2004	2000-2002	CS	Conv	402	0.00
(241) El Hazmi, 2004	2000-2002	CS	Conv	345	0.00
(241) El Hazmi, 2004	2000-2002	CS	Conv	276	3.62
(241) El Hazmi, 2004	2000-2002	CS	Conv	270	0.37
(241) El Hazmi, 2004	2000-2002	CS	Conv	774	0.39
(241) El Hazmi, 2004	NS	CS	Conv	7,744	0.48
(241) El Hazmi, 2004	NS	CS	Conv	7,974	0.45
(241) El Hazmi, 2004	NS	CS	Conv	8,455	0.35
(242) Abdullah, 2011	NS	CS	Conv	5,241	0.74
(242) Abdullah, 2011	NS	CS	Conv	5,334	0.39
(242) Abdullah, 2011	NS	CS	Conv	4,949	0.46

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
(242)					
Abdullah, 2011	NS	CS	Conv	4,903	0.33
(242)					
Halawani, 2012	2007-2009	CC	Conv	70	0.00
(243)					
Halawani, 2012	2007-2009	CC	Conv	50	2.00
(244)					
Abdullah, 2011	NS	CS	Conv	4,169	0.34
(242)					
Abdelaziz, 2013	2008-2012	CS	Conv	13,435	0.83
(245)					
Abdullah, 2011	NS	CS	Conv	5,353	0.22
(242)					
Elbjeirami, 2015	NS	CS	Conv	3,090	0.19
(246)					
Elbjeirami, 2015	NS	CS	Conv	5,731	0.40
(246)					
Kilany, 2015 ⁽²⁴⁷⁾	2012-2013	CS	Conv	7,267	0.07
Elbjeirami, 2015	NS	CS	Conv	6,947	0.62
(246)					
Elbjeirami, 2015	NS	CS	Conv	7,195	0.42
(246)					
Sarah, 2016 ⁽²⁴⁸⁾	NS	CS	Conv	238	7.14
Sarah, 2016 ⁽²⁴⁸⁾	NS	CS	Conv	123	7.32
Al-Mofarreh, 1991	NS	CS	Conv	403	1.24
(249)					

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Al-Mofarreh, 1991 (249)	NS	CS	Conv	177	4.52
Ayoola, 2001 ⁽²⁵⁰⁾	NS	CS	Conv	240	4.17
Ayoola, 2001 ⁽²⁵⁰⁾	NS	CS	Conv	248	3.63
Bernvil, 2001 ⁽²⁵¹⁾	NS	CS	Conv	4,850	0.33
Bernvil, 2001 ⁽²⁵¹⁾	NS	CS	Conv	1,694	1.42
Bernvil, 2001 ⁽²⁵¹⁾	NS	CS	Conv	1,824	0.27
Bernvil, 2001 ⁽²⁵¹⁾	NS	CS	Conv	2,548	0.27
Jamjoom, 1992 ⁽²⁵²⁾	NS	CS	Conv	317	1.89
Al Nasser, 1992 (253)	NS	CS	SRS	200	4.00
Ayoola, 1992 ⁽²⁵⁴⁾	NS	CS	Conv	488	3.89
Mitwalli, 1992 ⁽²⁵⁵⁾	NS	CS	Conv	730	0.82
Saeed, 1992 ⁽²⁵⁶⁾	NS	CS	Conv	1,472	1.49
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	918	1.74
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	114	27.19
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	105	1.90
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	67	1.49
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	53	1.89
Ahmad, 1995 ⁽⁴⁵⁾	NS	CS	Conv	182	0.55
Al Knawy, 1995 (41)	NS	CS	Conv	3,354	1.43
Al Knawy, 1995 (41)	NS	CS	Conv	204	21.08
Al Knawy, 1995	NS	CS	Conv	310	2.58

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
(41)					
Anwar, 2009 ⁽²⁵⁷⁾	NS	CS	Conv	15,280	0.92
Halawani, 2010 ⁽²⁵⁸⁾	NS	CS	Conv	50	2.00
Somalia					
Nur, 2000 ⁽²⁵⁹⁾	1995-1995	NS	Conv	157	0.64
EMRO, 2011 ⁽⁹⁶⁾	NS	NS	Conv	12,759	0.46
Sudan					
Nagi, 2007 ⁽²⁶⁰⁾	2005-2005	NS	SRS	78	1.28
Abou, 2009 ⁽²⁶¹⁾	2007-2007	NS	SRS	400	1.00
Elfaki, 2008 ⁽²⁶²⁾	NS	NS	Conv	260	0.00
Syria					
Ali, 2010 ⁽²⁶³⁾	2000-2000	CS	Conv	13,193	0.70
Ali, 2010 ⁽²⁶³⁾	2001-2001	CS	Conv	12,923	0.50
Ali, 2010 ⁽²⁶³⁾	2002-2002	CS	Conv	13,626	0.36
Ali, 2010 ⁽²⁶³⁾	2003-2003	CS	Conv	17,011	0.31
Ali, 2010 ⁽²⁶³⁾	2004-2004	CS	Conv	18,077	0.30
Ali, 2010 ⁽²⁶³⁾	2005-2005	CS	Conv	18,950	0.30
Ali, 2010 ⁽²⁶³⁾	2006-2006	CS	Conv	19,233	0.41
MENA	2006-2006	CS	Conv	55,549	0.28
HIV/AIDS					
Synthesis Project,					
2006 1st quarter					
^(96, 264)					
MENA	2006-2006	CS	Conv	87,920	0.42
HIV/AIDS					

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Synthesis Project, 2006 2nd quarter (96, 264)					
MENA HIV/AIDS	2006-2006	CS	Conv	77,734	0.57
Synthesis Project, 2006 3rd quarter (96, 264)					
MENA HIV/AIDS	2006-2006	CS	Conv	83,347	0.53
Synthesis Project, 2006 4th quarter (96, 264)					
Ali, 2010 ⁽²⁶³⁾	2007-2007	CS	Conv	18,390	0.37
MENA HIV/AIDS	2007-2007	CS	Conv	83,501	0.41
Synthesis Project, 2007 1st quarter (96, 264)					
MENA HIV/AIDS	2007-2007	CS	Conv	92,452	0.43
Synthesis Project, 2007 2nd quarter (96, 264)					
MENA HIV/AIDS	2007-2007	CS	Conv	83,560	0.48

Author, year (citation)	Year(s) of data collection	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Synthesis Project, 2007 3rd quarter (96, 264)					
MENA HIV/AIDS Synthesis Project, 2011 (96)	2011-2011	CS	Conv	416,984	0.56
Othman, 2002 (265)	NS	CS	Conv	2,100	0.95
Tunisia					
Abid, 1997 (266)	1994-1994	CS	Conv	43,000	0.18
Hatira, 2000 (267)	1994-1997	CS	Conv	34,130	0.43
Krichen, 2001 (268)	1995-1997	CS	Conv	34,769	1.78
Krichen, 2001 (268)	1995-1997	CS	Conv	7,854	1.40
Larabi, 2001 (269)	1997-1999	CS	Conv	3,480	1.18
Mastouri, 2005 (270)	2000-2000	CS	Conv	600	1.33
HIV/AIDS Quarterly Case Notification, 2006 (271)	2006-2006	CS	Conv	31,115	0.34
HIV/AIDS Quarterly Case Notification, 2006 (271)	2006-2006	CS	Conv	20,803	0.54
HIV/AIDS Quarterly Case	2006-2006	CS	Conv	28,428	0.30

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Notification, 2006 (271)					
HIV/AIDS Quarterly Case Notification, 2007 (272)	2007-2007	CS	Conv	259,890	0.26
HIV/AIDS Quarterly Case Notification, 2007 (272)	2007-2007	CS	Conv	24,247	0.87
HIV/AIDS Quarterly Case Notification, 2007 (272)	2007-2007	CS	Conv	10,526	0.64
HIV/AIDS Quarterly Case Notification, 2007 (272)	2007-2007	CS	Conv	58,368	0.36
Hannachi, 2010 (273)	2008-2009	CC	Conv	100	1.00
Ben Jemia, 2014 (274)	2010-2010	CS	Conv	14,442	0.40
Ben Jemia, 2014 (274)	2010-2010	CS	Conv	5,341	0.28
Coursaget, 1995 (275)	NS	CS	Conv	45	2.22

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Kallel, 2011 ⁽²⁷⁶⁾	NS	CC	Conv	300	0.33
Slama, 1991 ⁽²⁷⁷⁾	NS	CS	Conv	1,220	1.48
Slama, 1991 ⁽²⁷⁷⁾	NS	CS	Conv	786	1.02
Triki, 1994 ⁽²⁷⁸⁾	NS	CS	Conv	300	0.67
United Arab Emirates					
Al Shaer, 2012 ⁽²⁷⁹⁾	2004-2009	CS	Conv	169,781	0.11
Raouf, 2010 ⁽²⁸⁰⁾	2005-2009	CS	Conv	98,594	0.50
Yemen					
Scott, 1992 ⁽²⁸¹⁾	NS	NS	Conv	348	6.03
Haidar, 2002 ⁽²⁸²⁾	1999-1999	NS	Conv	2,343	1.11
El-Rab, 2004 ⁽²⁸³⁾	2003-2003	NS	Conv	1,540	1.56
Selm, 2010 ⁽²⁸⁴⁾	2007-2007	NS	Conv	100	1.00
Al-Waleedi, 2012 ⁽²⁸⁵⁾	2007-2007	NS	Conv	127	0.79
Al-Waleedi, 2012 ⁽²⁸⁵⁾	2007-2007	NS	Conv	133	1.50
Al-Waleedi, 2012 ⁽²⁸⁵⁾	2007-2007	NS	Conv	179	1.68
Omer, 2010 ⁽²⁸⁶⁾	2007-2008	NS	Conv	5,825	1.99
Saghir, 2012 ⁽²⁸⁷⁾	NS	NS	Conv	919	0.87
Saghir, 2012 ⁽²⁸⁷⁾	NS	NS	Conv	564	0.71
Alodini, 2012 ⁽²⁸⁸⁾	2010-2010	NS	Conv	3,000	3.13
Guneid, 1993 ⁽²⁸⁹⁾	NS	NS	NS	294	1.02
Sallam, 2003 ⁽²⁹⁰⁾	NS	NS	Conv	493	0.20
Sallam, 2003 ⁽²⁹⁰⁾	NS	NS	Conv	494	0.61

Author, year (citation)	Year(s) of data collection	Original study design^a	Sampling	Sample size	HCV Ab prevalence (%)
Oshaish, 2008 ⁽²⁹¹⁾	NS	NS	Conv	1,000	1.00

Abbreviations: Ab, antibody; AIDS, acquired immune deficiency syndrome; CC, case-control; Coh, cohort; Conv, convenience; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MENA, Middle East and North Africa; NS, not specified; SRS, simple random sampling.

^aThe reported study design is the original study design (case control, cross sectional, cohort, or randomized controlled trial). The included prevalence measures are those for the baseline measures at the beginning of the study.

Table S2. Studies reporting HCV Ab prevalence in the general population in Middle East and North Africa.

Author, year (citation)	Year(s) of data collection	Study population	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Afghanistan						
Pehlivanoglu, 2011 ⁽²⁹²⁾	2009-2009	Asylum seekers/refugees	CS	Conv	124	4.00
Richter, 2014 ⁽²⁹³⁾	2011-2011	Community	CS	Conv	293	1.00
Tanju, 2014 ⁽²⁹⁴⁾	2012-2012	Children	CS	Conv	161	0.00
Tanju, 2014 ⁽²⁹⁴⁾	2012-2012	Children	CS	Conv	169	1.20
Todd, 2008 ⁽²⁹⁵⁾	2006-2006	Pregnant women	CS	Conv	4,452	0.31
Todd, 2012 ⁽²⁹⁶⁾	2010-2012	Military /army personnel/army recruits	CS	SRS	6,849	0.73
Algeria						
Aidaoui, 2008 ⁽²⁹⁷⁾	2003-2004	Pregnant women	CS	Conv	3,032	0.63
Ayed, 1995 ⁽⁵⁾	1992-1993	Pregnant women	CS	Conv	424	0.24
Ayed, 1995 ⁽⁵⁾	1992-1993	Pregnant women	CS	Conv	91	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Belabas, 2015 (298)	2011- 2012	Pregnant women	CS	Conv	62	0.00
Clifford, 2017 (299)	NS	Population- based survey household members	CS	Systemati c random sampling	1,135	0.10
Egypt						
Abd Elrazek, 2014 ⁽³⁰⁰⁾	2004- 2013	Community center attendees	Coh	Conv	6,660	15.28
Abdel-Aziz, 2000 ⁽³⁰¹⁾	1997- 1997	Population- based survey household members	CS	Random cluster sampling	2,172	23.80
Abdel-Aziz, 2000 ⁽³⁰¹⁾	1997- 1997	Population- based survey household members	CS	Random cluster sampling	1,827	24.90
Abdel- Wahab, 1994 (302)	1992- 1992	Population- based survey household members	CS	Conv	58	0.00
Abdel- Wahab, 1994 (302)	1992- 1992	Children	CS	Conv	190	12.10

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Abdel- Wahab, 1994 (302)	1992- 1992	Population- based survey household members	CS	Conv	47	12.77
Abdel- Wahab, 1994 (302)	1992- 1992	Population- based survey household members	CS	Conv	77	14.28
Abdel- Wahab, 1994 (302)	1992- 1992	Population- based survey household members	CS	Conv	270	18.10
Abdel- Wahab, 1994 (302)	1992- 1992	Military /army personnel/ar my recruits	CS	Conv	300	22.10
Abdel- Wahab, 1994 (302)	1992- 1992	Population- based survey household members	CS	Conv	26	26.92
Abdel- Wahab, 1994 (302)	1992- 1992	Population- based survey household members	CS	Conv	30	36.67
Abdel-	1992-	Population-	CS	Conv	32	40.63

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Wahab, 1994 (302)	1992	based survey household members				
AbdulQawi, 2011 (303)	2003- 2008	Pregnant women	Coh	Conv	1,224	8.60
Agha, 1998 (304)	1996- 1997	Pregnant women	CS	Conv	767	13.69
Aguilar, 2008 (305)	NS	Other general population/ healthy population	CS	Conv	81	42.00
Aguilar, 2008 (305)	NS	Other general population/ healthy population	CS	Conv	78	51.00
Arafa, 2005 (306)	2002- 2003	Population- based survey household members	CS	Conv	1,202	16.60
Arafa, 2005 (306)	2002- 2003	Population- based survey household members	CS	Conv	1,059	21.40
Barakat, 2011 (307)	2005- 2005	Children	CS	Multi- stage	246	4.50

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
				cluster sampling		
Barakat, 2011 (307)	2005- 2005	Children	CS	Multi- stage cluster sampling	254	7.10
Bassily, 1993 (308)	NS	Population- based survey household members	CS	Conv	31	41.90
Bassily, 1995 (44)	NS	Healthy controls	CC	Conv	49	12.20
Cowgill, 2004 (309)	1999- 2003	Healthy controls	CC	Conv	87	32.18
Cowgill, 2004 (309)	1999- 2003	Healthy controls	CC	Conv	135	38.52
Darwish, 1995 (310)	NS	Population- based survey household members	CS	Conv	188	21.80
Darwish, 1996 (311)	1994- 1994	Population- based survey household members	CS	Conv	46	8.00
Darwish, 1996	1994-	Population-	CS	Conv	29	20.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(311)	1994	based survey household members				
Darwish, 1996 (311)	1994- 1994	Population- based survey household members	CS	Conv	47	51.00
Darwish, 2001 (312)	1994- 1994	Population- based survey household members	CC	Conv	796	40.00
Derbala, 2014 (313)	2008- 2010	Community center attendees	CS	Conv	908	8.50
Derbala, 2014 (313)	2008- 2010	Community center attendees	CS	Conv	658	11.10
Derbala, 2014 (313)	2008- 2010	Community center attendees	CS	Conv	322	19.30
Derbala, 2014 (313)	2008- 2010	Community center attendees	CS	Conv	447	23.00
Eassa, 2007 (314)	2006- 2007	Population- based survey	CS	Multi- stage	161	4.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		household members		cluster sampling		
Eassa, 2007 (314)	2006- 2007	Population- based survey	CS	Multi- stage	143	18.20
		household members		cluster sampling		
Edris, 2014 (315)	2011- 2012	Population- based survey	CS	Multi- stage	1,238	9.53
		household members		cluster sampling		
Edris, 2014 (315)	2011- 2012	Population- based survey	CS	Multi- stage	1,461	10.95
		household members		cluster sampling		
El Sayed Zaki, 2013 (316)	2012- 2013	Other general population/ healthy population	CC	Conv	29	0.00
El Sayed Zaki, 2013 (316)	2012- 2013	Other general population/ healthy population	CC	Conv	29	0.00
El Sayed Zaki, 2013 (317)	NS	Children	CC	Conv	40	0.00
el-Ghazzawi,	NS	Healthy	CC	Conv	40	27.50

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
1995 ⁽³¹⁸⁾		controls				
El-Kamary, 2015 ⁽³¹⁹⁾	2012- 2013	Pregnant women	CS	Conv	1,250	4.20
El-Karakasy, 2010 ⁽³²⁰⁾	2006- 2007	Children	CC	Conv	1,042	1.40
el-Nanawy, 1995 ⁽³²¹⁾	NS	Healthy controls	CC	Conv	110	11.80
El-Raziky, 2007 ⁽³²²⁾	2004- 2004	Children	CC	Conv	1,042	1.40
el-Sadawy, 2004 ⁽³²³⁾	NS	Population- based survey household members	CS	Multi- stage cluster sampling	640	23.40
el-Sadawy, 2004 ⁽³²³⁾	NS	Population- based survey household members	CS	Multi- stage cluster sampling	782	27.70
el-Sayed, 1996 (324)	1994- 1994	General population	CS	Conv	101	2.00
el-Sayed, 1996 (324)	1994- 1994	General population	CS	Conv	103	5.80
el-Sayed, 1996 (324)	1994- 1994	General population	CS	Conv	86	10.50
el-Sayed, 1996 (324)	1994- 1994	General population	CS	Conv	258	11.60

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
el-Sayed, 1996 (324)	1994- 1994	General population	CS	Conv	191	4.20
el-Sayed, 1997 (325)	1993- 1994	Population- based survey household members	CS	SRS	244	10.20
el-Sayed, 1997 (325)	1993- 1994	Population- based survey household members	CS	SRS	262	10.30
El-Sayed, 2006 (326)	2002- 2002	Healthy controls	CC	Conv	36	8.30
El-Sherbini, 2003 (327)	1994- 1994	Children	CS	Conv	294	5.80
El-Zanaty, 2008 (328)	2008- 2008	Population- based survey household members	CS	Multi- stage cluster sampling	82	2.50
El-Zanaty, 2008 (328)	2008- 2008	Population- based survey household members	CS	Multi- stage cluster sampling	87	5.00
El-Zanaty, 2008 (328)	2008- 2008	Population- based survey household	CS	Multi- stage cluster	631	7.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	members Population-	CS	sampling Multi-	1,182	7.60
	2008	based survey household		stage cluster		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	members Population-	CS	sampling Multi-	611	10.00
	2008	based survey household		stage cluster		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	members Population-	CS	sampling Multi-	1,084	11.50
	2008	based survey household		stage cluster		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	members Population-	CS	sampling Multi-	1,403	13.70
	2008	based survey household		stage cluster		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	members Population-	CS	sampling Multi-	560	13.70
	2008	based survey household		stage cluster		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	members Population-	CS	sampling Multi-	619	14.60
	2008	based survey household		stage cluster		
		members		sampling		

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	Population-	CS	Multi-	1,919	16.50
	2008	based survey household members		stage cluster sampling		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	Population-	CS	Multi-	1,209	19.60
	2008	based survey household members		stage cluster sampling		
El-Zanaty, 2008 ⁽³²⁸⁾	2008-	Population-	CS	Multi-	1,739	22.40
	2008	based survey household members		stage cluster sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014-	Population-	CS	Multi-	101	2.10
	2015	based survey household members		stage cluster sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014-	Population-	CS	Multi-	93	2.20
	2015	based survey household members		stage cluster sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014-	Population-	CS	Multi-	1,516	3.20
	2015	based survey household members		stage cluster sampling		
El-Zanaty,	2014-	Population-	CS	Multi-	1,706	3.90

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2015 ⁽³²⁹⁾	2015	based survey		stage		
		household		cluster		
		members		sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	1,466	4.00
		household		cluster		
		members		sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	3,817	4.10
		household		cluster		
		members		sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	1,489	5.30
		household		cluster		
		members		sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	1,558	5.60
		household		cluster		
		members		sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	1,306	7.20
		household		cluster		
		members		sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	3,257	7.20

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		household members		cluster sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	5,099	7.30
		household members		cluster sampling		
El-Zanaty, 2015 ⁽³²⁹⁾	2014- 2015	Population- based survey	CS	Multi- stage	4,638	9.50
		household members		cluster sampling		
Ezzat, 2005 ⁽³³⁰⁾	NS	Healthy controls	CC	Conv	63	30.20
Ezzat, 2005 ⁽³³⁰⁾	NS	Healthy controls	CC	Conv	113	45.10
Ezzat, 2005 ⁽³³⁰⁾	NS	Healthy controls	CC	Conv	37	54.10
Falseeh, 1999 ⁽³³¹⁾	1998- 1998	Outpatient clinic attendees	CS	SRS	284	22.54
Farghaly, 1994 ⁽³³²⁾	NS	Military /army personnel/ar my recruits	CC	Conv	346	22.50
Farghaly, 1994 ⁽³³²⁾	NS	Military /army	CC	Conv	326	36.80

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		personnel/ar my recruits				
Farghaly, 1994 ⁽³³²⁾	NS	Military /army	CC	Conv	41	48.80
		personnel/ar my recruits				
Farghaly, 1998 ⁽³³³⁾	NS	Healthy controls	CS	Conv	100	8.00
Farghaly, 2014 ⁽³³⁴⁾	NS	Children	CC	Conv	50	6.00
Gad, 2001 ⁽³³⁵⁾	1998- 1998	Healthy controls	CC	Conv	50	20.00
Goldman, 2009 ⁽³³⁶⁾	1999- 2004	Healthy controls	CC	Conv	786	37.40
Hadhoud, 2003 ⁽³³⁷⁾	NS	General population	CS	Conv	110	50.00
Hammad, 2009 ⁽³³⁸⁾	2008- 2008	Healthy controls	CC	Conv	25	0.00
Hassan, 1993 ⁽³³⁹⁾	NS	Pregnant women	CS	Conv	1,536	4.30
Hassan, 2001 ⁽³⁴⁰⁾	1995- 1996	Healthy controls	CC	Conv	35	42.90
Helmy, 1995 ⁽³⁴¹⁾	NS	Healthy controls	CC	Conv	110	8.10
Hindy, 1995	NS	Healthy	CC	Conv	35	17.10

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(342)		controls				
Ibrahim, 1999 (343)	1996- 1997	Healthy controls	CC	Conv	30	10.00
Jhaveri, 2015 (344)	2012- 2014	Pregnant women	Coh	Conv	2,514	3.90
Kalil, 2010 (345)	2004- 2005	Children	CC	Conv	150	8.00
Kamel, 1994 (346)	1992- 1992	Population- based survey household members	CS	Conv	1,259	15.90
Kandil, 2007 (347)	2004- 2006	Children	CC	Conv	100	38.00
Kassem, 2000 (348)	1996- 1996	Pregnant women	CS	Conv	100	19.00
Khalifa, 1993 (349)	1990- 1991	Healthy controls	CS	Conv	84	0.00
Khamis, 2014 (350)	NS	Pregnant women	CS	Conv	128	2.30
Khamis, 2014 (350)	NS	Pregnant women	CS	Conv	100	4.00
Khamis, 2014 (350)	NS	Pregnant women	CS	Conv	39	7.70
Khamis, 2014 (350)	NS	Pregnant women	CS	Conv	55	12.70

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Khamis, 2014 (350)	NS	Pregnant women	CS	Conv	38	13.20
Khedr, 1995 (351)	NS	Healthy controls	CC	Conv	91	18.70
Kumar, 1997 (352)	1994- 1996	Pregnant women	CS	Conv	499	13.00
Mansour, 2012 (353)	NS	Healthy controls	CC	Conv	100	0.00
Mohamed, 1996 (354)	NS	Expat workers mandatory Pre- employment screening	CS	Conv	89	6.70
Mohamed, 1996 (354)	NS	Expat workers mandatory Pre- employment screening	CS	Conv	146	6.80
Mohamed, 1996 (354)	NS	Expat workers mandatory Pre- employment screening	CS	Conv	37	10.80
Mohamed, 1996 (354)	NS	Expat workers mandatory	CS	Conv	183	13.10

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		Pre- employment screening				
Mohamed, 1996 ⁽³⁵⁴⁾	NS	Expatriate workers mandatory	CS	Conv	311	18.00
		Pre- employment screening				
Mohamed, 1996 ⁽³⁵⁴⁾	NS	Expatriate workers mandatory	CS	Conv	310	18.40
		Pre- employment screening				
Mohamed, 1996 ⁽³⁵⁴⁾	NS	Expatriate workers mandatory	CS	Conv	1,219	31.00
		Pre- employment screening				
Mohamed, 1996 ⁽³⁵⁴⁾	NS	Expatriate workers mandatory	CS	Conv	2,687	38.40
		Pre- employment screening				
Mohamed, 2006 ⁽³⁵⁵⁾	1997- 1997	Population- based survey	CS	Conv	1,423	2.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		household members				
Mohamed, 2006 ⁽³⁵⁵⁾	1997- 1997	Population- based survey	CS	Conv	1,385	2.70
		household members				
Mohamed, 2006 ⁽³⁵⁵⁾	1997- 1997	Population- based survey	CS	Conv	897	7.70
		household members				
Mohamed, 2006 ⁽³⁵⁵⁾	1997- 1997	Population- based survey	CS	Conv	926	8.60
		household members				
Mohamed, 2006 ⁽³⁵⁶⁾	2002- 2002	Population- based survey	CS	Conv	2,425	18.50
		household members				
Mostafa, 2010 ⁽³⁵⁷⁾	2001- 2006	Population- based survey	Coh	Multi- stage cluster sampling	4,129	12.30
		household members				
Nafeh, 2000 ⁽³⁵⁸⁾	NS	Population- based survey	CS	Conv	3,314	6.50
		household				

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Nafeh, 2000 (358)	NS	members Population- based survey household members	CS	Conv	2,717	11.30
Nooman, 1993 (359)	NS	Population- based survey household members	CS	Conv	1,000	1.00
Nooman, 1993 (359)	NS	Population- based survey household members	CS	Conv	2,000	1.90
Perumalswa mi, 2014 (360)	2009- 2011	General population immigrants	CS	Conv	192	15.60
Quinti, 1995 (10)	1992- 1994	fire brigade personnel	CS	Conv	541	39.00
Said, 2009 (361)	NS	Healthy controls	CC	Conv	50	0.00
Sayed, 2005 (362)	NS	Population- based survey household members	CS	SRS	84	14.30
Schiefelbein,	2007-	Healthy	CC	Conv	148	49.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2012 ⁽³⁶³⁾	2009	controls				
Shebl, 2009 ⁽³⁶⁴⁾	1997- 2001	Pregnant women	Coh	Conv	1,863	15.70
Stoszek, 2006 ⁽³⁶⁵⁾	1997- 2003	Pregnant women	CS	Conv	2,587	15.80
Strickland, 2002 ⁽³⁶⁶⁾	NS	Healthy controls	CC	Conv	212	46.70
Yates, 1999 ⁽³⁶⁷⁾	NS	Healthy controls	CC	Conv	94	3.00
Yates, 1999 ⁽³⁶⁷⁾	NS	Healthy controls	CC	Conv	114	6.00
Yates, 1999 ⁽³⁶⁷⁾	NS	Healthy controls	CC	Conv	186	18.00
Yates, 1999 ⁽³⁶⁷⁾	NS	Healthy controls	CC	Conv	72	42.00
Zakaria, 2005 ⁽³⁶⁸⁾	1999- 2002	Population- based survey household members	CS	Conv	1,439	20.80
Zakaria, 2005 ⁽³⁶⁸⁾	1999- 2002	Population- based survey household members	CS	Conv	866	21.00
Zuure, 2013 ⁽³⁶⁹⁾	2009- 2010	General population	CS	Non- probabilit	62	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		immigrants		y sampling / targeted sampling		
Zuure, 2013 (369)	2009- 2010	General population immigrants	CS	Non- probabilit y sampling / targeted sampling	197	1.52
Zuure, 2013 (369)	2009- 2010	General population immigrants	CS	Non- probabilit y sampling / targeted sampling	267	3.00
Iran						
Alavi, 2012 (370)	NS	Children	CC	Conv	90	0.00
Alavian, 2015 (371)	2012- 2012	Healthy controls	CC	Conv	275	0.00
Ansari-	2008-	Community	CS	Random	1,380	0.40

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Moghaddam, 2012 ⁽³⁷²⁾	2009			cluster sampling		
Ansari- Moghaddam, 2012 ⁽³⁷²⁾	2008- 2009	Community	CS	Random cluster sampling	1,207	0.70
Ardebili, 2012 (84)	2007- 2011	General population	CS	Conv	6,095	0.20
Arfaee, 2002 (373)	NS	Veterans	CS	Conv	307	1.00
Chamani, 2007 ⁽³⁷⁴⁾	NS	Couples undergoing fertility treatment	CS	NS	716	0.00
Chamani, 2007 ⁽³⁷⁴⁾	NS	Couples undergoing fertility treatment	CS	Conv	533	0.40
Esfandiarpou r, 2005 ⁽³⁷⁵⁾	2002- 2003	Other general population/ healthy population	CC	Conv	149	1.30
Esmaeili, 2004 (376)	NS	Children	CC	NS	100	0.00
Esmaeili, 2004 (376)	NS	Children	CC	NS	100	2.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Gerayli, 2015 (377)	NS	Healthy controls	CC	Conv	134	0.00
Ghadir, 2006 (378)	NS	General population	CS	NS	736	0.50
Ghadir, 2006 (378)	NS	General population	CS	NS	1,387	1.30
Ghezeldasht, 2015 (379)	2009- 2010	General population	CS	SRS	1,227	0.60
Hajiani, 2006 (380)	2003- 2004	Other General population/ healthy population	CC	NS	500	1.20
Heydarabad, 2012 (381)	2010- 2012	Pregnant women	CS	Conv	420	0.50
Jadali, 2005 (382)	NS	Other general population/ healthy population	CC	Conv	50	0.00
Jadali, 2005 (383)	NS	Other general population/ healthy population	CC	Conv	44	0.00
Jadali, 2005 (384)	NS	Other general population/ healthy	CC	NS	50	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Jamali, 2008 (385)	NS	General population	CS	Systemati c random cluster sampling	1,351	0.90
Jamali, 2008 (385)	NS	General population	CS	Conv	698	1.10
Kavoosi, 2008 (386)	2004- 2005	Other general population/ healthy population	CC	Conv	57	1.80
Kordi, 2011 (387)	NS	Other general population/ healthy population	CC	Multi- stage cluster sampling	410	0.00
Kordi, 2011 (387)	NS	Other general population/ healthy population	CC	Multi- stage cluster sampling	420	0.50
Merat, 2010 (388)	NS	General population	CS	Random cluster sampling	5,684	0.90
Moezzi, 2015 (389)	NS	General population	CS	Single- stage cluster	3,000	1.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
				sampling		
Mohebbi, 2011 ⁽³⁹⁰⁾	2007- 2008	Pregnant women	CC	Conv	174	0.00
Mohebbi, 2011 ⁽³⁹⁰⁾	2007- 2008	Pregnant women	CS	Conv	526	0.20
Mohebbi, 2011 ⁽³⁹⁰⁾	2007- 2008	Pregnant women	CS	Conv	127	0.80
Monsour- Ghanaei, 2007 ⁽³⁹¹⁾	NS	Community	CS	Conv	383	2.30
Moradi, 2007 ⁽³⁹²⁾	2001- 2002	Community	CS	Multi- stage cluster sampling	356	1.40
Motlagh, 2001 ⁽³⁹³⁾	1999- 2000	Pregnant women	CS	Conv	80	0.00
Mouasvi, 2011 ⁽³⁹⁴⁾	2009- 2010	Other general population/ healthy population	CS	Conv	52	0.00
Mouasvi, 2013 ⁽³⁹⁵⁾	2010- 2012	Other general population/ healthy population	CS	Conv	30	0.00
Mousavi,	NS	Other general	CS	Conv	79	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2010 ⁽³⁹⁶⁾		population/ healthy population				
Nikbakht, 2012 ⁽³⁹⁷⁾	2007- 2008	Couples undergoing fertility treatment	CS	Conv	712	0.40
Nikbakht, 2012 ⁽³⁹⁷⁾	2007- 2008	Couples undergoing fertility treatment	CS	Conv	712	0.80
Poustchi, 2011 ⁽³⁹⁸⁾	NS	General population	CS	Multi- stage cluster sampling	49,338	0.50
Sayad, 2008 ⁽³⁹⁹⁾	NS	Community	CS	Systemati c cluster sampling	1,721	0.90
Shaheli, 2015 ⁽⁴⁰⁰⁾	NS	Healthy controls	CC	Conv	100	0.00
Shakeri, 2013 ⁽⁴⁰¹⁾	2010- 2011	General population	CS	Multi- stage cluster sampling	3,870	0.10
Shamsdin,	2010-	General	CS	Conv	2,080	0.70

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2012 ⁽⁴⁰²⁾	2011	population				
Sohrabpour, 2010 ⁽⁴⁰³⁾	NS	General population	CS	Random cluster sampling	5,589	0.90
Tanomand, 2007 ⁽⁴⁰⁴⁾	NS	General population	CS	SRS	346	1.40
Vahidi, 2000 (405)	NS	Children	CC	Conv	107	0.00
Yazdani, 2006 (406)	1998- 2000	Pregnant women	CS	Conv	2,000	0.60
Zamani, 2013 (407)	2008- 2011	General population	CS	Random cluster sampling	2,662	0.00
Zamani, 2013 (407)	2008- 2011	General population	CS	Random cluster sampling	3,483	0.10
Zenouz, 2010 (408)	NS	Other general population/ healthy population	CC	NS	30	0.00
Iraq						
Al Wtaify, 2000 ⁽⁴⁰⁹⁾	1998- 1999	Outpatient clinic attendees	CC	SRS	200	0.50
Abdul-Aziz,	1999-	Pre-	CS	Conv	82	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2001 ⁽¹⁰²⁾	2001	employment screening				
Abdul-Aziz, 2001 ⁽¹⁰²⁾	1999- 2001	Pre- employment screening	CS	Conv	175	0.57
Al-Jebori, 2010 ⁽⁴¹⁰⁾	2003- 2004	Mixed general population	Retrospecti ve cohort	Conv	22,324	0.15
Al-Hamdani, 2012 ⁽⁴¹¹⁾	2003- 2003	Pre- employment screening	Retrospecti ve cohort	Conv	153	7.19
Al-Jebori, 2010 ⁽⁴¹⁰⁾	2004- 2005	Mixed general population	Retrospecti ve cohort	Conv	32,685	0.25
Al-Hamdani, 2012 ⁽⁴¹¹⁾	2004- 2004	Pre- employment screening	Retrospecti ve cohort	Conv	767	1.69
Hussain, 2008 ⁽⁴¹²⁾	2004- 2005	Other general population/ healthy population	CS	Conv	63	0.00
Hussain, 2008 ⁽⁴¹²⁾	2004- 2005	Other general population/ healthy population	CS	Conv	45	0.00
Al-Azzawi, 2006 ⁽⁴¹³⁾	2004- 2004	Pregnant women	CS	Conv	100	1.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Tarky, 2013 (414)	2005- 2006	Population- based survey household members	CS	Stratified random sampling	4,856	0.29
Tarky, 2013 (414)	2005- 2006	Population- based survey household members	CS	Stratified random sampling	4,754	0.50
Al-Jebori, 2010 (410)	2005- 2006	Mixed general population	Retrospecti ve cohort	Conv	12,727	0.06
Omer, 2011 (415)	2006- 2008	Other general population/ healthy population	CC	NS	350	0.29
Al-Jebori, 2010 (410)	2006- 2007	Mixed general population	Retrospecti ve cohort	Conv	25,544	0.18
Al-Hamdani, 2012 (411)	2006- 2006	Pre- employment screening	Retrospecti ve cohort	Conv	419	4.77
Salman, 2007 (416)	2006- 2007	Pregnant women	CS	Conv	60	0.00
Al-Jebori, 2010 (410)	2007- 2008	Mixed general population	Retrospecti ve cohort	Conv	10,075	0.04
Saadoon, 2008 (417)	2007- 2007	Pregnant women	CS	Conv	875	5.14

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Al-Zamili, 2009 ⁽⁴¹⁸⁾	2007- 2008	Children	CC	Conv	325	0.00
Al-Ani, 2011 ⁽⁴¹⁹⁾	2007- 2009	Children	CC	Conv	60	0.00
Al-Saad, 2009 ⁽⁴²⁰⁾	2008- 2008	Other General population/ healthy population	CC	Conv	73	0.00
Al-Saad, 2009 ⁽⁴²⁰⁾	2008- 2008	Other general population/ healthy population	CC	Conv	27	0.00
Al-Jebori, 2010 ⁽⁴¹⁰⁾	2008- 2009	Mixed general population	Retrospecti ve cohort	Conv	17,105	0.13
Abed, 2010 ⁽⁴²¹⁾	2008- 2008	Other general population/ healthy population	CC	SRS	31	3.23
Al-Hamdani, 2012 ⁽⁴¹¹⁾	2008- 2008	Pre- employment screening	Retrospecti ve cohort	Conv	867	2.19
Al-Hamdani, 2012 ⁽⁴¹¹⁾	2009- 2009	Pre- employment screening	Retrospecti ve cohort	Conv	1,956	2.35
Al-Dulaimi,	2010-	Healthy	CS	Conv	24	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2012 ⁽⁴²²⁾	2011	controls				
Fawzi, 2011 (423)	2010- 2010	Pregnant women	CS	Conv	127	0.00
Fawzi, 2011 (423)	2010- 2010	Pregnant women	CS	Conv	51	0.00
Fawzi, 2011 (423)	2010- 2010	Pregnant women	CS	Conv	26	0.00
Fawzi, 2011 (423)	2010- 2010	Pregnant women	CS	Conv	171	1.17
Fawzi, 2011 (423)	2010- 2010	Pregnant women	CS	Conv	52	1.92
Fawzi, 2011 (423)	2010- 2010	Pregnant women	CS	Conv	93	3.23
Richter, 2014 (293)	2011- 2011	Other general population/ healthy population	CS	Conv	290	0.34
Naji, 2013 ⁽⁴²⁴⁾	2011- 2012	Newly married individuals	CS	Conv	100	1.00
Naji, 2013 ⁽⁴²⁴⁾	2011- 2012	Newly married individuals	CS	Conv	100	2.00
Al-Greti, 2013 (425)	2011- 2012	Other general population/	CS	Conv	50	4.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		healthy population				
Al-Kubaisy, 2002 ⁽⁴²⁶⁾	NS	Pregnant women	CS	SRS	3,491	3.21
Chironna, 2003 ⁽⁴²⁷⁾	NS	Asylum seekers/refug ees	CS	Conv	71	0.00
Chironna, 2003 ⁽⁴²⁷⁾	NS	Asylum seekers/refug ees	CS	Conv	566	0.18
Toffik, 2006 ⁽¹²⁶⁾	NS	Outpatient clinic attendees	CS	Conv	100	0.00
Al-Kubaisy, 2000 ⁽⁴²⁸⁾	NS	Pregnant women	CS	Conv	3,491	3.21
Hussein, 2017 ⁽⁴²⁹⁾	NS	Community center attendees	CS	Conv	2,975	0.03
Hussein, 2017 ⁽⁴²⁹⁾	NS	Asylum seekers/refug ees	CS	Conv	880	0.00
Jordan						
Hamoudi, 2013 ⁽⁴³⁰⁾	NS	Community center attendees	CS	SRS	53	0.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Hamoudi, 2013 ⁽⁴³⁰⁾	NS	Community center attendees	CS	SRS	142	0.00
Hamoudi, 2013 ⁽⁴³⁰⁾	NS	Community center attendees	CS	SRS	511	0.59
Mansi, 2014 ⁽⁴³¹⁾	NS	Healthy controls	CS	Conv	40	0.00
Kuwait						
Al-Mutairi, 2013 ⁽⁴³²⁾	NS	Healthy controls	CC	Conv	1,148	0.52
Chehadeh, 2011 ⁽⁴³³⁾	NS	Healthy controls	CC	Conv	308	0.00
Chehadeh, 2011 ⁽⁴³³⁾	NS	Healthy controls	CC	Conv	132	3.00
Lebanon						
Nabulsi, 1997 ⁽⁴³⁴⁾	1993- 1995	Pregnant women	CS	NS	558	0.00
Abou Rached, 2016 ⁽⁴³⁵⁾	2011- 2012	Population- based survey (laboratories)	CS	Conv	1,928	0.21
Abou Rached, 2016 ⁽⁴³⁵⁾	2011- 2012	Population- based survey (laboratories)	CS	Conv	3,748	0.08
Abou Rached, 2016 ⁽⁴³⁵⁾	2011- 2012	Population- based survey (laboratories)	CS	Conv	13,950	0.13

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2016 ⁽⁴³⁵⁾	2012	based survey (laboratories)				
Abou Rached, 2016 ⁽⁴³⁵⁾	2011- 2012	Population- based survey (laboratories)	CS	Conv	5,296	0.60
Abou Rached, 2016 ⁽⁴³⁵⁾	2011- 2012	Population- based survey (laboratories)	CS	Conv	2,284	0.13
Abou Rached, 2016 ⁽⁴³⁵⁾	2011- 2012	Population- based survey (laboratories)	CS	Conv	3,941	0.10
Baddoura, 2002 ⁽⁴³⁶⁾	NS	Population- based survey (laboratories)	CS	Conv	2,879	0.59
Baddoura, 2002	NS	General population	CS	Conv	103	2.91
Baddoura Salem, 2003 (140)	NS	Outpatient clinic attendees	CS	SRS	70	0.00
Libya						
Daw, 2002 ⁽¹⁴²⁾	1999- 2001	Other general population/ healthy population	CS	Conv	800	1.60

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Shabash, 2010 (437)	2003- 2008	General population	CS	Conv	1,008,2 14	1.77
Elzouki, 2013 (438)	2005- 2005	Population- based survey household members	CS	Multi- stage cluster sampling	32,996	1.30
Elzouki, 2013 (438)	2005- 2005	Population- based survey household members	CS	Multi- stage cluster sampling	32,765	1.20
Daw, 2014 (439)	2011- 2011	General population	CS	Conv	7,500	0.56
Daw, 2014 (439)	2011- 2011	General population	CS	Conv	1,670	2.63
Morocco						
Cacoub, 2000 (440)	1995- 1996	Outpatient clinic attendees	CS	Conv	503	6.70
Lahlou Amine, 2010 (146)	2002- 2005	Military /army personnel/ar my recruits	CS	Conv	16,000	0.35
Baha, 2013 (148)	2005- 2011	General population	CS	Stratified random cluster	12,497	1.48

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Baha, 2013 (148)	2005- 2011	General population	CS	sampling Stratified random cluster sampling	28,772	1.62
Benouda, 2009 ⁽⁴⁴¹⁾	2005- 2007	General population	CS	Conv	5,124	1.82
Benouda, 2009 ⁽⁴⁴¹⁾	2005- 2007	General population	CS	Conv	3,202	2.13
Masvidal, 2010 ⁽⁴⁴²⁾	2005- 2006	Children	CS	Conv	231	0.43
Doblali, 2014 (443)	2010- 2012	Military /army personnel/ar my recruits	CS	Conv	15,320	0.25
Benjelloun, 1996 ⁽¹⁵³⁾	NS	Pregnant women	CS	Conv	676	1.00
Akil, 2012 ⁽⁴⁴⁴⁾	NS	Healthy controls	CC	Conv	161	1.20
Tagajdid, 2012 ⁽⁴⁴⁵⁾	NS	Pregnant women	CS	Conv	400	0.00
Oman						
Al Dhahry, 1993 ⁽¹⁵⁵⁾	NS	College students	CS	Conv	134	0.00
Pakistan						

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Agboatwalla, 1994 ⁽⁴⁴⁶⁾	1990- 1991	Children	CS	Conv	226	0.44
Luby, 1997 (447)	1993- 1993	General population	CS	SRS	309	6.50
Khan, 2000 (448)	1995- 1995	Outpatient clinic attendees	CS	Conv	50	32.00
Khan, 2000 (448)	1995- 1995	Outpatient clinic attendees	CS	Conv	85	51.00
Muhammad, 2005 ⁽⁴⁴⁹⁾	1998- 2002	Outpatient clinic attendees	CS	Conv	16,400	4.57
Idrees, 2008 (450)	1999- 2007	General population	CS	SRS	5,678	14.59
Idrees, 2008 (450)	1999- 2007	General population	CS	SRS	1,139	12.37
Aslam, 2001 (451)	NS	General population	CS	Conv	488	15.90
Aslam, 2001 (451)	NS	General population	CS	Conv	1,922	23.80
Khokhar, 2004 ⁽⁴⁵²⁾	2001- 2002	Pregnant women	CS	Conv	503	4.80
Jaffery, 2005 (453)	2001- 2002	Pregnant women	CC	Conv	947	3.27

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Hakim, 2008 (454)	2002- 2006	Women in childbearing ages	CS	Conv	4,000	5.23
Ali, 2009 (455)	2003- 2005	General population	CS	SRS	130	7.69
Ali, 2009 (455)	2003- 2005	General population	CS	SRS	336	8.92
Ali, 2009 (455)	2003- 2005	General population	CS	SRS	90	6.66
Ali, 2009 (455)	2003- 2005	General population	CS	SRS	176	5.68
Ali, 2009 (455)	2003- 2005	General population	CS	SRS	318	5.03
Ali, 2009 (455)	2003- 2005	General population	CS	SRS	116	5.17
Rifat uz, 2006 (456)	2004- 2004	General population	CS	Conv	924	7.36
Rifat uz, 2006 (456)	2004- 2004	General population	CS	Conv	2,133	4.14
Rifat uz, 2006 (456)	2004- 2004	General population	CS	Conv	867	3.92
Rifat uz, 2006 (456)	2004- 2004	General population	CS	Conv	491	6.52
Rifat uz, 2006 (456)	2004- 2004	General population	CS	Conv	1,213	4.70

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Rifat uz, 2006 (456)	2004- 2004	General population	CS	Conv	1,187	3.45
Butt, 2008 (457)	2004- 2005	Military /army personnel/ar my recruits	CS	Conv	2,296	1.92
Butt, 2008 (457)	2004- 2005	Military /army personnel/ar my recruits	CS	Conv	700	4.14
Butt, 2008 (457)	2004- 2005	Military /army personnel/ar my recruits	CS	Conv	2,378	0.88
Butt, 2008 (457)	2004- 2005	Military /army personnel/ar my recruits	CS	Conv	333	0.90
Sami, 2009 (458)	2005- 2005	Pregnant women	CS	Conv	5,902	1.80
Janjua, 2010 (459)	2005- 2005	General population	CS	Systemati c cluster sampling	649	19.00
Janjua, 2010 (459)	2005- 2005	General population	CS	Systemati c cluster	1,348	26.00

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
				sampling		
Aziz, 2011 ⁽⁴⁶⁰⁾	2005- 2009	ANC attendees	CS	Conv	18,000	5.79
Gul, 2009 ⁽⁴⁶¹⁾	2006- 2007	Pregnant women	CS	Conv	500	8.90
Shaikh, 2009 ⁽⁴⁶²⁾	2006- 2007	General population	CS	Conv	353	7.37
Shaikh, 2009 ⁽⁴⁶²⁾	2006- 2007	General population	CS	Conv	79	5.06
Sheikh, 2009 ⁽⁴⁶²⁾	2006- 2006	Pregnant women	CS	Conv	2,592	0.69
Hashmi, 2010 ⁽⁴⁶³⁾	2006- 2006	women in childbearing ages	CS	Multi- stage cluster sampling	252	24.60
Taseer, 2010 ⁽⁴⁶⁴⁾	2006- 2007	Pregnant women	CS	Purposiv e	208	5.28
Taseer, 2010 ⁽⁴⁶⁴⁾	2006- 2007	Pregnant women	CS	Purposiv e	263	6.84
Taseer, 2010 ⁽⁴⁶⁴⁾	2006- 2007	Pregnant women	CS	Purposiv e	29	20.68
Junejo, 2009 ⁽⁴⁶⁵⁾	2007- 2008	Outpatient clinic attendees	CS	Conv	931	17.20
Aziz, 2010 ⁽⁴⁶⁶⁾	2007-	General	CS	Conv	129	3.90

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
	2008	population				
Aziz, 2010 ⁽⁴⁶⁶⁾	2007-	General	CS	Conv	388	28.60
	2008	population				
Hyder, 2010 ⁽⁴⁶⁷⁾	2007-	Other general	CS	Conv	625	9.60
	2009	population/ healthy population				
Hyder, 2010 ⁽⁴⁶⁷⁾	2007-	Other general	CS	Conv	1,892	9.40
	2009	population/ healthy population				
Hyder, 2010 ⁽⁴⁶⁷⁾	2007-	Other general	CS	Conv	2,736	8.80
	2009	population/ healthy population				
Hyder, 2010 ⁽⁴⁶⁷⁾	2007-	Other general	CS	Conv	16,522	7.30
	2009	population/ healthy population				
Hyder, 2010 ⁽⁴⁶⁷⁾	2007-	Other general	CS	Conv	9,770	6.80
	2009	population/ healthy population				
Hyder, 2010 ⁽⁴⁶⁷⁾	2007-	Other general	CS	Conv	1,620	6.70
	2009	population/ healthy population				

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		healthy population				
Hyder, 2010 (467)	2007- 2009	Other general population/ healthy population	CS	Conv	445	6.70
Hyder, 2010 (467)	2007- 2009	Other general population/ healthy population	CS	Conv	24,707	6.20
Hyder, 2010 (467)	2007- 2009	Other general population/ healthy population	CS	Conv	363	5.00
Qureshi, 2010 (468)	2007- 2008	General population	CS	Multi- stage cluster sampling	24,444	4.90
Qureshi, 2010 (468)	2007- 2008	General population	CS	Multi- stage cluster sampling	22,599	4.80
Ahmed, 2012 (469)	2007- 2009	General population	CS	Multi- stage cluster	709	7.62

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Ahmed, 2012 (469)	2007- 2009	General population	CS	sampling Multi- stage cluster	1,291	4.34
Memon, 2012 (470)	2007- 2008	Outpatient clinic attendees	CS	sampling Conv	457	8.97
Saleem, 2011 (471)	2008- 2008	Outpatient clinic attendees	CS	Conv	4,230	6.08
Saleem, 2011 (471)	2008- 2008	Outpatient clinic attendees	CS	Conv	5,334	6.64
Khan, 2012 (472)	2008- 2008	Outpatient clinic attendees	CS	Conv	1,443	4.37
Ali, 2010 ⁽⁴⁷³⁾	2009- 2010	College students	CS	SRS	300	7.33
Ali, 2010 ⁽⁴⁷³⁾	2009- 2010	College students	CS	SRS	100	6.00
Rauf, 2011 ⁽⁴⁷⁴⁾	2009- 2009	Asylum seekers/refug ees	CS	Conv	290	6.20
Rauf, 2011 ⁽⁴⁷⁴⁾	2009-	Asylum	CS	Conv	300	11.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
	2009	seekers/refug ees				
Hossain, 2012 (475)	2009- 2011	Pregnant women	CS	Conv	47	12.80
Muhammad, 2012 (476)	2009- 2010	Children	CS	Conv	584	7.70
Jamil, 2010 (477)	2010- 2010	General population	CS	Conv	254	11.80
Jamil, 2010 (477)	2010- 2010	General population	CS	Conv	394	9.40
Hafeez ud, 2012 (478)	2010- 2010	Military /army personnel/ar my recruits	CS	Conv	14,027	3.13
Khan, 2013 (479)	2010- 2011	General population	CS	SRS	679	8.00
Seema, 2013 (480)	2010- 2010	Pregnant women	CS	Conv	3,078	4.70
Bhatti, 2016 (481)	2010- 2015	General population	CS	Conv	31,560	15.93
Nawaz, 2012 (482)	2011- 2011	General population	CS	Conv	435	12.20
Rauf, 2013 (483)	2011- 2011	General population	CS	Conv	117	8.50
Kumari, 2015	2012-	Pregnant	CS	Conv	300	13.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(484)	2012	women				
Azhar, 2016 (485)	2012- 2014	General population	CS	Conv	854	12.30
Ilyas, 2014 ⁽⁴⁸⁶⁾	2013- 2014	General population	CS	Conv	543	15.40
Ilyas, 2014 ⁽⁴⁸⁶⁾	2013- 2014	General population	CS	Conv	439	9.70
Gohar, 2016 (487)	2013- 2014	Industrial labor workers	CS	Conv	22,046	0.56
Ahmad, 2016 (488)	2013- 2014	Pregnant women	CS	Conv	10,288	1.42
Khan, 2018 (489)	2014- 2015	Refugees	CS	Conv & SRS	1,000	5.20
Donchuk, 2016 ⁽⁴⁹⁰⁾	2015- 2016	Outpatient clinic attendees	CS	Conv	4,589	27.00
Ghanghro, 2016 ⁽²⁰⁴⁾	2015- 2015	Pregnant women	CS	Conv	175	7.43
Parveen, 2017 (491)	2017- 2017	Pregnant women	NS	Conv	252	11.51
Parker, 1999 (492)	NS	Children	CS	Conv	538	1.30
Parker, 1999 (492)	NS	Pregnant women	CS	Conv	417	6.70
Aslam, 2005	NS	General	CS	Conv	523	14.90

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(493)		population				
Jafri, 2006 ⁽⁴⁹⁴⁾	NS	Children	CS	Conv	1,826	1.75
Jafri, 2006 ⁽⁴⁹⁴⁾	NS	Children	CS	Conv	1,707	1.35
Abbas, 2008	NS	General	CS	Systemati	471	35.90
(495)		population		c cluster sampling		
Abbas, 2008	NS	General	CS	Systemati	402	31.10
(495)		population		c cluster sampling		
Jalbani, 2009	NS	General	CS	Conv	406	30.29
(496)		population				
Abbas, 2010	NS	General	CS	Conv	504	3.17
(497)		population				
Iqbal, 2011	NS	General	CS	Conv	600	5.00
(498)		population				
Yousaf, 2011	NS	General	CS	SRS	120	29.17
(499)		population				
Abbas, 2013	NS	General	CS	Conv	1,872	7.50
(500)		population				
Abbas, 2013	NS	General	CS	Conv	928	5.90
(500)		population				
Ali, 2014 ⁽⁵⁰¹⁾	NS	General	CS	Conv	1,419	11.70
		population				
Khan, 2016	NS	General	CS	NS	205	11.71
(502)		population				

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Akhtar, 2016 (503)	NS	General population (male)	CS	Conv	139	73.38
Akhtar, 2016 (503)	NS	General population (female)	CS	Conv	91	61.54
Afsheen, 2017 (504)	NS	Pregnant women	CS	SRS	150	6.67
Afsheen, 2017 (504)	NS	Pregnant women	CS	SRS	150	6.00
Afsheen, 2017 (504)	NS	Pregnant women	CS	SRS	150	4.67
Afsheen, 2017 (504)	NS	Pregnant women	CS	SRS	150	3.33
Afsheen, 2017 (504)	NS	Pregnant women	CS	SRS	150	8.67
Palestine						
	NS	Outpatient clinic attendees	CS	SRS	124	8.87
Shemer-Avni, 1998 (223)						
Qatar						
Sharma, 2010 (505)	2008- 2009	General population	CS	Conv	7,212	0.80
Derbala, 2014 (313)	2008- 2010	Community	CS	Conv	908	8.50

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Derbala, 2014 (313)	2008- 2010	Community	CS	Conv	658	11.10
Derbala, 2014 (313)	2008- 2010	Community	CS	Conv	322	19.30
Sharma, 2014 (506)	NS	Outpatient clinic attendees	CS	Conv	4,000	0.80
Sharma, 2014 (506)	NS	Community	CS	Conv	3,212	1.00
Saudi Arabia						
Al-Faleh, 1991 (507)	1989- 1990	Children	CS	Single- stage cluster sampling	2,412	0.90
Al-Faleh, 1991 (507)	1989- 1990	Children	CS	Single- stage cluster sampling	2,084	0.80
Al Karawi, 1992 ⁽²²⁵⁾	1989- 1990	Pregnant women	CS	Conv	385	1.00
Bahakim, 2001 ⁽²²⁶⁾	1990- 1990	Pregnant women	CS	SRS	260	4.60
Al Nasser, 1992 ⁽⁵⁰⁸⁾	NS	Mixed general population	CS	Conv	441	3.60
Al Nasser,	NS	Mixed general	CS	Conv	390	3.10

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
1992 ⁽⁵⁰⁸⁾		population				
Al Nasser, 1992 ⁽⁵⁰⁸⁾	NS	Other general population/ healthy population	CS	Conv	44	4.50
Al Sohaibani, 1995 ⁽⁵⁰⁹⁾	1992- 1994	College students	CS	Conv	225	2.60
Njoh, 1997 (510)	1995- 1996	Other general population/ healthy population	CS	Conv	117	1.70
Njoh, 1997 (510)	1995- 1996	Other general population/ healthy population	CS	Conv	189	3.20
El Rifaei, 1998 (511)	1995- 1997	Other general population/ healthy population	CS	Conv	32	3.12
Ayoola, 2004 (512)	1995- 1998	Other general population/ healthy population	CC	SRS	118	3.40
Alsuhaibani, 2015 ⁽⁵¹³⁾	1996- 2014	Other general population/	CS	Conv	263	0.38

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
		healthy population				
Fakeeh, 1999 (331)	NS	Outpatient clinic attendees	CS	SRS	2,333	5.87
Fakeeh, 1999 ⁽³³¹⁾	NS	Outpatient clinic attendees	CS	SRS	284	22.54
Fakeeh, 1999 (331)	NS	Outpatient clinic attendees	CS	SRS	236	2.12
Fakeeh, 1999 (331)	NS	Outpatient clinic attendees	CS	SRS	201	4.98
Fakeeh, 1999 (331)	NS	Outpatient clinic attendees	CS	SRS	296	3.38
Qasim, 2003 (514)	NS	Military /army personnel/ar my recruits	CS	Conv	14,994	4.10
Tonsi, 2005 (515)	1999- 2001	Healthy controls	CS	SRS	65	4.60
Al Ajlan, 2011 (516)	2000- 2007	College students	CS	Conv	6,268	0.03

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Al Ajlan, 2011 (516)	2000- 2007	College students	CS	Conv	4,486	0.07
Al Ajlan, 2011 (516)	2000- 2007	College students	CS	Conv	3,584	0.31
Al Ajlan, 2011 (516)	2000- 2007	College students	CS	Conv	2,232	0.40
Khalaf, 2004 (517)	2002- 2003	Other General population/ healthy population	CS	Conv	36	5.60
Mansoor, 2011 (518)	2006- 2008	Couples undergoing fertility treatment	CS	Conv	462	1.10
Mansoor, 2011 (518)	2006- 2008	Couples undergoing fertility treatment	CS	Conv	462	0.00
Alswaidi, 2010 (519)	NS	Pre-marital screening	CS	Conv	11,771	0.35
Alswaidi, 2010 (519)	NS	Pre-marital screening	CS	Conv	1,577	0.95
Alswaidi, 2010 (519)	NS	Pre-marital screening	CS	Conv	3,434	0.67
Alswaidi,	NS	Pre-marital	CS	Conv	8,200	0.20

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2010 ⁽⁵¹⁹⁾		screening				
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	2,687	0.11
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	4,217	0.26
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	2,893	0.24
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	2,131	0.75
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	6,779	0.44
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	10,585	0.37
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	4,079	0.42
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	560	0.71
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	1,617	0.19
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	4,090	0.00
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	2,331	0.17
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	1,592	0.31

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	2,506	0.44
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	976	0.31
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	1,739	0.06
Alswaidi, 2010 ⁽⁵¹⁹⁾	NS	Pre-marital screening	CS	Conv	898	0.11
Abdel- Moneim, 2012 ⁽⁵²⁰⁾	2008- 2011	General population	CS	Conv	7,914	7.94
Abdel- Moneim, 2012 ⁽⁵²⁰⁾	2008- 2011	General population	CS	Conv	7,409	6.69
Aljarbou, 2012 ⁽⁵²¹⁾	2008- 2010	General population	CS	Conv	4,041	0.70
Aljarbou, 2012 ⁽⁵²¹⁾	2008- 2010	General population	CS	Conv	4,041	0.20
Halawani, 2014 ⁽⁵²²⁾	2008- 2010	Other General population/ healthy population	CS	Conv	50	0.00
Eisa, 2012 ⁽⁵²³⁾	2009- 2010	Pre-marital screening	CS	Conv	28,134	0.22
Al-Mandeel,	2010-	Pregnant	CS	Conv	3,051	0.07

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
2015 ⁽⁵²⁴⁾	2011	women				
Fakunle, 1991 ⁽⁵²⁵⁾	NS	General population	CS	Conv	511	1.17
Al Nasser, 1992 ⁽²⁵³⁾	NS	Pregnant women	CS	Conv	180	3.30
Al Mugeiren, 1992 ⁽⁵²⁶⁾	NS	Children	CS	Multi- stage cluster sampling	280	1.00
Al Fawaz, 1993 ⁽⁵²⁷⁾	NS	Children	CS	Conv	120	0.80
Al Faleh, 1995 ⁽⁵²⁸⁾	NS	General population	CS	Conv	705	2.30
Al Faleh, 1995 ⁽⁵²⁸⁾	NS	General population	CS	Conv	777	1.40
Bakir, 1995 ⁽⁵²⁹⁾	NS	Children	CS	Conv	168	1.20
Al Fawaz, 1996 ⁽⁵³⁰⁾	NS	Children	CS	Conv	50	6.00
Al Fawaz, 1996 ⁽⁵³⁰⁾	NS	Children	CS	Conv	143	1.40
Al Mugeiren, 1996 ⁽⁵³¹⁾	NS	Children	CC	Conv	220	1.40
Harakati, 2000 ⁽⁵³²⁾	NS	Healthy controls	CC	SRS	104	3.00

Author, year (citation)	Year(s) of data collection	Study population	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Shoobakshi, 2003 ⁽⁵³³⁾	NS	Children	CS	Conv	3,854	0.10
Shoobakshi, 2003 ⁽⁵³³⁾	NS	Pregnant women	CS	Conv	3,127	0.70
Alzahrani, 2009 ⁽⁵³⁴⁾	NS	Expat workers mandatory pre-employment screening	CS	Conv	875	0.46
Alqahtani, 2014 ⁽⁵³⁵⁾	NS	College students	CS	Conv	300	0.30
Somalia						
Bile, 1992 ⁽⁵³⁶⁾	NS	Children	NS	Conv	309	1.90
Bile, 1992 ⁽⁵³⁶⁾	NS	Children	NS	Conv	287	1.00
Aceti, 1993 ⁽⁵³⁷⁾	1988-1990	Other general population/ healthy population	NS	Conv	309	0.97
Bile, 1993 ⁽⁵³⁸⁾	1989-1989	Healthy controls	NS	Conv	62	6.50
Watts, 1994 ⁽⁵³⁹⁾	NS	Military /army personnel/army recruits	NS	Conv	79	1.30
Sudan						

Author, year (citation)	Year(s) of data collection	Study population	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
McCarthy, 1994 ⁽⁵⁴⁰⁾	1989-1989	Outpatient clinic attendees	NS	Conv	651	3.20
Omer, 2001 ⁽⁵⁴¹⁾	1996-1998	General population	NS	Single-stage cluster sampling	199	1.50
Mudawi, 2007 ⁽⁵⁴²⁾	2000-2000	General population	NS	Conv	410	2.20
Elsheikh, 2007 ⁽⁵⁴³⁾	2006-2006	Pregnant women	NS	Conv	423	0.60
Osman, 2014 ⁽⁵⁴⁴⁾	2011-2011	Pregnant women	NS	Conv	396	1.30
Mohamedani, 2014 ⁽⁵⁴⁵⁾	2014-2014	General population	NS	Conv	100	4.00
Syria						
Karim, 2008 ⁽⁵⁴⁶⁾	2004-2004	Community	CS	Multi-stage cluster sampling	2,445	0.65
Syrian Ministry of Health, 2006 ⁽⁵⁴⁷⁾	2005-2006	Community	CS	Random cluster sampling	1,217	1.56
Syrian	2005-	Community	CS	Random	763	2.10

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Ministry of Health, 2006 (⁵⁴⁷)	2006			cluster sampling		
Angeletti, 2016 (⁵⁴⁸)	2015- 2015	Asylum seekers/refug ees	CS	Conv	48	0.00
Tunisia						
Coursaget, 1990 (⁵⁴⁹)	1982- 1986	General population	CS	Conv	99	3.00
Triki, 1997 (⁵⁵⁰)	1993- 1994	Military /army personnel/ar my recruits	CS	Conv	2,230	0.31
Triki, 1997 (⁵⁵⁰)	1993- 1994	Military /army personnel/ar my recruits	CS	Conv	7,894	0.15
Gorgi, 1998 (⁵⁵¹)	1994- 1996	General population	CS	Multi- stage cluster sampling	1,203	0.09
Gorgi, 1998 (⁵⁵¹)	1994- 1996	General population	CS	Multi- stage cluster sampling	1,876	0.61

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
Mejri, 2005 (552)	1996- 1996	Population- based survey household members	CS	Populatio n-based survey	1,777	1.52
Mejri, 2005 (552)	1996- 1996	General population	CS	Populatio n-based survey	2,380	1.89
Mejri, 2005 (552)	1996- 1996	General population	CS	Populatio n-based survey	3,113	0.16
Mejri, 2005 (552)	1996- 1996	General population	CS	Populatio n-based survey	4,237	0.21
Bizid, 2015 (553)	2003- 2012	Military /army personnel/ar my recruits	CS	Conv	175,322	0.07
Kaabia, 2009 (554)	2003- 2003	Population- based survey (laboratories)	CS	Conv	1,315	0.60
Ben Alaya Bouafif, 2007 (555)	2004- 2004	Community	CS	Conv	294	3.05
Hannachi, 2011 (556)	2006- 2006	Pregnant women	CS	Conv	404	0.50

Author, year (citation)	Year(s) of data collection	Study population	Original study design ^a	Sampling	Sample size	HCV Ab prevalence (%)
Hannachi, 2010 (273)	2008-2009	Children	CC	Conv	60	0.00
Langar, 2005 (557)	NS	Healthy controls	CC	Conv	180	0.00
Samoud, 2011 (558)	NS	Healthy controls	CC	Conv	64	0.00
Triki, 1994 (278)	NS	Other General population/ healthy population	CS	Conv	735	0.40
Bettaieb, 2017 (559)	NS	Population-based survey household members	CS	Multi-stage cluster sampling	1,279	1.96
Bettaieb, 2017 (559)	NS	Population-based survey household members	CS	Multi-stage cluster sampling	1,919	4.33
Tunisia, Morocco, Algeria						
Bahri, 2011 (560)	2002-2005	Healthy controls	CC	Conv	250	4.40
United Arab Emirates						
Kumar, 1997 (352)	1994-1996	Pregnant women	CS	Conv	499	13.00
Kumar, 1998	1994-	Pregnant	CS	Conv	699	13.40

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(561)	1996	women				
Newson- Smith, 2010	NS	expat workers mandatory pre- employment screening	CS	Conv	157	4.50
(562)						
Fakhry, 2011	2008- 2010	College students	CS	Conv	1,264	0.40
(563)						
EMRO, 2011	NS	Pre-marital screening	CS	Conv	18,379	0.51
(96)						
Sheek- Hussein, 2012	2011- 2012	College students	CS	Conv	182	0.00
(564)						
Yemen						
Denis, 1994	1988- 1990	Mixed general population	NS	Conv	51	3.90
(565)						
Gray, 1999	1992- 1992	General population	NS	Conv	253	0.00
(566)						
Gray, 1999	1992- 1992	General population	NS	Conv	158	1.30
(566)						
Gray, 1999	1992- 1992	General population	NS	Conv	175	1.10
(566)						
Salem, 2009	2005- 2007	Healthy controls	NS	SRS	8,055	3.50
(567)						
Salem, 2009	2005-	Healthy	NS	SRS	12,274	4.30

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(⁵⁶⁷)	2007	controls				
Al-Nabehi, 2015 (⁵⁶⁸)	NS	General population	NS	Multi- stage cluster sampling	261	1.50
Al-Nabehi, 2015 (⁵⁶⁸)	NS	General population	NS	Multi- stage cluster sampling	171	0.60
Al-Nabehi, 2015 (⁵⁶⁸)	NS	General population	NS	Multi- stage cluster sampling	696	0.00
Gacche, 2012 (⁵⁶⁹)	2010- 2010	General population	NS	Systemati c random cluster sampling	168	0.18
Gacche, 2012 (⁵⁶⁹)	2010- 2010	General population	NS	Systemati c random cluster sampling	386	1.81
Gacche, 2012 (⁵⁶⁹)	2010- 2011	General population	NS	Systemati c random sampling	2,379	1.30
Murad, 2013	2011-	Pregnant	NS	Conv	400	8.50

Author, year (citation)	Year(s) of data collecti on	Study population	Original study design ^a	Samplin g	Sampl e size	HCV Ab prevalen ce (%)
(570)	2011	women				
Guneid, 1993 (289)	NS	Pregnant women	NS	Conv	243	3.30
Guneid, 1993 (289)	NS	Other General population/ healthy population	NS	NS	537	2.10
Al-Moslih, 2001 ⁽⁵⁷¹⁾	NS	Healthy controls	NS	Conv	120	4.20

Abbreviations: Ab, antibody; AIDS, acquired immune deficiency syndrome; CC, case-control; Coh, cohort; Conv, convenience; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MENA, Middle East and North Africa; NS, not specified; SRS, simple random sampling.

^aThe reported study design is the original study design (case control, cross sectional, cohort, or randomized controlled trial). The included prevalence measures are those for the baseline measures at the beginning of the study.

Table S3. Studies reporting HCV viremic rate in blood donors and the general population in Middle East and North Africa.

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
Blood donors				
Tanaka, 2004 (16)	1999- 1999	Egypt	317	71.00
Obied, 2014 (120)	2012- 2013	Fertile Crescent	20	65.00
Tawfeeq, 2013 (119)	2011- 2012	Fertile Crescent	45	68.90
Rashdan, 2008 (128)	2004- 2006	Fertile Crescent	29	89.60
Shemer-Avni, 1998 (223)	NS	Fertile Crescent	34	71.00
Doosti, 2009 (69)	2003- 2004	Iran	66	62.00
Farshadpour, 2010 (90)	2007- 2008	Iran	55	81.82

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
Karim, 2016 ⁽⁵⁷²⁾	2015- 2015	Pakistan	60	93.00
Other General populations				
Abdel-Aziz, 2000 ⁽³⁰¹⁾	1997- 1997	Egypt	973	65.50
AbdulQawi, 2011 ⁽³⁰³⁾	2003- 2008	Egypt	105	79.00
Agha, 1998 ⁽³⁰⁴⁾	1996- 1997	Egypt	105	26.87
Aguilar, 2008 ⁽³⁰⁵⁾	NS	Egypt	40	67.50
Aguilar, 2008 ⁽³⁰⁵⁾	NS	Egypt	34	72.00
Arafa, 2005 ⁽³⁰⁶⁾	2002- 2003	Egypt	475	59.90
Barakat, 2011	2005-	Egypt	29	75.90

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
⁽³⁰⁷⁾	2005			
Cowgill, 2004	1999-	Egypt	80	65.00
⁽³⁰⁹⁾	2003			
Darwish, 1995	NS	Egypt	41	76.00
⁽³¹⁰⁾				
Derbala, 2014	2008-	Egypt	315	100
⁽³¹³⁾	2010			
El-Kamary, 2015 ⁽³¹⁹⁾	2012- 2013	Egypt	52	58.00
El-Karaksy, 2010 ⁽³²⁰⁾	2006- 2007	Egypt	15	33.30
el-Sadawy, 2004 ⁽³²³⁾	NS	Egypt	367	29.70
El-Sherbini, 2003 ⁽³²⁷⁾	1994- 1994	Egypt	17	41.00
El-Zanaty, 2008 ⁽³²⁸⁾	2008- 2008	Egypt	182	67.79

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
El-Zanaty, 2008 (328)	2008- 2008	Egypt	145	66.90
El-Zanaty, 2008 (328)	2008- 2008	Egypt	140	70.20
El-Zanaty, 2008 (328)	2008- 2008	Egypt	129	69.32
El-Zanaty, 2008 (328)	2008- 2008	Egypt	122	65.20
El-Zanaty, 2008 (328)	2008- 2008	Egypt	116	60.01
El-Zanaty, 2008 (328)	2008- 2008	Egypt	114	68.75
El-Zanaty, 2008 (328)	2008- 2008	Egypt	96	62.85
El-Zanaty, 2008 (328)	2008- 2008	Egypt	87	70.44
El-Zanaty, 2008	2008-	Egypt	75	76.66

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	70	62.60
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	70	73.78
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	58	53.61
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	54	66.15
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	52	61.12
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	40	65.03
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	32	74.61
(328)	2008			
El-Zanaty, 2008	2008-	Egypt	28	71.08
(328)	2008			

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
El-Zanaty, 2015 (329)	2015- 2015	Egypt	207	74.99
El-Zanaty, 2015 (329)	2015- 2015	Egypt	185	66.45
El-Zanaty, 2015 (329)	2015- 2015	Egypt	162	66.35
El-Zanaty, 2015 (329)	2015- 2015	Egypt	155	63.68
El-Zanaty, 2015 (329)	2015- 2015	Egypt	114	69.48
El-Zanaty, 2015 (329)	2015- 2015	Egypt	108	69.82
El-Zanaty, 2015 (329)	2015- 2015	Egypt	100	75.07
El-Zanaty, 2015 (329)	2015- 2015	Egypt	80	73.35
El-Zanaty, 2015	2015-	Egypt	71	81.13

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
(329)	2015			
El-Zanaty, 2015 (329)	2015- 2015	Egypt	73	73.92
El-Zanaty, 2015 (329)	2015- 2015	Egypt	64	57.49
El-Zanaty, 2015 (329)	2015- 2015	Egypt	80	78.15
El-Zanaty, 2015 (329)	2015- 2015	Egypt	63	69.68
El-Zanaty, 2015 (329)	2015- 2015	Egypt	40	68.43
El-Zanaty, 2015 (329)	2015- 2015	Egypt	40	66.06
El-Zanaty, 2015 (329)	2015- 2015	Egypt	24	72.82
El-Zanaty, 2015 (329)	2015- 2015	Egypt	18	42.57

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
El-Zanaty, 2015 (329)	2015- 2015	Egypt	16	78.01
El-Zanaty, 2015 (329)	2015- 2015	Egypt	10	70.55
El-Zanaty, 2015 (329)	2015- 2015	Egypt	11	67.11
El-Zanaty, 2015 (329)	2015- 2015	Egypt	17	27.54
Jhaveri, 2015 (344)	2012- 2014	Egypt	98	55.00
Kalil, 2010 ⁽³⁴⁵⁾	2004- 2005	Egypt	121	72.00
Kassem, 2000 (348)	1996- 1996	Egypt	19	73.70
Khamis, 2014 (350)	NS	Egypt	22	45.00
Kumar, 1997	1994-	Egypt	65	31.00

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
⁽³⁵²⁾	1996			
Nafeh, 2000 ⁽³⁵⁸⁾	NS	Egypt	522	63.00
Strickland, 2002 ⁽³⁶⁶⁾	NS	Egypt	99	74.70
Zuure, 2013 ⁽³⁶⁹⁾	2009- 2010	Egypt	11	90.91
Shemer-Avni, 1998 ⁽²²³⁾	NS	Fertile Crescent	11	64.00
Baha, 2013 ⁽¹⁴⁸⁾	2005- 2011	Maghreb	651	70.90
Benouda, 2009 ⁽⁴⁴¹⁾	2005- 2007	Maghreb	161	39.24
Mejri, 2005 ⁽⁵⁵²⁾	1996- 1996	Maghreb	72	82.00
Mejri, 2005 ⁽⁵⁵²⁾	1996- 1996	Maghreb	14	71.40
Aziz, 2011 ⁽⁴⁶⁰⁾	2005-	Pakistan	1,043	79.70

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
	2009			
Donchuk, 2016 (490)	2015- 2016	Pakistan	1,107	89.00
Idrees, 2008 (450)	1999- 2007	Pakistan	857	49.24
Idrees, 2008 (450)	1999- 2007	Pakistan	141	50.35
Khokhar, 2004 (452)	2001- 2002	Pakistan	24	72.00
Rauf, 2011 (474)	2009- 2009	Pakistan	34	50.00
Rauf, 2011 (474)	2009- 2009	Pakistan	18	44.40
Bhatti, 2016 (481)	2010- 2015	Pakistan	5,028	85.80
Afsheen, 2017 (504)	NS	Pakistan	44	22.73

Author, year (citation)	Year(s) of data collecti on	Subregio n	Numb er of HCV antibo dy- positiv e popula tions tested for RNA	HCV viremic rate (%)
Khan, 2018 ⁽⁴⁸⁹⁾	2014- 2015	Pakistan	52	75.00

Abbreviations: HCV, hepatitis C virus; MENA, Middle East and North Africa; NS, not specified; RNA, Ribonucleic acid.

References

1. Dupire B, Abawi AK, Ganteaume C, Lam T, Truze P, Martet G. [Establishment of a blood transfusion center at Kabul (Afghanistan)]. *Sante (Montrouge, France)*. 1999;9(1):18-22.[PMID: 10210798,doi:
2. Attaullah S, Rehman S, Khan S, Ali I, Ali S, Khan SN. Prevalence of hepatitis B virus genotypes in HBsAg positive individuals of Afghanistan. *Virology journal*. 2011;8:281.[PMID: 21649888,doi: 10.1186/1743-422x-8-281]
3. Central Blood Bank. Kabul, Afghanistan: Ministry of Public Health; 2015.
4. Afghanistan National AIDS Control Program. UNGASS Country Progress Report 2010: Islamic Republic of Afghanistan. Islamic Republic of Afghanistan: Ministry of Public Health, Director General of Preventive Medicine & Primary Health Care, Communicable Disease Directorate (CDC); 2010.
5. Ayed Z, Houinato D, Hocine M, Ranger-Rogez S, Denis F. [Prevalence of serum markers of hepatitis B and C in blood donors and pregnant women in Algeria]. *Bulletin de la Societe de pathologie exotique (1990)*. 1995;88(5):225-8.[PMID: 8646011,doi:
6. Bouali S, Hammadi M, Deba T. Seroprevalence of hepatitis C virus among blood donors in Oran, algeria: From 2009 to 2012.[PMID,doi:
7. Dray X, Dray-Spira R, Bronstein JA, Mattera D. [Prevalences of HIV, hepatitis B and hepatitis C in blood donors in the Republic of Djibouti]. *Medecine tropicale : revue du Corps de sante colonial*. 2005;65(1):39-42.[PMID: 15903075,doi:
8. Dray X, Dray-Spira R, Bronstein J, Mattera D. Prevalences of HIV, hepatitis B and hepatitis C in blood donors in the Republic of Djibouti. *Medecine tropicale: revue du Corps de sante colonial*. 2005;65(1):39-42.[PMID,doi:
9. el Gohary A, Hassan A, Nooman Z, Lavanchy D, Mayerat C, el Ayat A, et al. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. *Acta tropica*. 1995;59(2):155-61.[PMID: 7545863,doi:
10. Quinti I, Renganathan E, El Ghazzawi E, Divizia M, Sawaf G, Awad S, et al. Seroprevalence of HIV and HCV infections in Alexandria, Egypt. *Zentralblatt fur*

Bakteriologie : international journal of medical microbiology. 1995;283(2):239-44.[PMID: 8825115,doi:

11. Abdelaal M, Rowbottom D, Zawawi T, Scott T, Gilpin C. Epidemiology of hepatitis C virus: a study of male blood donors in Saudi Arabia. *Transfusion*. 1994;34(2):135-7.[PMID: 8310483,doi:
12. Arthur RR, Hassan NF, Abdallah MY, el-Sharkawy MS, Saad MD, Hackbart BG, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1997;91(3):271-4.[PMID: 9231192,doi:
13. Al Omar AS, El Zuebi F. Disease markers in blood donors at King Fahad Hospital, Al Baha. *Annals of Saudi medicine*. 1996;16(1):37-41.[PMID: 17372401,doi:
14. Mehdi SR, Pophali A, Al-Abdul Rahim KA. Prevalence of hepatitis B and C and blood donors. *Saudi medical journal*. 2000;21(10):942-4.[PMID: 11369958,doi:
15. El Damaty SI, Hassan SK, Mohamed MK, El Hosini M, Rekacewicz C, Fontanet A. Surveillance system for HCV infection: testing a model based on blood banks. *The Journal of the Egyptian Public Health Association*. 2007;82(5-6):451-71.[PMID: 18706299,doi:
16. Tanaka Y, Agha S, Saady N, Kurbanov F, Orito E, Kato T, et al. Exponential spread of hepatitis C virus genotype 4a in Egypt. *Journal of molecular evolution*. 2004;58(2):191-5.[PMID: 15042339,doi: 10.1007/s00239-003-2541-3]
17. Khattab MA, Eslam M, Sharwae MA, Hamdy L. Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. *American journal of infection control*. 2010;38(8):640-1.[PMID: 20400204,doi: 10.1016/j.ajic.2009.12.016]
18. Eissa SA, Abdel Meguid LM, Ebeid SM, Abou Elfetouh RM, Abdel Moneim GM. National Cancer Institute Experience in Healthy Egyptian Blood Donors as Regards Blood Group Frequencies and Seroprevalence of Hepatitis B Virus, Hepatitis C Virus&HIV: 10 Year Evaluation. *Journal of the Egyptian National Cancer Institute*. 2007;19(1):71-6.[PMID: 18839037,doi:

19. Ismail AM, Ziada HN, Sheashaa HA, Shehab El-Din AB. Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: a glimmer of hope. *European journal of internal medicine*. 2009;20(5):490-3.[PMID: 19712851,doi: 10.1016/j.ejim.2009.03.005]
20. El-Gilany AH, El-Fedawy S. Bloodborne infections among student voluntary blood donors in Mansoura University, Egypt. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2006;12(6):742-8.[PMID: 17333818,doi: 10.1016/j.ejim.2009.03.005]
21. Eita N. Prevalence of HCV and HBV infections among blood donors in Dakahilia, Egypt. *Vox Sanguinis*. 2009;96:106-7.[PMID: 70097498,doi: <http://dx.doi.org/10.1111/j.1423-0410.2009.01156.x>]
22. El-Zayadi AR, Ibrahim EH, Badran HM, Saeid A, Moneib NA, Shemis MA, et al. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. *Transfusion medicine (Oxford, England)*. 2008;18(1):55-61.[PMID: 18279193,doi: 10.1111/j.1365-3148.2007.00806.x]
23. Hussein E. Blood donor recruitment strategies and their impact on blood safety in Egypt. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2014;50(1):63-7.[PMID: 24325889,doi: 10.1016/j.transci.2013.11.005]
24. Rushdy O, Moftah F, Zakareya S. Trasmitted transfused viral infections among blood donors during years 2006 and 2007 in suez canal area, Egypt. *Vox Sanguinis*. 2009;96:86-7.[PMID: 70097448,doi: <http://dx.doi.org/10.1111/j.1423-0410.2009.01156.x>]
25. Ashour D, Moftah F, Gobran H, Ekram D. Decreasing the risk of transfusion transmitted infections (TTIS) in the Egyptian Blood Transfusion Services. *Vox Sanguinis*. 2009;96:103-4.[PMID: 70097491,doi: <http://dx.doi.org/10.1111/j.1423-0410.2009.01156.x>]
26. Wasfi OA, Sadek NA. Prevalence of hepatitis B surface antigen and hepatitis C virus antibodies among blood donors in Alexandria, Egypt. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2011;17(3):238-42.[PMID: 21735965,doi: 10.1016/j.ejim.2009.03.005]

27. Elkareh S. HCv screening of donors in Governmental Blood Transfusion Centers at Menoufia Governorate (from Jan. 2008 to Oct. 2008). *Vox Sanguinis*. 2009;96:89-90.[PMID: 70097457,doi: <http://dx.doi.org/10.1111/j.1423-0410.2009.01156.x>]
28. Abdel Messih IY, Ismail MA, Saad AA, Azer MR. The degree of safety of family replacement donors versus voluntary non-remunerated donors in an Egyptian population: a comparative study. *Blood transfusion = Trasfusione del sangue*. 2014;12(2):159-65.[PMID: 23245714,doi: 10.2450/2012.0115-12]
29. Hamed H. Detection of occult hepatitis B virus infection and prevalence of hepatitis B surface antigen and hepatitis c virus antibodies among blood donors in south egypt. *Transfusion Medicine*. 2012;22:52.[PMID: 70950130,doi: <http://dx.doi.org/10.1111/cyt.12004>]
30. El-Shanshory MR, Kabbash IA, Soliman HH, Nagy HM, Abdou SH. Prevalence of hepatitis C infection among children with beta-thalassaemia major in Mid Delta, Egypt: a single centre study. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2013;107(4):224-8.[PMID: 23343507,doi: 10.1093/trstmh/trs024]
31. Teruya J, Hussein EA. Blood supply operation during egyptian revolution. *Transfusion*. 2011;51:249A.[PMID: 70539514,doi: http://dx.doi.org/10.1111/j.1537-2995.2011.03301_2.x]
32. Maha AR, El Kareh S, Afaf A, Ahmed A. Evaluation of hcv reactive donors according to type of donor, gender (SEX) and age groups at shebin EL KOM regional blood transfusion center (RBTC) (from january 2011 to december 2011). *Vox Sanguinis*. 2012;103:171.[PMID: 71016194,doi: <http://dx.doi.org/10.1111/j.1423-0410.2012.01615-2.x>]
33. Farouk Badr R. Safety of vnrbdvs versus family replacement blood donors in Egypt, evidence based approach. *Vox Sanguinis*. 2013;105:104.[PMID: 71070096,doi: <http://dx.doi.org/10.1111/vox.12048>]
34. Farouk Badr R, Farouk R, Ahmed Ali A. Evaluation of nucleic acid testing to detect HBV infections in egyption blood donors. *Vox Sanguinis*. 2015;109:210-1.[PMID: 71948127,doi:

35. Agha S, El-Mashad N, El-Malky M, El-Shony H, El-Sherif MZ, El-Hasan MA, et al. Prevalence of low positive anti-HCV antibodies in blood donors: Schistosoma mansoni co-infection and possible role of autoantibodies. *Microbiology and immunology*. 2006;50(6):447-52.[PMID: 16785716,doi:
36. el-Zayadi AR, Selim O, Ibrahim EH, Hamdy H, Dabbous H, Ahdy A, et al. Does schistosomiasis play a role in the high sero prevalence of HCV antibody among Egyptians? *Tropical gastroenterology : official journal of the Digestive Diseases Foundation*. 1997;18(3):98-100.[PMID: 9385849,doi:
37. Darwish NM, Abbas MO, Abdelfattah FM, Darwish MA. Hepatitis C virus infection in blood donors in Egypt. *The Journal of the Egyptian Public Health Association*. 1992;67(3-4):223-36.[PMID: 1296960,doi:
38. Awadalla HI, Ragab MH, Nassar NA, Osman MA. Risk factors of hepatitis C infection among Egyptian blood donors. *Central European journal of public health*. 2011;19(4):217-21.[PMID: 22432397,doi:
39. El-Zayadi A, Osaima S, Hess G, Zdunek D, Ahdy A. Seroprevalence of anti-HGV E2 and HGV RNA among Egyptian blood donors. *LaboratoriumsMedizin*. 1998;22(6):363-5.[PMID: 1998235010,doi:
40. Attia MA, Zekri AR, Goudsmit J, Boom R, Khaled HM, Mansour MT, et al. Diverse patterns of recognition of hepatitis C virus core and nonstructural antigens by antibodies present in Egyptian cancer patients and blood donors. *Journal of clinical microbiology*. 1996;34(11):2665-9.[PMID: 8897161,doi:
41. Al-Knawy B, El Mekki AA, Hamdi J, Thiga R, Sheikha A. Prevalence of antibody to hepatitis C virus in Saudi blood donors, PREVALENCE DE L'ANTICORPS ANTI-VIRUS DE L'HEPATITE C CHEZ DES DONNEURS DE SANG SAOUDIENS. *Canadian Journal of Gastroenterology*. 1995;9(3):141-3.[PMID: 1995168583,doi:
42. Hashish MH, El-Barrawy MA, Mahmoud OA, Abdel Rahman NW. TT virus among blood donors in Alexandria. *The Journal of the Egyptian Public Health Association*. 2005;80(5-6):651-64.[PMID: 17187747,doi:

43. Hagag SA, Koura SK, Abdel Hameed MF. Seroprevalence of hepatitis C virus infection among the volunteer blood donors in Zagazig. *Zagazig University Medical Journal* 1998;4(7):199-209.[PMID,doi:
44. Bassily S, Hyams KC, Fouad RA, Samaan MD, Hibbs RG. A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. *The American journal of tropical medicine and hygiene*. 1995;52(6):503-5.[PMID: 7541968,doi:
45. Ahmad MS, Mahtab AM, Abdullatif AS, Tashkandy MA, Kashreed MS, Maulana A. Prevalence of antibodies against the hepatitis C virus among voluntary blood donors at a makkah hospital. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 1995;6(2):122-4.[PMID: 18583848,doi:
46. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: A case-control study. *Journal of gastroenterology and hepatology*. 2002;17(10):1092-7.[PMID: 2002327941,doi:
47. Afzali H, Ardakani AT, Vali GR. Seroepidemiology of hepatitis B and C in blood donors in Kashan, 1996-2001. *Feyz Journals of Kashan University of Medical Sciences*. 2002;6(3).[PMID,doi:
48. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. *Journal of Viral Hepatitis*. 2002;9(5):390-2.[PMID: 2002337716,doi:
49. Mansour-Ghanaei F, Fallah M-S, Jafarshad R, Joukar F, Salari A, Tavafzadeh R. Prevalence of hepatitis B surface antigen and hepatitis C virus antibody and their risk factors among Guilan's volunteer blood donors (1998-2003). *Hepatitis monthly*. 2007;7(4):239-41.[PMID,doi:
50. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-ihhiyah li-sharq al-mutawassi*. 2000;6(5-6):1114-6.[PMID: 12197336,doi:

51. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Hepatitis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. *World Journal of Gastroenterology*. 2006;12(43):7025-8.[PMID: 2006586348,doi:
52. Tahereh Vahid M, Seyed-Moayed Alavian M, Ali Kabir M, Jafar Kafaee M. Hepatitis B Prevalence and Risk Factors in Blood Donors in Ghazvin, IR. Iran. *Hepatitis monthly*. 2005;5(4):117-22.[PMID,doi:
53. Rahnema Z, Esfandiarpour I, Farajzadeh S. The relationship between lichen planus and hepatitis C in dermatology outpatients in Kerman, Iran. *International Journal of Dermatology*. 2005;44(9):746-8.[PMID: 2005415908,doi:
54. Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. *International Journal of Drug Policy*. 2004;15(2):151-5.[PMID: 2004133202,doi:
55. Emamghorashi F, Fathi G, Mohtashami A. Evaluation of demographic characteristics and hepatitis B, C and HIV prevalence among blood donors in Jahrom. *SJIBTO*. 2006;2:373-8.[PMID,doi:
56. Pourshams A, Malekzadeh R, Monavvari A, Akbari MR, Mohamadkhani A, Yarahmadi S, et al. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. *Journal of gastroenterology and hepatology*. 2005;20(2):229-33.[PMID: 2005116984,doi:
57. Moniri R, Mosayebii Z, Mossavi G. Seroprevalence of cytomegalovirus, hepatitis B, hepatitis C and human immunodeficiency virus antibodies among volunteer blood donors. *Iranian journal of public health*. 2004;33(4):38-42.[PMID,doi:
58. Farajzadeh S, Shakibi MR, Moghaddam SD, Rahnema Z. Behcet disease: clinical spectrum and association with hepatitis B and C viruses. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2005;11(1-2):68-72.[PMID: 16532673,doi:

59. Masaeli Z, Jaberi M, Magsudlu M. A comparison of seroprevalence of blood-borne infections among regular, sporadic, and first-time blood donors in Isfahan. 2006.[PMID,doi:
60. Salehi H, Salehi M, Ardestani MK, Khorvash F, Zadeh KM. Comparing the Blood Safety on the Blood Donors within the Religious Ceremonies and Routine Conditions. *Journal of Isfahan Medical School*. 2011;28(122).[PMID,doi:
61. Aghajaanipour K, Zandieh T. Seroepidemiology of hepatitis B, C and HIV in healthy blood donors in Babol city center in 2002 [Persian]. *Blood Quarterly Journal*. 2006;2(7):339-41.[PMID,doi:
62. Barhaghtalab MY, Saboori S, Damiri M, Ekrahi M. Prevalence of Viral Markers for Hepatitis B and C in Healthy Volunteer Blood Donors in Fasa Region, South Iran. *International Journal of Infectious Diseases*. 2008;12:e87.[PMID,doi:
63. Mahmoodian-Shooshtari M, Pourfathollah A. An overview analysis of blood donation in the Islamic Republic of Iran. *Archives of Iranian medicine*. 2006;9(3):200-3.[PMID: 2006356593,doi:
64. Delavari M, Tabatabaei S. Frequency of hepatitis C and its related factors in blood donors in Kerman in 2003. 2004.[PMID,doi:
65. Taheri Azbarmi Z, Sh N, Joukar F, Jafashad R, Haajikarimian K, Alinezhad S. Transfusion transmitted disease in Rasht blood donors. *The Scientific Journal of Iranian Blood Transfusion Organization*. 2008;4(5):337-43.[PMID,doi:
66. Kazemi Nejad V AHR, Molana A, Dehbashi GR. Frequency of Hepatitis B virus, Hepatitis C virus and human immunodeficiency virus in blood donors and patients in Gorgan Blood Transfusion Organization in 2003 (in Persian). *Journal of Gorgan University of Medical Sciences*. 2005;15:84-6.[PMID,doi:
67. Habibzadeh S, Davarnia B, JS B, G K. Epidemiological evaluation of transfusion transmitted diseases in Ardabil in Tasoua and Ashoura 1381 (2003). *The Scientific Journal of Iranian Blood Transfusion Organization*. 2005;1(2):55-60.[PMID,doi:

68. Kasraian L. National disasters in Iran and blood donation: Bam earthquake experience. *Iranian Red Crescent Medical Journal*. 2010;12(3):316-8.[PMID: 2010324207,doi:
69. Doosti A, Arnini-Bavil-Olyae S, Tajbakhsh E, Adeli A, Mahboudi F. Prevalence of viral hepatitis and molecular analysis of HBV among voluntary blood donors in west Iran. *New Microbiologica*. 2009;32(2):193-8.[PMID: 19579699,doi:
70. Mowla K, Hajiani E. Prevalence of Hepatitis C Virus Infection in Patients with Systemic Lupus Erythematosus: A Case-Control Study. *Hepatitis monthly*. 2008;8(1):41-4.[PMID,doi:
71. Khedmat H, Alavian SM, Miri SM, Amini M, Abolghasemi H, Hajibeigi B, et al. Trends in seroprevalence of hepatitis B, hepatitis C, HIV, and syphilis infections in Iranian blood donors from 2003 to 2005. *Hepatitis monthly*. 2009;9(1):24-8.[PMID: 2009311536,doi:
72. Gachkar L, Taremi M, MAHMOODARABI S, KHERADPEZHOUH M, KHOUSHBATEN M, DEHKHODA R, et al. Frequency of antibodies to hepatitis E virus among male blood donors in Tabriz. 2005.[PMID,doi:
73. Metanat M, SHARIFIMOUD B, SANEI ME, ALAVI NR, NADERI M, Khosravi S, et al. Prevalence of hepatitis C among diabetes mellitus patients in Zahedan. 2006.[PMID,doi:
74. Javadzadeh Shahshahani H, Vaziri M, Mansouri F. Seven Years Trends in Prevalence of Transfusion-Transmissible Viral Infections in Yazd blood Transfusion Organization. *Iranian journal of pediatric hematology and oncology*. 2013;3(3):119-24.[PMID: 24575283,doi:
75. Amini Kafi-Abad S, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. *Transfusion*. 2009;49(10):2214-20.[PMID: 2009560243,doi:

76. Karimi A, Hoseini SM. Seroprevalence of hepatitis B and C virus and HIV markers among blood donors from Shahre-Kord, Iran (2004-2006). *Kuwait Medical Journal*. 2008;40(4):285-7.[PMID: 2009422696,doi:
77. Maneshi HO, Zare S, Karimi M, Hajiani GR. HBV and HCV viral markers seroprevalence in first-time healthy blood donors referred to transfusion centers of bushehr province, South of Iran (April 2004 to March 2008). *Retrovirology*. 2010;7:P151.[PMID: 70261866,doi:
78. Rezazadeh M, MANI KK, Mohammadi A, Zandvakili H, Lotfi A, Bahrami H, et al. Prevalence of human immunodeficiency, hepatitis B and hepatitis C viruses in the first time, repeat and regular donors in blood transfusion center, Hamadan, 2004-2005. 2006.[PMID,doi:
79. Tajbakhsh E, Yaghobi R, Vahedi AR. A serological survey on hepatitis C virus Antibody in blood donors with an ELISA method. *Tehran University Medical Journal*. 2007;65(8):69-73.[PMID,doi:
80. Ghaderi R, Makhmalbaf Z. The Relationship between Lichen Planus and Hepatitis C in Birjand, Iran. *Shiraz E-Med J*. 2007;8(2):72-9.[PMID,doi:
81. Farshadpour F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, Hajiani G, Sharifi N, et al. Prevalence and trends of transfusion-transmissible viral infections among blood donors in south of Iran: an eleven-year retrospective study. *PloS one*. 2016;11(6):e0157615.[PMID,doi:
82. Assarehzadegan MA, Shakerinejad G, Amini A, Rezaee SAR. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, Southwest Iran. *International Journal of Infectious Diseases*. 2008;12(4):387-90.[PMID: 2008273285,doi:
83. Sorouri Zanjani R, Mazloomzadeh S, Koocheki A, Noori M. Prevalence of Hepatitis B, C and HIV Infection in Blood Donors in Zanjan, 2005-2006. *Preventive Care in Nursing & Midwifery Journal*. 2013;3(1):56-63.[PMID,doi:
84. Ardebili M, Fattahi MR, Khademolhosseini F, Shirazi ZH, Doust FM. Hepatitis C infection in a rural population in southern Iran: A report from kavar cohort study. *Hepatology International*. 2012;6 (1):154.[PMID: 70812328,doi:

85. Mohammadali F, Pourfathollah A. Association of ABO and Rh blood groups to blood-borne infections among blood donors in Tehran-Iran. *Iranian journal of public health*. 2014;43(7):981.[PMID,doi:
86. Khedmat H, Fallahian F, Abolghasemi H, Alavian SM, Hajibeigi B, Miri SM, et al. Seroepidemiologic study of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis infections in Iranian blood donors. *Pakistan Journal of Biological Sciences*. 2007;10(24):4461-6.[PMID: 19093512,doi:
87. Ghafouri M, Ameli M. Comparing prevalence of transfusion transmitted viral infections in various population groups of South Khorasan. 2011.[PMID,doi:
88. Esmaili H, Hajiani G, Mankhian A, Poumehdi Broujeni M. Seroepidemiological survey of hepatitis B, C, HIV and syphilis among blood donors in Bushehr-Iran. *ISMJ*. 2009;11(2):183-90.[PMID,doi:
89. Kasraian L, Tavassoli A. Prevalence of hepatitis C and its risk factors in blood donors at Shiraz transfusion center. *Koomesh*. 2008;10(1):Pe7-Pe12, En2.[PMID,doi:
90. Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. *Indian Journal of Medical Microbiology*. 2010;28(1):54-6.[PMID: 2010071877,doi:
91. Aghamohamad A, Montazeri M, Akbari M. Prevalence of hepatitis B and hepatitis C in blood donors at Semnan province from 2008 to 2011. [Persian]. *Koomesh*. 2014;15(2):162-7.[PMID: 2014593455,doi:
92. Sofian M, Aghakhani A, Izadi N, Banifazl M, Kalantar E, Eslamifar A, et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. *International Journal of Infectious Diseases*. 2010;14(4):e308-e10.[PMID: 2010173911,doi:
93. Keshvari M, Sharafi H, Alavian SM, Mehrabadi H, Zolfaghari S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. *Transfusion and Apheresis Science*. 2015;53(1):38-47.[PMID,doi:
94. Bozorgi SH, Ramezani H, Nooranipour M, Ahmadi M, Baghernejad A, Mostajeri A, et al. Risk factors of viral hepatitis: yet to explore. *Transfusion and apheresis science* :

official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2012;47(2):145-9.[PMID: 22858443,doi: 10.1016/j.transci.2012.06.023]

95. Seyed-Askari SM, Beigzadeh A, Mohammadpoor-Ravari M. The prevalence of transfusion transmitted infections among blood donors in Kerman, Iran. *Journal of Kerman University of Medical Sciences*. 2015;22(6):669-76.[PMID,doi:

96. Additional country-level data provided through the MENA HIV/ AIDS Epidemiology Synthesis Project database by the World Health Organization Regional Office for the Eastern Mediterranean. 2014.[PMID,doi:

97. Rezaie M. Prevalence of hepatitis B, hepatitis C and HIV in blood donors in Semnan Province (Iran) from 2011 to 2015. *Koomesh*. 2016:501-8.[PMID,doi:

98. Samadi M, Ghasemzade A, Sarizade G, Ebrahimi S, Saati S, Abassinejad-Pour A, et al. The comparison of the prevalence rates of HBV, HCV, and HIV in blood donors having deferred for high risk behaviors. *Scientific Journal of Iranian Blood Transfusion Organization*. 2014;10(4):347-52.[PMID,doi:

99. Amini S, Mahmoodabadi SA, Lamian S, Joulaie M, Farahani MM. Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. *Iranian journal of public health*. 2005;34(4):41-6.[PMID: 2006060851,doi:

100. Mogaddam MR, Anamzade F. Survey of relationship between hepatitis C and lichen planus among dermatology outpatients of Imam Hospital of Ardabil city. *Journal of Pakistan Association of Dermatologists*. 2010;20(1):19-22.[PMID: 2010326287,doi:

101. Hassan A. S. Prevalence of anti-hepatitis C virus antibodies among blood donors and risky groups in Diyala. *Journal of the Faculty of Medicine of Baghdad*. 2008;50(4):467-70.[PMID,doi:

102. Abdul-Aziz M, Abdul-Karem K, Shamse-El-Den S, Al-Moula GA. Prevalence of hepatitis B & C among people attending Kirkuk Public Health Laboratory. *Al-Taqani*. 2001;23(3):6-15.[PMID,doi:

103. Chiad I. A., Al-Rubaii A., Al-Ani W., Al-Jaf A. A., Kadhem M. Sero-prevalence of hepatitis B virus, hepatitis C virus and human immuno deficiency virus infections

- among blood donors in the National Center of Blood Transfusion in Baghdad. *Iraqi Journal of Community Medicine*. 2009;22(4):215-7.[PMID,doi:
104. Al-Doori A.M. Prevalence of hepatitis B and hepatitis C among blood donors in Al-Anbar governorate. *Journal of the Faculty of Medicine of Baghdad*. 2006;48(2):149-51.[PMID,doi:
105. Aljooani O. AA., Al-Hayani N. N., Mohammed M. J. The infection with HBV and HCV and their relationship to ABO blood group among blood donors. *Journal of the Faculty of Medicine of Baghdad*. 2012;54(1):52-6.[PMID,doi:
106. Abdullah B. A., Khaled M. D., Maarouf M. N. Detection of hepatitis C virus (HCV) by ELISA, RIBA and Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) technique among kidney dialysis patients in Nineveh governorate/Iraq. *Science Journal of Thi-Qar* 2012;3(2):55-67.[PMID,doi:
107. Ataallah TM, Hanan KA, Maysoun KS, Sadoon AA. Prevalence of hepatitis B and C among blood donors attending the National Blood Transfusion Center in Baghdad, Iraq from 2006-2009. *Saudi medical journal*. 2011;32(10):1046-50.[PMID: 22008925,doi:
108. Hussein A. H. Seroprevalence of hepatitis B and C viruses among blood donors in Sulaimani Major Blood Bank for the years 2006 and 2007: a comparative study. *Journal of Zankoy Sulaimani*. 2010;13(1):15-20.[PMID,doi:
109. Al-Kamil E. A., Al-Yassin A. K. Transfusion transmitted diseases among blood donors of Basrah blood bank. *Journal of the Arab Board of Health Specializations*. 2011;12(1):35-40.[PMID,doi:
110. Ali MK. Prevalence of hepatitis B and hepatitis C among blood donors in Baghdad, August 2007-December 2008. *Journal of the Faculty of Medicine of Baghdad University*. 2009;51(4):419-22.[PMID,doi:
111. Al-Juboury A. W. F., Salih H. A. L. M., Al-Assadi M. K., Ali A. M. Seroprevalence of Hepatitis B and C among blood donors in Babylon Governorate-Iraq. *Medical Journal of Babylon*. 2010;7(1-2).[PMID,doi:
112. Salih N. I., Saadoon I. H. Seroprevalence of hepatitis C virus among risk groups in Mosul city. *Tikrit Journal of Pharmaceutical Sciences*. 2007;3(2):138-41.[PMID,doi:

113. Amin RM. Prevalence of HBV and HCV in blood donors in Mosul city. *Al-Taqani*. 2012;25(2):70-7.[PMID,doi:
114. Hamim S. S. Seroprevalence of hepatitis B and C among blood voluntaries in Iraq for 2008 and 2009. *Journal of College of Education for Pure Science*. 2012;2(2):125-4.[PMID,doi:
115. Hussain S. M., Hasan A. Does hepatitis C virus infection is a relevant factor for thyroid dysfunction. *Diyala Journal for Pure Science*. 2010;6(3):140-5.[PMID,doi:
116. Strak SK, Al-Hamdi KI, Alabbood MH. A study of lichen planus and its association with hepatitis C infection. *Journal of Taibah University Medical Sciences*. 2015;10(2):222-6.[PMID,doi:
117. Noaman N.G. Prevalence of hepatitis C virus infection among blood donors and certain risky groups in Diyala Province. *Diyala Journal of Medicine*. 2012;2(1):46-52.[PMID,doi:
118. Al-Duliami A. A., Al-Kiali K. K., Hasan AR. Is there any relationship between hepatitis C virus infection and skin diseases? *Diyala Journal of Medicine*. 2012;3(1):51-6.[PMID,doi:
119. Tawfeeq WF. Detection of hepatitis C virus infection and genotypes among seropositive blood donors by polymerase chain reaction in babylon Governorate, Iraq. *Medical Journal of Babylon*. 2013;10(1):25-37.[PMID,doi:
120. Obied H.M., Alrodhan M.A., Mallah M.O. Molecular and immunological detection of hepatitis C virus infection among blood donors in Al-Muthanna province-Iraq. *International Journal of Advanced Research*. 2014;2(6):295-315.[PMID,doi:
121. Al-Rubaye A, Tariq Z, Alrubaiy L. Prevalence of hepatitis B seromarkers and hepatitis C antibodies in blood donors in Basra, Iraq. *BMJ open gastroenterology*. 2016;3(1):e000067.[PMID,doi:
122. Khalid MD, Abdullah BA. Prevalence of anti-HCV antibodies among thalassemia patients in Mosul City, Iraq. *Journal of Life Sciences*. 2012;6(5):489-91.[PMID,doi:
123. Saadoon A. A. Prevalence of viral hepatitis B and C among selected group in Thi-Qar. *Thi-Qar Medical Journal*. 2012;6(1):79-89.[PMID,doi:

124. Jassim A. N., Abdul-Hadi A. M., Al-Waysi S. A. Epidemiological study of viral hepatitis / Chibayish Marsh Reality in Iraq. *Journal of Baghdad for Science*. 2011;8(1):23-8.[PMID,doi:
125. Albaitushi A., Tariq G., Mahmood M. Viral infections and diabetes mellitus. *Journal of the Biotechnology Research Center*. 2011;5(3):29-33.[PMID,doi:
126. Toffik K. A., Al-Diwan J. K., Al-Hadithi T. S., Al-Waiz M. M., Omer A. R. Prevalence of the serological markers of hepatitis B, C, and D among patients with sexually transmitted diseases (STDs) in Baghdad, Iraq. *Journal of the Arab Board of Medical Specializations*. 2006;8(1):105-9.[PMID,doi:
127. Jbara I, Abu Alshiekh NK, Almomani AM, Khasawneh RH, Omari AK. Prevalence of hepatitis C virus antibodies among blood donors at Prince Hashem Hospital, Zarka- Jordan. *Jordan Medical Journal*. 2006;40(3):190-3.[PMID: 2007107899,doi:
128. Rashdan A, Hijjawi S, Jadallah K, Matalaka I. Prevalence of hepatitis C virus antibodies among blood donors in Northern Jordan. *Jordan Medical Journal*. 2008;42(3):179-83.[PMID: 2009005380,doi:
129. Al-Gani FA. Prevalence of HBV, HCV, and HIV-1, 2 infections among blood donors in Prince Rashed Ben Al-Hassan Hospital in North region of Jordan. *International Journal of Biological & Medical Research*. 2011;2(4):912-6.[PMID,doi:
130. Al Abbadi B., Al Amr M., Abasi L., Saleem A., Abu Hazeem N., Marafi A. Seroprevalence of HBV, HCV, HIV and syphilis infections among blood donors at Blood Bank of King Hussein Medical Center: a 3 year study. *Middle East Journal of Family Medicine* 2014;12(6):10-3.[PMID,doi:
131. Souan L, Tout F, Siag M, Sughayer MA. Seroprevalence rates of transfusion-transmitted infections among blood donors in Jordan. *The Journal of Infection in Developing Countries*. 2016;10(04):377-83.[PMID,doi:
132. Ameen R, Sanad N, Al-Shemmari S, Siddique I, Chowdhury RI, Al-Hamdan S, et al. Prevalence of viral markers among first-time Arab blood donors in Kuwait. *Transfusion*. 2005;45(12):1973-80.[PMID: 16371052,doi: 10.1111/j.1537-2995.2005.00635.x]

133. Irani-Hakime N, Musharrafieh U, Samaha H, Almawi WY. Prevalence of antibodies against hepatitis B virus and hepatitis C virus among blood donors in Lebanon, 1997-2003. *American journal of infection control*. 2006;34(4):241-3.[PMID: 16679184,doi: 10.1016/j.ajic.2005.06.009]
134. Tamim H, Irani-Hakime N, Aoun JP, Khoury S, Samaha H, Almawi WY. Seroprevalence of hepatitis C virus (HCV) infection among blood donors: a hospital-based study. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. 2001;24(1):29-35.[PMID: 11515608,doi:
135. Irani-Hakime N, Tamim H, Samaha H, Almawi WY. Prevalence of antibodies against hepatitis C virus among blood donors in Lebanon, 1997-2000. *Clinical and laboratory haematology*. 2001;23(5):317-23.[PMID: 11703415,doi:
136. Ramia S, Ramlawi F, Kanaan M, Klayme S, Naman R. Frequency and significance of antibodies against hepatitis B core (anti-HBc) antigen as the only serological marker for hepatitis B infection in Lebanese blood donors. *Epidemiology and infection*. 2005;133(4):695-9.[PMID: 16050516,doi:
137. Araj GF, Kfoury-Baz EE, Barada KA, Nassif RE, Alami SY. Hepatitis C virus : prevalence in Lebanese blood donors and brief overview of the disease. *Le Journal medical libanais The Lebanese medical journal*. 1995;43(1):11-6.[PMID: 8676356,doi:
138. Naman RE, Mansour I, Klayme S, Khalil G. [Hepatitis C virus in hemodialysis patients and blood donors in Lebanon]. *Le Journal medical libanais The Lebanese medical journal*. 1996;44(1):4-9.[PMID: 8965318,doi:
139. Ramia S, Klayme S, Naman R. Infection with hepatitis B and C viruses and human retroviruses (HTLV-I and HIV) among high-risk Lebanese patients. *Annals of tropical medicine and parasitology*. 2003;97(2):187-92.[PMID: 12803874,doi: 10.1179/000349803235001363]
140. Salem Z, Nuwairyri-Salti N, Ramlawi F, Ramia S. Hepatitis C virus infection in Lebanese patients with B-cell non-Hodgkin's lymphoma. *European journal of epidemiology*. 2003;18(3):251-3.[PMID: 12800950,doi: 10.1023/a:1023380316098]

141. Saleh MG, Pereira LM, Tibbs CJ, Ziu M, al-Fituri MO, Williams R, et al. High prevalence of hepatitis C virus in the normal Libyan population. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994;88(3):292-4.[PMID: 7974663,doi:
142. Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. *Saudi medical journal*. 2002;23(11):1356-60.[PMID: 12506296,doi:
143. Daw MA, Shabash A, El-Bouzedi A, Dau AA, Habas M, Libyan Study Group Of H, et al. Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy. *World journal of virology*. 2016;5(1):14-22.[PMID: 26870670,doi: 10.5501/wjv.v5.i1.14]
144. Elzouki AN, Beeching NJ, Mutton KJ, Garson JA. Anti-HCV antibodies and HCV RNA in Libyan blood donors. *Vox Sang*. 1995;68(1):65.[PMID: 7536992,doi:
145. Lo BB, Meymouna M, Boulahi MA, Tew M, Sow A, Ba A, et al. [Prevalence of serum markers of hepatitis B and C virus in blood donors of Nouakchott, Mauritania]. *Bulletin de la Societe de pathologie exotique (1990)*. 1999;92(2):83-4.[PMID: 10399594,doi:
146. Lahlou Amine I, Zouhair S, Chegri M, L'Kassmi H. [Seroprevalence of anti-HCV in patients of the Military Hospital Moulay Ismail (Meknes, Morocco): Data analysis of the medical biology laboratory (2002-2005)]. *Bulletin de la Societe de pathologie exotique (1990)*. 2010;103(4):255-8.[PMID: 20596810,doi: 10.1007/s13149-010-0064-x]
147. Aqodad N, Lahbabi M, Elyousfi M, Mellouki I, Benajah D, Elabkari M, et al. Prevalence of VHC-Ab and HBsAg among blood donors in Guelmim in the south of Morocco. 2011.[PMID,doi:
148. Baha W, Foulous A, Dersi N, They-they TP, El alaoui K, Nourichafi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. *BMC public health*. 2013;13:50.[PMID: 23331910,doi: 10.1186/1471-2458-13-50]
149. Zohoun A, Hadeif R, Zahid H, Benkirane M. [Seroprevalence of HBV and HCV in blood donors at the Blood Transfusion Center of Mohammed V Military Teaching

- Hospital in Rabat Morocco]. *Medecine tropicale : revue du Corps de sante colonial*. 2011;71(5):513-4.[PMID: 22235634,doi:
150. Doblali T, Hadeif R. Hepatitis C virus seroprevalence in the Mohammed V Military Teaching Hospital in Rabat.[PMID,doi:
151. Uwingabiye J, Zahid H, Unyendje L, Hadeif R. Seroprevalence of viral markers among blood donors at the Blood Donor Center of Mohammed V Military Teaching Hospital of Rabat, Morocco. *The Pan African medical journal*. 2016;25:185-.[PMID,doi:
152. Laouina A, Alami R, Adouani B, Benahadi A, Boulahdid S, Tazi mokha A, et al. PREVALENCE OF TRANSMISSIBLE INFECTIOUS MARKERS TRANSFUSION AMONG BLOOD DONORS IN MOROCCO. *Vox Sanguinis* 2016;111(Issue Supplement S1):172.[PMID,doi:
153. Benjelloun S, Bahbouhi B, Sekkat S, Bennani A, Hda N, Benslimane A. Anti-HCV seroprevalence and risk factors of hepatitis C virus infection in Moroccan population groups. *Research in virology*. 1996;147(4):247-55.[PMID: 8837233,doi:
154. Laouina A, Abouyoub A, Soulaymani A, Alami R. Alanine transaminase level in a healthy population in Morocco. *Pakistan journal of biological sciences : PJBS*. 2012;15(5):238-43.[PMID: 24199458,doi:
155. Al-Dhahry SHS, Aghanashinikar PN, Al-Hasani MK, Buhl MR, Daar AS. Prevalence of antibodies to hepatitis C virus among Omani patients with renal disease. *Infection*. 1993;21(3):164-7.[PMID: 1993197158,doi:
156. Al Dhahry SH, Nograles JC, Rajapakse SM, Al Toqi FS, Kaminski GZ. Laboratory diagnosis of viral hepatitis C: The Sultan Qaboos University Hospital experience. *Journal for scientific research Medical sciences/Sultan Qaboos University*. 2003;5(1-2):15.[PMID,doi:
157. Schuster H, Serebour E, Nograles J, Al-Belushi I, Hassan K. Prevalence of blood-borne viruses amongst antenatal clinic patients and blood donors in a tertiary referral hospital in Oman. *Clinical Microbiology and Infection*. 2009;15:S587.[PMID: 70071995,doi: <http://dx.doi.org/10.1111/j.1469-0691.2009.02858.x>]

158. Ashraf TM, Alain JP. Anti-hepatitis B core testing of blood donors- Oman experience. *Vox Sanguinis*. 2010;99:285.[PMID: 70237473,doi:
<http://dx.doi.org/10.1111/j.1423-0410.2010.01343-2.x>]
159. Pathare N, Al Abri SR, Al Siyabi B, Serebour F, Pathare A, Alkindi S. Seroprevalence of HBSAG, HCV, HIV, HBV PCR and RPR affecting the donor deferral patterns. *Transfusion*. 2012;52:216A.[PMID: 70878251,doi:
<http://dx.doi.org/10.1111/j.1537-2995.2012.03833-1.x>]
160. Alnaqy A, Al-Harthy S, Kaminski G, Al-Dhahry S. Detection of serum antibodies to hepatitis C virus in 'false-seronegative' blood donors in Oman. *Medical Principles and Practice*. 2006;15(2):111-3.[PMID: 2006087904,doi:
<http://dx.doi.org/10.1159/000090914>]
161. Kakepoto GN, Bhally HS, Khaliq G, Kayani N, Burney IA, Siddiqui T, et al. Epidemiology of blood-borne viruses: a study of healthy blood donors in Southern Pakistan. *The Southeast Asian journal of tropical medicine and public health*. 1996;27(4):703-6.[PMID: 128192719,doi:
162. Abdul Mujeeb S, Aamir K, Mehmood K. Seroprevalence of HBV, HCV and HIV infections among college going first time voluntary blood donors. *Jpma*. 2000;*The Journal of the Pakistan Medical Association*. 50(8):269-70.[PMID: 31370527,doi:
163. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. *Jpma*. 2002;*The Journal of the Pakistan Medical Association*. 52(9):398-402.[PMID: 36498221,doi:
164. Qureshi H, Ahsan T, Mujeeb SA, Jawad F, Mehdi I, Ahmed W, et al. Diabetes mellitus is equally frequent in chronic HCV and HBV infection. *Jpma*. 2002;*The Journal of the Pakistan Medical Association*. 52(7):280-3.[PMID: 35540447,doi:
165. Mujeeb SA, Shahab S, Hyder AA. Geographical display of health information: Study of hepatitis C infection in Karachi, Pakistan. *Public Health*. 2000;114(5):413-5.[PMID: 30756887,doi:

166. Abdul Mujeeb S, Nanan D, Sabir S, Altaf A, Kadir M. Hepatitis B and C infection in first-time blood donors in Karachi-a possible subgroup for sentinel surveillance. *EMHJ-Eastern Mediterranean Health Journal*, 12 (6), 735-741, 2006. 2006.[PMID,doi:
167. Mumtaz S. Frequency of seropositive blood donors for hepatitis B, C and HIV viruses in railway hospital Rawalpindi. *Pak j med res*. 2002;51-3.[PMID,doi:
168. Asif N, Khokhar N, Ilahi F. Sero-prevalence of HBV, HCV, and HIV infection among voluntary non remunerated & replacement donors in Northern Pakistan. *Pakistan journal of medical sciences*. 2004;20(1):24-8.[PMID,doi:
169. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: Implications for transfusion practice. *Transfusion*. 2007;47(1):74-9.[PMID: 46006312,doi: <http://dx.doi.org/10.1111/j.1537-2995.2007.01066.x>]
170. Ahmad N, Asgher M, Shafique M, Qureshi JA. An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan. *Saudi medical journal*. 2007;28(3):390-5.[PMID: 46605059,doi:
171. Sultan F, Mehmood T, Mahmood MT. Infectious pathogens in volunteer and replacement blood donors in Pakistan: a ten-year experience. *International Journal of Infectious Diseases*. 2007;11(5):407-12.[PMID: 47239449,doi: <http://dx.doi.org/10.1016/j.ijid.2006.10.004>]
172. Mujeeb SA, Pearce MS. Temporal trends in hepatitis B and C infection in family blood donors from interior Sindh, Pakistan. *BMC infectious diseases*. 2008;8 (no pagination)(43).[PMID: 351587045,doi: <http://dx.doi.org/10.1186/1471-2334-8-43>]
173. Irfan SM, Uddin J, Zaheer HA, Sultan S, Baig A. Trends in transfusion transmitted infections among replacement blood donors in Karachi, Pakistan Karachi, Pakistan'daki kan bagi{dotless}sci{dotless}lari{dotless}nda transfuzyonla bulasan enfeksiyonlari{dotless}n yaygi{dotless}nli{dotless}gi{dotless}. *Turkish Journal of Hematology*. 2013;30(2):163-7.[PMID: 369140184,doi: <http://dx.doi.org/10.4274/Tjh.2012.0132>]

174. Abbas SZ, Ali M, Muhammad AH, Shaw S, Abbas SQ. Frequency of HCV infection and its genotypes among patients attending a liver clinic and voluntary blood donors in a rural area of Pakistan. *Pakistan Journal of Medical Sciences*. 2009;25(4):579-82.[PMID: 355272830,doi:
175. Karim F, Moiz B. Seroprevalence of infectious markers among blood donors in pakistan-trend over a decade. *Vox Sanguinis*. 2017;112 (Supplement 1):175.[PMID: 616917290,doi:
176. Bangash MH, Bangash TH, Alam S. Prevalance of hepatitis B and hepatatis C among healthy blood donors at Kurram Agency. *JPMI - Journal of Postgraduate Medical Institute*. 2009;23(2):140-5.[PMID: 359791074,doi:
177. Bangash MH, Bangash TH, Ali J. Frequency of hepatitis B and C in healthy subjects in Parachinar. *Journal of Postgraduate Medical Institute*. 2009;23(4):347-51.[PMID: 360082736,doi:
178. Shah SM, Khattak IU, Ali A, Tariq M. Seropositivity for hepatitis B and C in voluntary blood donors. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2010;22(3):149-51.[PMID: 364571737,doi:
179. Borhany M, Shamsi T, Boota S, Ali H, Tahir N, Naz A, et al. Transfusion transmitted infections in patients with hemophilia of Karachi, Pakistan. *Clinical and Applied Thrombosis/Hemostasis*. 2011;17(6):651-5.[PMID: 364289718,doi: <http://dx.doi.org/10.1177/1076029611398122>]
180. Qadeer MI, Hasnain S, Yasmeen H. Sero-prevalence of sexually transmitted disease (Hiv, Syphilis, Hepatitis-B and Hepatitis-C) in Volunteer Donors of Gaol Inmates and Student Community in Punjab Province of Pakistan. *Sexually Transmitted Infections Conference: STI and AIDS World Congress*. 2013;89(no pagination).[PMID: 71442852,doi: <http://dx.doi.org/10.1136/sextrans-2013-051184.0820>]
181. Mukhtar Hussain Sangji Z. Prevalence of blood screening markers in blood donor population of Pakistan at Husaini Haematology and Oncology Trust.Khi. *Pakistan. Vox Sanguinis*. 2009;97:148.[PMID: 70092488,doi: <http://dx.doi.org/10.1111/j.1423-0410.2009.01262.x>]

182. Jadoon N, Shahzad A, Yaqoob R. Frequency of hepatitis C virus infection in Pakistani patients with type 2 diabetes mellitus. *International Journal of Infectious Diseases*. 2010;14:S68.[PMID: 70216088,doi: <http://dx.doi.org/10.1016/S1201-9712%2810%2960208-1>]
183. Safi SZ, Afzal MS, Waheed Y, Butt UJ, Fatima K, Parvez Y, et al. Seroprevalence of hepatitis C and human immunodeficiency viruses in blood donors of northwestern Pakistan. *Asian Biomedicine*. 2011;5(3):389-92.[PMID: 368003565,doi: <http://dx.doi.org/10.5372/1905-7415.0503.049>]
184. Attaullah S, Khan S, Khan J. Trend of transfusion transmitted infections frequency in blood donors: Provide a road map for its prevention and control. *Journal of translational medicine*. 2012;20.[PMID: 51841684,doi: <http://dx.doi.org/10.1186/1479-5876-10-20>]
185. Khan NU, Ali I, Ahmad NU, Iqbal A, Rehman LU, Munir I, et al. Prevalence of active HCV infection among the blood donors of Khyber Pakhtunkwa and FATA region of Pakistan and evaluation of the screening tests for anti-HCV. *Virology journal*. 2011;8 (no pagination)(154).[PMID: 51349801,doi: <http://dx.doi.org/10.1186/1743-422X-8-154>]
186. Khan S. Improving the safety of blood products through stringent donor selection, pre and post donation screening of blood. *Vox Sanguinis*. 2012;103:98-9.[PMID: 71015982,doi: <http://dx.doi.org/10.1111/j.1423-0410.2012.01615-2.x>]
187. Ansari SH, Shamsi TS, Khan MT, Perveen K, Farzana T, Erum S, et al. Seropositivity of Hepatitis C, Hepatitis B and HIV in chronically transfused $\beta\beta$ -thalassaemia major patients. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. 2012;22(9):610-1.[PMID,doi:]
188. Bhutta AZ, Tahir Z, Ayub S, Mushtaq S. Seroprevalence of anti-HCV in non-professional blood donors. *Pakistan Journal of Medical and Health Sciences*. 2012;6(1):175-8.[PMID: 368679223,doi:]
189. Waheed U, Zaheer HA, Astori S. Transfusion transmitted infections among blood donors of a teaching hospital in Islamabad, Pakistan. *Vox Sanguinis*.

2012;103:157.[PMID: 71016152,doi: <http://dx.doi.org/10.1111/j.1423-0410.2012.01615-2.x>]

190. Ijaz R, Bhatti S, Ullah S. Prevalence of hepatitis B and C in healthy blood donors in a peripheral hospital - Ghurki trust hospital, Lahore. *Pakistan Journal of Medical and Health Sciences*. 2012;6(3):568-9.[PMID: 365901276,doi:

191. Khan A, Tareen AM, Ikram A, Rahman H, Wadood A, Qasim M, et al. Prevalence of HCV among the young male blood donors of Quetta region of Balochistan, Pakistan. *Virology journal*. 2013;10 (no pagination)(83).[PMID: 52490813,doi: <http://dx.doi.org/10.1186/1743-422X-10-83>]

192. Moiz B, Moatter T, Shaikh U, Adil S, Ali N, Mahar F, et al. Estimating window period blood donations for human immunodeficiency virus Type1, hepatitisC virus, and hepatitisB virus by nucleic acid amplification testing in Southern Pakistan. *Transfusion*. 2014;54(6):1652-9.[PMID: 52945659,doi: <http://dx.doi.org/10.1111/trf.12521>]

193. Sadia Sultan MBBS F, Siddiqui M, Zaidi SMH. Current trends of seroprevalence of transfusion transmitted infections in Pakistani [Beta]-thalassaemic patients. *The Malaysian journal of pathology*. 2016;38(3):251.[PMID,doi:

194. Ahmad M, Saeed M, Arif M, Rasheed N, Akhtar M, Ghaznavi S. Trends of transfusion transmissible infectious diseases among Pakistani blood donors. *Vox Sanguinis*. 2017;112 (Supplement 1):190-1.[PMID: 616917279,doi:

195. Niazi SK, Bhatti FA, Salamat N, Ghani E, Tayyab M. Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan. *Transfusion*. 2015;55(7):1803-11.[PMID: 602101849,doi: <http://dx.doi.org/10.1111/trf.13017>]

196. Niazi SUK, Alam M, Mahmood A. Three year follow-up of HBV-NAT reactive Pakistani blood donors. *Vox Sanguinis*. 2016;111 (Supplement 1):58.[PMID: 611869436,doi:

197. Butt KK, Shafiq F, Yousaf MA. Prevalence of HIV, ANTI-HCV, HBsAg and VDRL positive cases in blood donors of bhatti international Trust Hospital, Kasur. *Pakistan Journal of Medical and Health Sciences*. 2013;7(3):662-3.[PMID: 370085847,doi:

198. Parveen S, Latif A, Ashraf M. Seroprevalence of hepatitis C virus (HCV) in southern Punjab. *Medical Forum Monthly*. 2014;25(11):2-4.[PMID: 601833153,doi:
199. Nepal B. Frequency of reactive blood donors in a tertiary care hospital, Karachi, Pakistan. *Haematologica*. 2016;101:649-50.[PMID: 615549344,doi:
200. Ata U, Shaikh I, Jamal S. Seroprevalence of hepatitis c in voluntary nonremunerated blood donors versus replacement blood donors in Pakistan. *Vox Sanguinis*. 2017;112 (Supplement 1):174-5.[PMID: 616917260,doi:
201. Noorulamin M, Babur A, Salman S, Faheem R, Waheed U, Hassan A. Prevalence of transfusion transmissible infections in blood donors in a tertiary level cardiac hospital in Pakistan: A 02 year experience. *Vox Sanguinis*. 2016;111 (Supplement 1):201.[PMID: 611869554,doi:
202. Saeed M, Hussain S, Rasheed F, Ahmad M, Arif M, Rahmani MTH. Silent killers: Transfusion transmissible infections-tti, among asymptomatic population of Pakistan. *Journal of the Pakistan Medical Association*. 2017;67(3):369-74.[PMID: 614564986,doi:
203. Karim F, Nasar A, Alam I, Alam I, Hassam S, Gul R. Incidence of active HCV infection amongst blood donors of Mardan District, Pakistan. *Asian Pacific journal of cancer prevention : APJCP*. 2016;17:235-8.[PMID,doi:
204. Ghanghro A, Jokhio P. High prevalence of hepatitis C and hepatitis B infection among pregnant women and their blood donors attending a surgical referral clinic in District Naushahro Feroze, Sindh, Pakistan 2014. *International Journal of Infectious Diseases*. 2016;45:437.[PMID,doi:
205. Waheed U, Abbas Zaheer H. Blood donor deferral pattern in Islamabad, Pakistan. *Vox Sanguinis*. 2017;112 (Supplement 2):68.[PMID: 619349936,doi:
206. Amin F, Zafar A, Chattha HA. Frequency of hepatitis B, C & HIV among blood donors in Blood Bank of Lahore General Hospital, Lahore. *Pakistan Journal of Medical and Health Sciences*. 2017;11(3):878-81.[PMID: 619052491,doi:
207. AKRAM S, SHAHID S. Blood Donors Awareness to Know their Blood Group and Prevalence of HIV, HBsAg and Anti HCV Screening at Dharampura District Lahore.[PMID,doi:

208. Khattak MN, Akhtar S, Mahmud S, Roshan TM. Factors influencing hepatitis C virus sero-prevalence among blood donors in north west Pakistan. *Journal of Public Health Policy*. 2008;29(2):207-25.[PMID: 351799123,doi: <http://dx.doi.org/10.1057/jphp.2008.7>]
209. Jadoon NA, Shahzad MA, Yaqoob R, Hussain M, Ali N. Seroprevalence of hepatitis C in type 2 diabetes: Evidence for a positive association. *Virology journal*. 2010;7 (no pagination)(304).[PMID: 51142846,doi: <http://dx.doi.org/10.1186/1743-422X-7-304>]
210. Zaffar G, Ali R, Ayyub M, Ahmed A, Ali A, Khan F. Frequency and trends of infectious pathogen in blood donors at a tertiary care hospital in Pakistan. *Hepatology International*. 2013;7:S346.[PMID: 71308392,doi: <http://dx.doi.org/10.1007/s12072-013-9429-0>]
211. Sheikh A. Seroprevalence of blood borne viruses among blood donors attended during an earthquake campaign at Gwadar Port, a south-west coastal area of Pakistan. *Annals of Oncology*. 2015;26:ix159.[PMID: 72189813,doi: <http://dx.doi.org/10.1093/annonc/mdv535.14>]
212. Kanwal N, Nasir B, Abrar MA, Kaukab I, Nawaz A, Nisar N, et al. PREVALENCE OF HEPATITIS C IN DIABETIC PATIENTS: A PROSPECTIVE STUDY. *Acta poloniae pharmaceutica*. 2016;73(3):771-5.[PMID: 27476296,doi:
213. Arshad A, Borhany M, Anwar N, Naseer I, Ansari R, Boota S, et al. Prevalence of transfusion transmissible infections in blood donors of Pakistan. *BMC hematology*. 2016;16(1):1-6.[PMID,doi:
214. Wazeer A, Qasim Z, Waheed U, Abbas Zaheer H. Incidence of hepatitis B and c viruses among blood donors of a teaching hospital in Mirpur, Azad Jammu Kashmir, Pakistan. *Vox Sanguinis*. 2017;112 (Supplement 2):96.[PMID: 619350713,doi:
215. Novack L, Shinar E, Safi J, Soliman H, Yaari A, Galai N, et al. Evaluation of pooled screening for anti-HCV in two blood services set-ups. *Tropical medicine & international health : TM & IH*. 2007;12(3):415-21.[PMID: 17313513,doi: 10.1111/j.1365-3156.2006.01810.x]

216. Palestinian Health Information Center. Health Annual Report 2003. URL: <http://www.moh.ps/?lang=1&page=4&id=137>; 2004.
217. Palestinian Health Information Center. Health Annual Report 2005. URL: <http://www.moh.ps/?lang=1&page=4&id=9>; 2006.
218. Palestinian Health Information Center. Health Annual Report 2006. URL: <http://www.moh.ps/?lang=1&page=4&id=142>; 2007.
219. Palestinian Health Information Center. Health Annual Report 2007. URL: <http://www.moh.ps/?lang=1&page=4&id=139>; 2008.
220. Palestinian Health Information Center. Health Annual Report 2009. URL: <http://www.moh.ps/?lang=1&page=4&id=150>; 2010.
221. Palestinian Health Information Center. Health Annual Report 2013. URL: <http://www.moh.ps/?lang=1&page=4&id=939>; 2014.
222. Center PHI. Health Annual Report 2014. URL: <http://site.moh.ps/#>; 2015.
223. Shemer-Avni Y, el Astal Z, Kemper O, el Najjar KJ, Yaari A, Hanuka N, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. *Journal of medical virology*. 1998;56(3):230-3.[PMID: 9783690,doi:
224. Fawzi Z, Al Hilali A, Al Malki A, Al Matawa H, Yousef B, Ali Bin Ali A, et al. Survey of hepatitis markers among donors in the State of Qatar. *Qatar Medical Journal*. 2007;16(2):47-50.[PMID: 2008481374,doi:
225. Al Karawi MA, Shariq S, El Shiekh Mohamed AR, Saeed AA, Ahmed AMM. Hepatitis C virus infection in chronic liver disease and hepatocellular carcinoma in Saudi Arabia. *Journal of gastroenterology and hepatology*. 1992;7(3):237-9.[PMID: 1992173994,doi:
226. Bahakim H, Bakir TMF, Arif M, Ramia S. Hepatitis C virus antibodies in high-risk Saudi groups. *Vox Sanguinis*. 1991;60(3):162-4.[PMID: 1991177724,doi:
227. Fathalla SE. Hepatitis C infection among Egyptian blood donors in the eastern Saudi Arabia with / without past history of schistosomiasis. *Archives of AIDS research*. 1994;8(1-2):71-5.[PMID: 12287878,doi:

228. International AIDS Society conferences. 2015. Available at:
<https://www.iasociety.org/Default.aspx?pageId=3> [Available from:
<https://www.iasociety.org/Default.aspx?pageId=3>.
229. Tamimi WG, Altraif IM, Aljumah A, Albuharian BS, Alenzi FQB, Bernvil S, et al. Impact of new AABB guidelines on hepatitis B and C testing among Saudi blood donors. *British Journal of Biomedical Science*. 2004;61(4):215-7.[PMID: 2005019493,doi:
230. Altamimi W, Altraif I, Elsheikh M, Alkshan A, Qasem L, Sohaibani M. Prevalence of HBsAg and anti-HCV in Saudi blood donors. *Annals of Saudi Medicine*. 1998;18(1):60-2.[PMID: 1998222434,doi:
231. Kashgari RH, Mohamad AA. Seroepidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) and relationship to alanine transferase (alt) in saudi workers at yanbu industrial city. *Journal of family & community medicine*. 1997;4(1):24-9.[PMID: 23008562,doi:
232. Ankra-Badu GA, Ahmad M, Sowayan S, Bashawri L. Demographic characteristics of seropositive donors in AL-Khobar. *Annals of Saudi Medicine*. 2001;21(1-2):113-6.[PMID: 2001415245,doi:
233. Abdelaal M, Zawawi TH, Al Sobhi E, Jeje O, Gilpin C, Kinsara A, et al. Epidemiology of hepatitis E virus in male blood donors in Jeddah, Saudi Arabia. *Irish Journal of Medical Science*. 1998;167(2):94-6.[PMID: 1998192252,doi:
234. Arif MA. Importance of confirmatory testing in donated blood. *Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association*. 1998;4(2):76-80.[PMID: 19864773,doi:
235. Madani TA. Hepatitis C virus infections reported over 11 years of surveillance in Saudi Arabia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2009;103(2):132-6.[PMID: 2009015757,doi:
<http://dx.doi.org/10.1016/j.trstmh.2008.08.001>]
236. Bashawri LA. Pattern of blood procurement, ordering and utilization in a University Hospital in Eastern Saudi Arabia. *Saudi medical journal*. 2002;23(5):555-61.[PMID: 2002209657,doi:

237. Mehdi SR, Al Ajlan AR. Hepatitis B&C virus infection in cases of Non-Hodgkin's lymphoma in Saudi Arabia. *Turkish Journal of Hematology*. 2006;23(4):200-4.[PMID: 2007396449,doi:
238. Mitwalli AH, Al Wakeel JS, Alam AA, Nauman T, Al Rashed RS, Ramia S. Hepatitis G virus (HGV) infection in Saudi dialysis patients and healthy controls. *Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association*. 2000;6(2):79-83.[PMID: 19864716,doi:
239. Bashawri LAM, Fawaz NA, Ahmad MS, Qadi AA, Almawi WY. Prevalence of seromarkers of HBV and HCV among blood donors in eastern Saudi Arabia, 1998-2001. *Clinical and Laboratory Haematology*. 2004;26(3):225-8.[PMID: 2004246461,doi: <http://dx.doi.org/10.1111/j.1365-2257.2004.00601.x>]
240. Al-Bahrani A, Panhotra BR. Prevalence of HBsAG and anti-HCV antibodies in blood donors of the Al-Hasa region of Saudi Arabia. *Annals of Saudi Medicine*. 2001;21(3-4):234-5.[PMID: 2002086240,doi:
241. El-Hazmi MM. Prevalence of HBV, HCV, HIV-1,2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia. *Saudi medical journal*. 2004;25(1):26-33.[PMID: 2004096772,doi:
242. Abdullah S. Prevalence of hepatitis B virus and hepatitis C virus among Saudi blood donors in the Jazan region of Saudi Arabia. *Vox Sanguinis*. 2011;101:208.[PMID: 70428239,doi: <http://dx.doi.org/10.1111/j.1423-0410.2011.01498-2.x>]
243. Halawani M. Screening of hepatitis C virus genotypes in urticaria patients in Saudi Arabia. *Genetic testing and molecular biomarkers*. 2012;16(8):964-7.[PMID: 2012516082,doi: <http://dx.doi.org/10.1089/gtmb.2012.0014>]
244. Halawani M, Bakir TM. Determination of hepatitis C virus genotypes in pruritus patients in Saudi Arabia. *Genetic testing and molecular biomarkers*. 2012;16(1):46-9.[PMID: 2012058146,doi: <http://dx.doi.org/10.1089/gtmb.2011.0064>]
245. Abdelaziz H. Routine use of mini-pool nucleic acid testing (MPNAT) multiplex assay for sero-negative blood donors. 2013;105((Abdelaziz) Cairo University, Dammam, Saudi Arabia):278.[PMID,doi:

246. Elbjeirami W, Arsheed N, Al-Jedani H, Elnagdy N, Hazem M. Prevalence and trends of HBV, HCV, and HIV serological and NAT markers and profiles in Saudi blood donors. *J Blood Disord Transfus*. 2015;6(280):2.[PMID,doi:
247. Kilany M, Bin Dajem SM, Ibrahim YM, Alshehri A, Aljeamelani AA, Ibrahim EH. Seroprevalence of anti-Treponemapallidum antibodies (Syphilis) in blood donors in the southern area of Saudi Arabia. *RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES*. 2015;6(1):549-56.[PMID,doi:
248. Sarah YAEGA, Ali A. Seropositivity of TTIs among blood donors in Hail, Saudi Arabia, from 2014 to 2015. *Asian Pacific Journal of Tropical Disease*. 2016;6(2):141-6.[PMID,doi:
249. Al-Mofarreh M, Fakunle YM, El-Karamany WM, Ezzat HO, Ballesteros MN, Khawaji MZ, et al. Prevalence of antibodies to hepatitis C virus in blood donors in Riyadh. *Annals of Saudi Medicine*. 1991;11(5):501-3.[PMID: 1991287154,doi:
250. Ayoola EA, Huraib S, Arif M, Al-Faleh FZ, Al-Rashed R, Ramia S, et al. Prevalence and significance of antibodies to hepatitis C virus among Saudi haemodialysis patients. *Journal of medical virology*. 1991;35(3):155-9.[PMID: 1991338948,doi:
251. Bernvil SS, Andrews VJ, Kariem AA. Hepatitis C antibody prevalence in Saudi Arabian blood donor population. *Annals of Saudi Medicine*. 1991;11(5):563-7.[PMID: 1991287167,doi:
252. Jamjoom GA, Quli SK. Serodiagnosis of hepatitis C in acute and chronic liver disease in southwestern Saudi Arabia. *Journal of Tropical Medicine and Hygiene*. 1992;95(6):428-31.[PMID: 1993023282,doi:
253. Al Nasser MN, Al Mugeiren MA, Assuhaimi SA, Obineche E, Onwabalili J, Ramia S. Seropositivity to hepatitis C virus in Saudi haemodialysis patients. *Vox Sanguinis*. 1992;62(2):94-7.[PMID: 1992122440,doi:
254. Ayoola EA, Al-Mofleh IA, Al- Faleh FZ, Al-Rashed R, Arif MA, Ramia S, et al. Prevalence of antibodies to hepatitis C virus among Saudi patients with chronic liver diseases. *Hepato-gastroenterology*. 1992;39(4):337-9.[PMID: 1992281928,doi:

255. Mitwalli A, al-Mohaya S, al Wakeel J, el Gamal H, Rotimi V, al-Zeben A, et al. Hepatitis C in chronic renal failure patients. *American journal of nephrology*. 1992;12(5):288-91.[PMID: 1336933,doi:
256. Saeed AA, Ahmed AMM, Al-Karawi MA, Mohamed ARES, Al-Saud AA, Shariq SA. The association between hepatitis C virus antibody and hepatocellular carcinoma in relation to hepatitis B viral infection (RAFH experience). *Annals of Saudi Medicine*. 1992;12(3):283-5.[PMID: 1992172634,doi:
257. Anwar F, Abdelaal M, Khalid H, Mowallad A, Bawazeer A, Alshareef B, et al. Living with nat: Our experience at king khalid National Guard Hospital, Jeddha, Saudi Arabia. *Vox Sanguinis*. 2009;96:89.[PMID: 70097455,doi: <http://dx.doi.org/10.1111/j.1423-0410.2009.01156.x>]
258. Halawani M, Balbisi A, Alotaibi H, Alsaif F, Bakir TM. The prevalence of HCV antibodies in skin disease patients in Saudi Arabia. *Saudi Pharmaceutical Journal*. 2010;18(1):35-9.[PMID: 2010072691,doi: <http://dx.doi.org/10.1016/j.jsps.2009.12.003>]
259. Nur YA, Groen J, Elmi AM, Ott A, Osterhaus AD. Prevalence of serum antibodies against bloodborne and sexually transmitted agents in selected groups in Somalia. *Epidemiology and infection*. 2000;124(1):137-41.[PMID: 10722141,doi:
260. Nagi AM, Al Tayeb HA, Ahmed MA. Seroprevalence of hepatitis Band C viral infections among blood donors in Shendi, River Nile State, Sudan. *Research Journal of Medicine and Medical Sciences*. 2007;2(2):122-6.[PMID,doi:
261. Abou MA, Eltahir YM, Ali AS. Seroprevalence of hepatitis B virus and hepatitis C virus among blood donors in Nyala, South Dar Fur, Sudan. *Virology journal*. 2009;6:146.[PMID: 19775459,doi: 10.1186/1743-422x-6-146]
262. Elfaki AMH, Eldour AAA, Elsheikh NMH. Sero-prevalence of immunodeficiency virus, hepatitis B and C and syphilis among blood donors at ElObeid Teaching Hospital, West Sudan. *Sudan Journal of Medical Sciences*. 2008;3(4):333-7.[PMID,doi:
263. Ali T., Al-Daher N. Prevalence des infections transmissibles par transfusion chez les donneurs de sang au centre de transfusion sanguine de l'Universite de Damas et

l'importance des mesures de la securite transfusionnelle. Journal of Public Health of Damascus University. 2010;26(1):107-23.[PMID,doi:

264. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, Tawil O.

Characterizing the HIV/ AIDS epidemic in the Middle East and North Africa : Time for strategic action. World Bank/UNAIDS/WHO Publication, editor. Washington DC: The World Bank Press; 2010.

265. Othman BM, Monem FS. Prevalence of hepatitis C virus antibodies among intravenous drug abusers and prostitutes in Damascus, Syria. Saudi medical journal. 2002;23(4):393-5.[PMID: 11953762,doi:

266. Abid S, Fkih S, Khlass B, Cherif W, Toumi NH, Jenhani F, et al. [Screening and confirmation of anti-HCV antibodies in Tunisian blood donors]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 1997;4(2):221-6.[PMID: 9162428,doi:

267. Hatira SA, Yacoub-Jemni S, Houissa B, Kaabi H, Zaeir M, Kortas M, et al. [Hepatitis C virus antibodies in 34130 blood donors in Tunisian Sahel]. La Tunisie medicale. 2000;78(2):101-5.[PMID: 10894044,doi:

268. Krichen CH, Rekik H, Feki H, Dammak J, Gargouri J. Prevalence of viral markers among blood donors in Tunisia. Clinical laboratory. 2001;47(9-10):509-16.[PMID: 11596914,doi:

269. Larabi K, Tourjemene K. [Epidemiology of hepatitis C virus infection in the Menzel-Bourguiba region]. La Tunisie medicale. 2001;79(12):672-5.[PMID: 11892441,doi:

270. Mastouri M, Safer IL, Pozzetto B, Bourlet T, Khedher M. [Prevalence of hepatitis G virus among Tunisian blood donors]. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2005;11(5-6):1053-60.[PMID: 16761677,doi:

271. Tunisia Ministry of Health. HIV/ AIDs Quarterly Case Notification.

2006. .[PMID,doi:

272. Tunisia Ministry of Health. HIV/ AIDS Quarterly Case Notification.

2017. .[PMID,doi:

273. Hannachi N, Boughammoura L, Marzouk M, Tififha M, Khelif A, Soussi S, et al. [Viral infection risk in polytransfused adults: seroprevalence of seven viruses in central Tunisia]. *Bulletin de la Societe de pathologie exotique (1990)*. 2011;104(3):220-5.[PMID: 21695497,doi: 10.1007/s13149-010-0103-7]
274. Ben Jemia R, Gouider E. Seroprevalency of transfusion-transmitted infections in first-time volunteer and replacement donors in Tunisia. *Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine*. 2014;21(6):303-8.[PMID: 25458983,doi: 10.1016/j.tracli.2014.10.001]
275. Coursaget P, Leboulleux D, Gharbi Y, Enogat N, Ndao MA, Coll-Seck AM, et al. Etiology of acute sporadic hepatitis in adults in Senegal and Tunisia. *Scandinavian journal of infectious diseases*. 1995;27(1):9-11.[PMID: 7784826,doi:]
276. Kallel L, Fekih M, Ouaz A, Ben Mustapha N, Karoui S, Serghini M, et al. Prevalence and risk factors of viral B and C hepatitis among Tunisian inflammatory bowel disease: A case control study.[PMID,doi:]
277. Slama H, Mojaat N, Dahri R, Boukef K. [Epidemiologic study of anti-HCV antibodies in Tunisian blood donors]. *Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine*. 1991;34(6):459-64.[PMID: 1663358,doi:]
278. Triki H. [Epidemiology of hepatitis B virus, hepatitis C virus and Delta virus in the general population and in liver cirrhosis in Tunisia]. *Archives de l'Institut Pasteur de Tunis*. 1994;71(3-4):403-6.[PMID: 8801835,doi:]
279. Al Shaer L, Abdulrahman M, John TJ, Alhashimi A. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: Impact of individual-donation nucleic acid testing, 2004 through 2009. *Transfusion*. 2012;52(11):2300-9.[PMID: 2012673309,doi: <http://dx.doi.org/10.1111/j.1537-2995.2012.03740.x>]
280. Raouf M, Al Amiri A, Gammon R. Demographic profile of blood donors and its influence on the safety of blood transfusion in the United Arab Emirates. *Transfusion*.

2010;50:205A.[PMID: 70288448,doi: <http://dx.doi.org/10.1111/j.1537-2995.2010.02833-1.x>]

281. Scott DA, Constantine NT, Callahan J, Burans JP, Olson JG, al-Fadeel M, et al. The epidemiology of hepatitis C virus antibody in Yemen. *The American journal of tropical medicine and hygiene*. 1992;46(1):63-8.[PMID: 1311155,doi: 1311155]
282. Haidar NA. Prevalence of hepatitis B and hepatitis C in blood donors and high risk groups in Hajjah, Yemen Republic. *Saudi medical journal*. 2002;23(9):1090-4.[PMID: 12370719,doi: 12370719]
283. Abdul El-Rab A, Alkobati F, Mohammad Y. Prevalence of HbsAg, HCV antibody and HIV virus among blood donors at Al-Thawra Hospital Sana'a. *Sana'a University Journal for Medical Sciences*. 2004;1(2).[PMID,doi: 1311155]
284. Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2010;21(6):1165-8.[PMID: 21060200,doi: 21060200]
285. Al-Waleedi AA, Khader YS. Prevalence of hepatitis B and C infections and associated factors among blood donors in Aden City, Yemen. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2012;18(6):624-9.[PMID: 22888620,doi: 22888620]
286. Omer HH. Distribution of Hepatitis B virus, and Hepatitis C virus among blood donors in Aden Blood Center. *Abstracts of Researches*. 2010;14(1):7.[PMID,doi: 21060200]
287. Saghir SAM, Al-Hassan FM, Alsalahi OSA, Alhariry AEAA, Baqir HS. Frequencies of HBV, HCV, HIV, and syphilis markers among blood donors: A hospital-based study in Hodeidah, Yemen. *Tropical Journal of Pharmaceutical Research*. 2012;11(1):132-6.[PMID: 2012100199,doi: 2012100199]
<http://dx.doi.org/http://dx.doi.org/10.4314/tjpr.v11i1.17>]
288. Alodini AQ. Prevalence of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Infections among Blood Donors at Al-Thawra Hospital Sana'a City-Yemen. *Yemeni Journal for Medical Sciences*. 2012;6.[PMID,doi: 2012100199]

289. El Guneid AM, Gunaid AA, O'Neill AM, Zureikat NI, Coleman JC, Murray-Lyon IM. Prevalence of hepatitis B, C, and D virus markers in Yemeni patients with chronic liver disease. *Journal of medical virology*. 1993;40(4):330-3.[PMID: 8228926,doi:
290. Sallam TA, Tong CY, Cuevas LE, Raja'a YA, Othman AM, Al-Kharsa KR. Prevalence of blood-borne viral hepatitis in different communities in Yemen. *Epidemiology and infection*. 2003;131(1):771-5.[PMID: 12948378,doi:
291. Oshaish HA, El Shazly H, Elabsii AR. Prevalence of HBS Ag virus, anti-hepatitis C virus and anti-HIV among volunteer blood donor in Taiz private hospital, Yemen Republic. *Assiut Medical Journal*. 2008;32(3):163-70.[PMID,doi:
292. Pehlivanoglu F, Yasar KK, Sengoz G. Asylum seekers: Do we need new approaches to their health problems?. [Turkish] *Siginmacilar: Saglik problemleri icin yeni yaklasimlara ihtiyac var mi*. *Nobel Medicus*. 2011;7(1):102-5.[PMID: 2011286946,doi:
293. Richter C, Beest GT, Gisolf EH, Van Bentum P, Waegemaekers C, Swanink C, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, the Netherlands. *Epidemiology and infection*. 2014;142(10):2140-6.[PMID: 2014550226,doi: <http://dx.doi.org/10.1017/S0950268813003415>]
294. Tanju IA, Levent F, Sezer RG, Cekmez F. Hepatitis B, hepatitis C and human immunodeficiency virus seropositivity among children in Kabul, Afghanistan: A cross-sectional study. *Hepatitis monthly*. 2014;14(3):e16154.[PMID: 2014206489,doi:
295. Todd CS, Ahmadzai M, Atiqzai F, Miller S, Smith JM, Ghazanfar SA, et al. Seroprevalence and correlates of HIV, syphilis, and hepatitis B and C virus among intrapartum patients in Kabul, Afghanistan. *BMC infectious diseases*. 2008;8:119.[PMID: 18798996,doi: 10.1186/1471-2334-8-119]
296. Todd CS, Mansoor GF, Sahibzada SM, Sakhizada MA, Shinwari K, Yaftali AZ, editors. Seroprevalence of sexually and blood-borne transmitted infections among Afghan National Security Forces recruits. Abstract TUPE144. 19th International AIDS Conference 2012.

297. Aidaoui M, Bouzbid S, Laouar M. [Seroprevalence of HIV infection in pregnant women in the Annaba region (Algeria)]. *Revue d'epidemiologie et de sante publique*. 2008;56(4):261-6.[PMID: 18687541,doi: 10.1016/j.respe.2008.05.023]
298. Belabas N, Zeroual M, Ihaddadene N, Dif A. The acceptability of screening for human immunodeficiency virus hepatitis C and B virus infections among pregnant women results of a survey in a testing center in Algiers.[PMID,doi:
299. Clifford GM, Waterboer T, Dondog B, Qiao YL, Kordzaia D, Hammouda D, et al. Hepatitis C virus seroprevalence in the general female population of 9 countries in Europe, Asia and Africa. *Infectious Agents and Cancer*. 2017;12(1):1-8.[PMID: 614249469,doi:
300. Abd Elrazek AE, Bilasy SE, Elbanna AE, Elsherif AE. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. *Medicine*. 2014;93(28):e204.[PMID: 25526438,doi: 10.1097/md.0000000000000204]
301. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology*. 2000;32(1):111-5.[PMID: 10869297,doi: 10.1053/jhep.2000.8438]
302. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. *The American journal of tropical medicine and hygiene*. 1994;51(5):563-7.[PMID: 7527186,doi:
303. AbdulQawi K, Youssef A, Metwally MA, Ragih I, AbdulHamid M, Shaheen A. Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. *Croatian medical journal*. 2010;51(3):219-28.[PMID: 20564765,doi:
304. Agha S, Sherif LS, Allam MA, Fawzy M. Transplacental transmission of hepatitis C virus in HIV-negative mothers. *Research in virology*. 1998;149(4):229-34.[PMID: 9783338,doi:

305. Aguilar CE, Soliman AS, McConnell DS, Zekri AR, Banerjee M, Omar A, et al. Androgen profiles among Egyptian adults considering liver status. *Journal of gastroenterology and hepatology*. 2008;23(7 Pt 2):e137-45.[PMID: 17524040,doi: 10.1111/j.1440-1746.2007.04949.x]
306. Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. *J Hepatol*. 2005;43(3):418-24.[PMID: 16019104,doi: 10.1016/j.jhep.2005.03.021]
307. Barakat SH, El-Bashir N. Hepatitis C virus infection among healthy Egyptian children: prevalence and risk factors. *Journal of viral hepatitis*. 2011;18(11):779-84.[PMID: 21992795,doi: 10.1111/j.1365-2893.2010.01381.x]
308. Bassily S. International Conference on Schistosomiasis. The Srp 1993 - Le Caire, 14-18 Fevrier 1993. Hepatite B, Hepatite C Et Bilharziose. *Medecine et Chirurgie Digestives*. 1993;22(7):441-2.[PMID: 1994006178,doi: 10.1093/ije/dyh183]
309. Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Abdel-Hamid M, Fahmy A, et al. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. *International journal of epidemiology*. 2004;33(5):1034-9.[PMID: 15155696,doi: 10.1093/ije/dyh183]
310. Darwish NM, Abbas MO, Hady SI, Mohammed TA. Study of the high prevalence of HCV in Egypt. *The Journal of the Egyptian Public Health Association*. 1995;70(3-4):397-414.[PMID: 17214166,doi: 10.1093/ije/dyh183]
311. Darwish MA, Faris R, Clemens JD, Rao MR, Edelman R. High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. *The American journal of tropical medicine and hygiene*. 1996;54(6):554-8.[PMID: 8686770,doi: 10.1093/ije/dyh183]
312. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, et al. Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. *The American journal of tropical medicine and hygiene*. 2001;64(3-4):147-53.[PMID: 11442209,doi: 10.1093/ije/dyh183]

313. Derbala M, Chandra P, Amer A, John A, Sharma M, Amin A, et al.
Reexamination of the relationship between the prevalence of hepatitis C virus and parenteral antischistosomal therapy among Egyptians resident in Qatar. *Clinical and experimental gastroenterology*. 2014;7:427-33.[PMID: 25395869,doi: 10.2147/ceg.s65369]
314. Eassa S, Eissa M, Sharaf SM, Ibrahim MH, Hassanein OM. Prevalence of hepatitis C virus infection and evaluation of a health education program in el-ghar village in zagazig, egypt. *The Journal of the Egyptian Public Health Association*. 2007;82(5-6):379-404.[PMID: 18706295,doi:
315. Edris A, Nour MO, Zedan OO, Mansour AE, Ghandour AA, Omran T.
Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate, Egypt. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2014;20(10):605-13.[PMID: 25356691,doi:
316. El Sayed Zaki M, El Aal AA, Badawy A, El-Deeb DR, El-Kheir NY.
Clinicolaboratory study of mother-to-neonate transmission of hepatitis E virus in Egypt. *American journal of clinical pathology*. 2013;140(5):721-6.[PMID: 24124153,doi: 10.1309/ajcpt55tdmjnppllv]
317. El Sayed Zaki M, Magdy Abd El Razek H, Magdy Abd El Razek M. Hepatitis E viral seroprevalence among multiple transfused Egyptian children. *Journal of Viral Hepatitis*. 2013;20:40-1.[PMID: 71357297,doi: <http://dx.doi.org/10.1111/jvh.12165>]
318. el-Ghazzawi E, Drew L, Hamdy L, El-Sherbini E, Sadek Sel D, Saleh E.
Intravenous drug addicts: a high risk group for infection with human immunodeficiency virus, hepatitis viruses, cytomegalo virus and bacterial infections in Alexandria Egypt. *The Journal of the Egyptian Public Health Association*. 1995;70(1-2):127-50.[PMID: 17214204,doi:
319. El-Kamary SS, Hashem M, Saleh DA, Ehab M, Sharaf SA, El-Mougy F, et al.
Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. *The Journal of infection*. 2015;70(5):512-9.[PMID: 25623176,doi: 10.1016/j.jinf.2015.01.009]

320. El-Karaksy H, Anwar GH, El-Raziky MS, El-Hawary M, Hashem M, El-Sayed R, et al. Anti-HCV prevalence among diabetic and non-diabetic Egyptian children. *Current diabetes reviews*. 2010;6(6):388-92.[PMID: 20879976,doi:
321. el-Nanawy AA, el Azzouni OF, Soliman AT, Amer AE, Demian RS, el-Sayed HM. Prevalence of hepatitis-C antibody seropositivity in healthy Egyptian children and four high risk groups. *Journal of tropical pediatrics*. 1995;41(6):341-3.[PMID: 8606441,doi:
322. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N, Mohsen N, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. *World journal of gastroenterology : WJG*. 2007;13(12):1828-32.[PMID: 17465475,doi:
323. el-Sadawy M, Ragab H, el-Toukhy H, el-Mor Ael L, Mangoud AM, Eissa MH, et al. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. *Journal of the Egyptian Society of Parasitology*. 2004;34(1 Suppl):367-84.[PMID: 15124747,doi:
324. el-Sayed NM, Gomatos PJ, Rodier GR, Wierzba TF, Darwish A, Khashaba S, et al. Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and *Treponema pallidum* infections: association of hepatitis C virus infections with specific regions of Egypt. *The American journal of tropical medicine and hygiene*. 1996;55(2):179-84.[PMID: 8780457,doi:
325. el-Sayed HF, Abaza SM, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for *Schistosoma mansoni* in Sinai, Egypt. *Acta tropica*. 1997;68(2):229-37.[PMID: 9386797,doi:
326. El-Sayed GM, Mohamed WS, Nouh MA, Moneer MM, El-Mahallawy HA. Viral genomes and antigen detection of hepatitis B and C viruses in involved lymph nodes of Egyptian non-Hodgkin's lymphoma patients. *The Egyptian journal of immunology / Egyptian Association of Immunologists*. 2006;13(1):105-14.[PMID: 17974155,doi:
327. El-Sherbini A, Hassan W, Abdel-Hamid M, Naeim A. Natural history of hepatitis C virus among apparently normal schoolchildren: follow-up after 7 years. *Journal of tropical pediatrics*. 2003;49(6):384-5.[PMID: 14725420,doi:

328. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International; 2009.
329. Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], and ICF International. Egypt Health Issues Survey 2015. Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International; 2015.
330. Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. *International journal of hygiene and environmental health*. 2005;208(5):329-39.[PMID: 16217918,doi: 16217918,doi: 16217918]
331. Fakeeh M, Zaki AM. Hepatitis C: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. *The American journal of tropical medicine and hygiene*. 1999;61(6):889-92.[PMID: 10674665,doi: 10674665,doi: 10674665]
332. Farghaly AG, Barakat RM. Prevalence, impact and risk factors of hepatitis C infection in Egypt. [French] *Prevalence, Impact Et Facteurs De Risques De L'hepatite C En Egypte. Medecine et Chirurgie Digestives*. 1994;23(3):171-3.[PMID: 1994163292,doi: 1994163292,doi: 1994163292]
333. Farghaly AG, Mansour GA, Mahdy NH, Yousri A. Hepatitis B and C virus infections among patients with gingivitis and adult periodontitis: seroprevalence and public health importance. *The Journal of the Egyptian Public Health Association*. 1998;73(5-6):707-35.[PMID: 17217032,doi: 17217032,doi: 17217032]
334. Farghaly HS, Metwalley KA, El-Hafeez HA. Hepatitis C virus infection in Egyptian children with type 1 diabetes mellitus: A single center study. *Indian journal of endocrinology and metabolism*. 2014;18(2):197-201.[PMID: 24741516,doi: 10.4103/2230-8210.129111]
335. Gad A, Tanaka E, Orii K, Rokuhara A, Nooman Z, Serwah AH, et al. Relationship between hepatitis C virus infection and schistosomal liver disease: not simply an additive effect. *Journal of gastroenterology*. 2001;36(11):753-8.[PMID: 11757747,doi: 11757747,doi: 11757747]

336. Goldman L, Ezzat S, Mokhtar N, Abdel-Hamid A, Fowler N, Gouda I, et al. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes. *Cancer causes & control : CCC*. 2009;20(6):981-7.[PMID: 19263231,doi: 10.1007/s10552-009-9316-0]
337. Hadhoud A, Abdulaziz AM, Menawi LA, Shaheen FA, Abdulghaffar A, Abas FA, et al. The relationship between HLA typing and HCV infection and outcome of renal transplantation in HCV positive patients. *Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation*. 2003;1(1):19-25.[PMID: 15859903,doi:
338. Hammad AM, Zaghloul MH. Hepatitis G virus infection in Egyptian children with chronic renal failure (single centre study). *Annals of clinical microbiology and antimicrobials*. 2009;8:36.[PMID: 20015406,doi: 10.1186/1476-0711-8-36]
339. Hassan NF, Kotkat A. Prevalence of antibodies to hepatitis C virus in pregnant women in Egypt. *The Journal of infectious diseases*. 1993;168(1):248-9.[PMID: 8390542,doi:
340. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. *Journal of clinical gastroenterology*. 2001;33(2):123-6.[PMID: 11468438,doi:
341. Helmy MF, Abdel Aziz, Gihan A.W, S. M. Hepatitis C Virus Infection among hemodialysis patients. *Egyptian Journal of Medical Microbiology*. 1995;4(2):289-92.[PMID,doi:
342. Hindy AM, Abdelhaleem ES, Aly RH. Hepatitis B and C viruses among Egyptian dentists. *Egyptian dental journal*. 1995;41(3):1217-26.[PMID: 9497659,doi:
343. Ibrahim HA, Baddour MM, Morsi MG, Abdelkader AA. Should we routinely check for hepatitis B and C in patients with lichen planus or cutaneous vasculitis? *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 1999;5(1):71-8.[PMID: 10793783,doi:

344. Jhaveri R, Hashem M, El-Kamary SS, Saleh DA, Sharaf SA, El-Mougy F, et al. Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors. *Open forum infectious diseases*. 2015;2(2):ofv089.[PMID: 26180831,doi: 10.1093/ofid/ofv089]
345. Kalil KA, Farghally HS, Hassanein KM, Abd-Elsayed AA, Hassanein FE. Hepatitis C virus infection among paediatric patients attending University of Assiut Hospital, Egypt. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2010;16(4):356-61.[PMID: 20795415,doi:
346. Kamel MA, Miller FD, el Masry AG, Zakaria S, Khattab M, Essmat G, et al. The epidemiology of *Schistosoma mansoni*, hepatitis B and hepatitis C infection in Egypt. *Annals of tropical medicine and parasitology*. 1994;88(5):501-9.[PMID: 7979640,doi:
347. Kandil ME, Rasheed MA, Saad NE. Hepatitis C and B viruses among some high risk groups of Egyptian children. *Journal of Medical Sciences*. 2007;7(8):1259-67.[PMID: 2007615566,doi:
348. Kassem AS, el-Nawawy AA, Massoud MN, el-Nazar SY, Sobhi EM. Prevalence of hepatitis C virus (HCV) infection and its vertical transmission in Egyptian pregnant women and their newborns. *Journal of tropical pediatrics*. 2000;46(4):231-3.[PMID: 10996985,doi:
349. Khalifa AS, Mitchell BS, Watts DM, el-Samahy MH, el-Sayed MH, Hassan NF, et al. Prevalence of hepatitis C viral antibody in transfused and nontransfused Egyptian children. *The American journal of tropical medicine and hygiene*. 1993;49(3):316-21.[PMID: 7690525,doi:
350. Khamis HH, Farghaly AG, Shatat HZ, El-Ghitany EM. Prevalence of hepatitis C virus infection among pregnant women in a rural district in Egypt. *Tropical doctor*. 2014.[PMID: 25515736,doi: 10.1177/0049475514561330]
351. Khedr M.S, Abdel-Hamid A. S, Abdel-Alla E.M, Abdel-Moneim S.M, E.f I. Liver injury in diabetic patients with hepatitis C virus antibodies. *Scientific Medical Journal*. 1995;7(4):105-16.[PMID,doi:

352. Kumar RM, Frossad PM, Hughes PF. Seroprevalence and mother-to-infant transmission of hepatitis C in asymptomatic Egyptian women. *European journal of obstetrics, gynecology, and reproductive biology*. 1997;75(2):177-82.[PMID: 9447371,doi: 353. Mansour AK, Aly RM, Abdelrazek SY, Elghannam DM, Abdelaziz SM, Shahine DA, et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. *Hematology/oncology and stem cell therapy*. 2012;5(1):54-9.[PMID: 22446611,doi: 10.5144/1658-3876.2012.54]
354. Mohamed MK, Hussein MH, Massoud AA, Rakhaa MM, Shoeir S, Aoun AA, et al. Study of the risk factors for viral hepatitis C infection among Egyptians applying for work abroad. *The Journal of the Egyptian Public Health Association*. 1996;71(1-2):113-47.[PMID: 17217004,doi: 355. Mohamed MK, Magder LS, Abdel-Hamid M, El-Daly M, Mikhail NN, Abdel-Aziz F, et al. Transmission of hepatitis C virus between parents and children. *The American journal of tropical medicine and hygiene*. 2006;75(1):16-20.[PMID: 16837701,doi: 356. Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, et al. HCV-related morbidity in a rural community of Egypt. *Journal of medical virology*. 2006;78(9):1185-9.[PMID: 16847958,doi: 10.1002/jmv.20679]
357. Mostafa A, Taylor SM, el-Daly M, el-Hoseiny M, Bakr I, Arafa N, et al. Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. *Liver international : official journal of the International Association for the Study of the Liver*. 2010;30(4):560-6.[PMID: 20141592,doi: 10.1111/j.1478-3231.2009.02204.x]
358. Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swiffee Y, Abdel-Hamid M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. *The American journal of tropical medicine and hygiene*. 2000;63(5-6):236-41.[PMID: 11421370,doi: 359. International Conference on Schistosomiasis. The SRP 1993 - Le Caire, 14-18 Februari 1993. *Hepatitis B, Hepatitis C and Schistosomiasis*. [French]

- International Conference on Schistosomiasis. The Srp 1993 - Le Caire, 14-18 Fevrier 1993. Hepatite B, Hepatite C Et Bilharziose. *Medecine et Chirurgie Digestives*. 1993;22(7):441-2.[PMID: 1994006178,doi:
360. Perumalswami PV, DeWolfe Miller F, Orabee H, Regab A, Adams M, Kapelusznik L, et al. Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. *Liver international : official journal of the International Association for the Study of the Liver*. 2014;34(2):253-8.[PMID: 23890188,doi: 10.1111/liv.12259]
361. Said ZN, El-Sayed MH, El-Bishbishi IA, El-Fouhil DF, Abdel-Rheem SE, El-Abedin MZ, et al. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies. *Liver international : official journal of the International Association for the Study of the Liver*. 2009;29(4):518-24.[PMID: 19192168,doi: 10.1111/j.1478-3231.2009.01975.x]
362. Sayed HA, El Ayyat A, El Dusoki H, Zoheiry M, Mohamed S, Hassan M, et al. A cross sectional study of hepatitis B, C, some trace elements, heavy metals, aflatoxin B1 and schistosomiasis in a rural population, Egypt. *The Journal of the Egyptian Public Health Association*. 2005;80(3-4):355-88.[PMID: 16900614,doi:
363. Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung Ch W, et al. Hepatitis C virus and other risk factors in hepatocellular carcinoma. *Acta virologica*. 2012;56(3):235-40.[PMID: 23043603,doi:
364. Shebl FM, El-Kamary SS, Saleh DA, Abdel-Hamid M, Mikhail N, Allam A, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. *Journal of medical virology*. 2009;81(6):1024-31.[PMID: 19382251,doi: 10.1002/jmv.21480]
365. Stoszek SK, Abdel-Hamid M, Narooz S, El Daly M, Saleh DA, Mikhail N, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006;100(2):102-7.[PMID: 16289168,doi: 10.1016/j.trstmh.2005.05.021]

366. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. *The American journal of tropical medicine and hygiene*. 2002;67(4):436-42.[PMID: 12452500,doi:
367. Yates SC, Hafez M, Beld M, Lukashov VV, Hassan Z, Carboni G, et al. Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. *The American journal of tropical medicine and hygiene*. 1999;60(4):714-20.[PMID: 10348253,doi:
368. Zakaria S, Esmat G, Al Boraey Y, El Raziky M, Fouad R, El-Garem H, et al. A community-based study of viral hepatitis infection in Giza Governorate, Egypt: Seroprevalence, risk factors and associated morbidity. *The Medical Journal of Cairo University* 2005;73(4):899.[PMID,doi:
369. Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. *Liver international : official journal of the International Association for the Study of the Liver*. 2013;33(5):727-38.[PMID: 23448397,doi: 10.1111/liv.12131]
370. Alavi S, Valeshabad AK, Sharifi Z, Nourbakhsh K, Arzani MT, Navidinia M, et al. Torque teno virus and hepatitis C virus co-infection in Iranian pediatric thalassemia patients. *Turkish journal of haematology : official journal of Turkish Society of Haematology*. 2012;29(2):156-61.[PMID: 24744647,doi: 10.5505/tjh.2012.20280]
371. Alavian SM, Ataei B, Ebrahimi A, Pirhaji O, Azad R, Olya B, et al. Anti-hepatitis e antibody in hemodialysis patients in Isfahan, Iran: Prevalence and risk factors. *Hepatitis monthly*. 2015;15 (9) (no pagination)(e23633).[PMID: 2015416228,doi:
372. Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of Hepatitis B Surface Antigen and Anti Hepatitis C Antibody in Zahedan City, Iran: A Population-Based Study. *Hepatitis monthly*. 2012;12(9):1-7.[PMID: 2012609509,doi:
373. Arfaee R, Goshbahifar S, Parvz N, Morteza R, Mahmoodabadi SA, Alavian SM, et al. The prevalence of hepatitis B and C virus infection in war veterans of the 27th

Islamic Revolutionary Guard Corps [Persian]. *Military Medicine Magazine*. 2002;4(1):6-9.[PMID,doi:

374. Chamani L, Zera'ati H, Asgari S, Shabestari O, Soltan-Ghorayi H, Habibzadeh-Shoja'i A. Seroepidemiologic study of CMV, toxoplasma and hepatitis B and C in clients of Avicenna Infertility Clinic. *Iran J Infect Dis Trop Med*. 2007;11(35):59-63.[PMID,doi:

375. ESFANDIARPOUR I.* ZS, RAHNAMA Z., DARVISH DAMAVANDI F. The prevalence of hepatitis C antibody in psoriatic patients in Kerman SCIENTIFIC JOURNAL OF HAMADAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES. 2005;12(1 (25)):5-9.[PMID,doi:

376. Esmaeili M, Mostafazadeh A, Sharbatdarn M, Hajiahmadi M, Alijanpoor M. Hepatitis C in blood products receivers. *Iranian Journal of Pediatrics*. 2004;14(1):15-20.[PMID,doi:

377. Gerayli S, Meshkat Z, Pasdar A, Mozafari PM, Banihashemi E, Khajavi MA, et al. The association between oral lichen planus and hepatitis C virus infection; a report from northeast of Iran. *Jundishapur Journal of Microbiology*. 2015;8 (4):e16741.[PMID: 2015039098,doi:

378. Ghadir M, Jafari E, Amiriani M, Rezvan H, Aminikafiabad S, Pourshams A. Hepatitis C in Golestan Province-Iran. *GOVARESH*. 2006;11(3):158-62.[PMID,doi:

379. Ghezdasht SA, Hassannia T, Rafatpanah H, Hekmat R, Valizadeh N, Mobarhan MG, et al. Oncogenic virus infections in the general population and end-stage renal disease patients with special emphasis on Kaposi's Sarcoma Associated Herpes Virus (KSHV) in Northeast of Iran. *Jundishapur Journal of Microbiology*. 2015;8 (3):e14920.[PMID: 2015920396,doi:

380. Hajiani e, Hashemi sj, Masjedi-zade a, Cheraghi m. Risk of Hepatitis C Virus transmission Following Upper Gastrointestinal Endoscopy. *Yafteh*. 2006;8(3):47-54.[PMID,doi:

381. Sharify Heydarabad H, Farid Soltany F, Montazam SH. Seroepidemiology of sti viruses in pregnant women: A retrospective study 2010-2011. *Journal of Sexual Medicine*. 2012;9:395.[PMID: 70954335,doi:

382. Jadali Z, Esfahanian F, Eslami MB, Sanati MH. Serum Antibodies against Hepatitis C Virus in Iranian Patients with Graves' Disease. *Iranian journal of allergy, asthma, and immunology*. 2005;4(2):91-4.[PMID: 17301428,doi: 04.02/ijaai.9194]
383. Jadali Z, Eslami MB, Sanati MH, Mansouri P, Mahmoudi M, Maghsoudi N, et al. Hepatitis C virus antibodies and vitiligo disease. *Iranian journal of public health*. 2005;34(1):23-6.[PMID: 2005431406,doi:
384. Za J, Fb E, DDc F, SMd A, MMe SD. Hashimoto's Thyroiditis and Its Association with Hepatitis C Virus Infection. *Int J Endocrinol Metab*. 2005;3:116-20.[PMID,doi:
385. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Kalhori AB, et al. Persistent alanine aminotransferase elevation among the general Iranian population: Prevalence and causes. *World Journal of Gastroenterology*. 2008;14(18):2867-71.[PMID: 2008357857,doi:
386. Kavooosi H, Ebrahimi A, Rezaei M, Jahani M. Association of Lichen Planus with Hepatitis B and C. *Journal of Kermanshah University of Medical Sciences*. 2008;11(4).[PMID,doi:
387. Kordi R, Neal K, Pourfathollah AA, Mansournia MA, Wallace WA. Risk of hepatitis B and C infections in Tehranian wrestlers. *Journal of athletic training*. 2011;46(4):445-50.[PMID: 21944078,doi:
388. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: The first population-based study from Iran. *International Journal of Infectious Diseases*. 2010;14(SUPPL. 3):e113-e6.[PMID: 2010551080,doi:
389. Moezzi M, Imani R, Karimi A, Pourheidar B. Hepatitis C seroprevalence and risk factors in adult population of Chaharmahal and Bakhtiari province of Iran in 2013. *Journal of Clinical and Diagnostic Research*. 2015;9(10):LC13-LC7.[PMID: 2015446426,doi:
390. Mohebbi SR, Sanati A, Cheraghipour K, Rostami Nejad M, Shalmani HM, Zali MR. Hepatitis C and hepatitis B virus infection: epidemiology and risk factors in a large

cohort of pregnant women in Lorestan, West of Iran. *Hepatitis monthly*. 2011;11(9):736-9.[PMID: 22235217,doi: 10.5812/kowsar.1735143X.749]

391. Mansour-Ghanaei F, Fallah M, Jafarshad R, Joukar F, Pourtahmasbi A, Bahari-Moghaddam A. Seroprevalence of hepatitis B and C among residents of Guilan Nursing Home. *Hepatitis monthly*. 2007;7(3):139-1141.[PMID,doi:

392. Moradi A, Mohagheghi AH, Shahraki S, Borji A, Marjani A, Sanei-Moghadam E, et al. Seroepidemiology of Rubella, Measles, HBV, HCV and B19 Virus Within Women in Child Bearing Ages (Saravan City of Sistan and Bloochastan Province). *Research Journal of Microbiology*. 2007;2(3).[PMID,doi:

393. Motlagh M.E, Makvandi M, M J. Prevalence of anti-HCV among pregnant women. *The Journal of Qazvin University of Medical Science*. 2001;5(2):59-63.[PMID,doi:

394. Mousavi SSB, Hayati F. Do we need to screen our patients for EBVIgGantibody before kidney transplantation? *Nephro-Urology Monthly*. 2011;3(2):122-4.[PMID: 2011181127,doi:

395. Mousavi SSB, Faramarzi M. Do we need to screen uremic patients for toxoplasmosis before kidney transplantation? *Shiraz E Medical Journal*. 2013;14(4).[PMID: 2014134213,doi:

396. Beladi Mousavi SS, Hayati F, Ghorbani A. Seroprevalence of cytomegalovirus antibody in renal transplant recipients and donors in Khuzestan Province, Iran. *Shiraz E Medical Journal*. 2010;11(4):203-8.[PMID: 2010578268,doi:

397. Nikbakht R, Saadati N, Firoozian F. Prevalence of HBsAG, HCV and HIV antibodies among infertile couples in Ahvaz, South-West Iran. *Jundishapur Journal of Microbiology*. 2012;5(2):393-7.[PMID: 2012272411,doi:

398. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, et al. The impact of illicit drug use on Spontaneous Hepatitis C Clearance: Experience from a large cohort population study. *PloS one*. 2011;6(8).[PMID: 2011471989,doi:

399. Sayad B, Saeed FS, Keyvani H, Rezali M, Asadi T, Vaziri S, et al. Seroepidemiology of hepatitis C in Kermanshah (West of Iran, 2006). *Hepatitis monthly*. 2008;8(2):141-6.[PMID: 2008321653,doi:
400. Shaheli M, Yaghobi R, Rezaeian A, Saadi MI, Ramzi M. Study of the associations between TT Virus single and mixed infections with leukemia. *Jundishapur Journal of Microbiology*. 2015;8(4):e18212.[PMID: 2015049663,doi:
401. Shakeri MT, Nomani H, Mobarhan MG, Sima HR, Gerayli S, Shahbazi S, et al. The prevalence of hepatitis C virus in Mashhad, Iran: A population-based study. *Hepatitis monthly*. 2013;13(3).[PMID: 2013222815,doi:
402. Shamsdin SA, Fattahi MR, Amirzadeh fard S. The prevalence of hepatitis C infection in general population in Shiraz, southern Iran. *International Journal of Infectious Diseases*. 2012;16:e110.[PMID: 70868774,doi:
403. Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim M, Merat S, Pourshams A. Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study. *Middle East journal of digestive diseases*. 2010;2(1):14-9.[PMID: 25197507,doi:
404. A.Tanomand HMaMK. Seroepidemiology of Hepatitis C Antibody Between Rural and Urban People: A Retrospective Study in June to December of 2005 in Malekan City, Iran. *Research Journal of Biological Sciences*. 2007;2:561-3.[PMID,doi:
405. Vahidi A, Taheri A, Nikian Y. Prevalence of Hepatitis C among Thalassemic patients referring to Kerman university of medical sciences hospital No. 1 in 1996. *Journal of Kerman University of Medical Sciences*. 2000;7(3):110-4.[PMID,doi:
406. Yazdani M, Shakeri S. Vertical transmission of hepatitis C from pregnant-mothers to their. *Bimonthly Journal of Hormozgan University of Medical Sciences*. 2006;10(2):145-9.[PMID,doi:
407. Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, et al. Prevalence and risk factors of hepatitis C virus infection in Amol city, north of Iran: A population-Based study (2008-2011). *Hepatitis monthly*. 2013;13(12).[PMID: 2013779483,doi:

408. Taghavi Zenouz A, Mehdipour M, Gholizadeh N, Naghili B, Jafari Heydarlou M. Evaluation of Relationship between Lichen Planus and HCV Antibody. *Journal of dental research, dental clinics, dental prospects*. 2010;4(1):10-3.[PMID: 22991587,doi: 10.5681/joddd.2010.003]
409. Al Wtaify AS, Hassan MK. Prevalence of hepatitis C virus infection among multitransfused thalassemic children in Basrah - Iraq. *Qatar Medical Journal*. 2000;9(2):58-61.[PMID: 2001134222,doi:
410. Al-Jebori A. S., Hassan A. S., Al-Duliami A. A. Seroprevalence of hepatitis B and hepatitis C virus infections in Diyala province during 2003-2008. *Diyala Journal For Pure Science*. 2010;6(1):292-302.[PMID,doi:
411. Al-Hamdani A.H., Al-Rawy S. K., Khamees H. A. Retrospective seroprevalence study of hepatitis B and C in Iraqi population at Baghdad: a hospital based study. *Iraqi Journal of Community Medicine*. 2012(3):186-90.[PMID,doi:
412. Hussain A. K., Mohammed S. H., Abd K. H. Screening of hepatitis B and C viral markers in Iraqi patients with proteinuria. *Iraqi Postgraduate Medical Journal*. 2008;7(4):362-8.[PMID,doi:
413. Al-Azzawi M. K. K. Study of the spread of viral hepatitis pattern (C) among pregnant women in the city of Baquba. *Journal of Diyala for Humanity Research* 2006(22):106-12.[PMID,doi:
414. Tarky A. M., Akram W., Al-Naaimi A. S., Omer A. R. Epidemiology of viral heaptitis B and C in iraq: a national survey 2005-2006. *Zanco Journal of Medical Sciences*. 2013;17(1):370-80.[PMID,doi:
415. Omer AR, Salih JI, Al-Nakshabandi AA. Frequency of blood-borne viral infections among leukemic patients in central Iraq. *Saudi medical journal*. 2011;32(1):55-61.[PMID: 21212918,doi:
416. Salman Y. G. Serological cross reaction among some causative agents of women abortions (*Toxoplasma gondii* & *Cytomegalo virus* & *Rubella virus*), with the incidence of hepatitis virus (B & C). *Tikret Journal of Pharmaceutical Sciences*. 2007;3(2):102-11.[PMID,doi:

417. Saadoon I. H., Salih N. I., Saihood S. T. Hepatitis C virus infection and abortion among pregnant women in Mosul city. *Medical Journal of Tikrit*. 2008;1(141):161-4.[PMID,doi:
418. Al-Zamili A. H., Al-Shebani A. M., Mohsin R. K. Prevalence of hepatitis C viral infection among multi-transfused thalassemic patients. *Al-Qadisiyah Medical Journal*. 2009;5(7):89-99.[PMID,doi:
419. Al-Ani M. H., Rasul T. H. Hepatitis B and C viral infections in children with acute leukemia in Erbil city. *Journal of the Arab Board of Health Specializations*. 2011;12(1):21-9.[PMID,doi:
420. Al-Saad T, Al-Alousi BM, Khalaf NM, Abdul Razak W. Prevalence of hepatitis B and C viruses among medical staff in Ramadi General Hospital. *Al-Anbar Medical Journal*. 2009;7(1):68-75.[PMID,doi:
421. Abed B. A. Prevalence of hepatitis C virus (HCV) among thalassemia patients in Ibn Al-Balady Hospital. *Journal of Al-Nahrain University*. 2010;13(1):121-6.[PMID,doi:
422. Al-Dulaimi S. B. K., Al-Ubadi A. E., Al-Ubadi A. E., Al-Bayatti E. N., Al-Saday S. D. K. *Toxoplasma gondii*, HCV, and HBV seroprevalence in Haemodialysis patients with chronic renal failure in Al-Kindy Hospital Baghdad, Iraqi. *Al-Mustansiriyah Journal of Science*. 2012;23(5):33-8.[PMID,doi:
423. Fawzi N., Muhsin K. A. A. Screening for hepatitis B and hepatitis C viral infection among a sample of pregnant women in Al-Fallujah. *Iraqi Medical Journal*. 2011;57(2):119-25.[PMID,doi:
424. Naji MY, Abdulzahra AA, Hmood AR. Prevalence of viral hepatitis B and C in newly married persons. *Kufa Journal for Nursing Sciences*. 2013;3(3).[PMID,doi:
425. Al-Greti S. H. H. Prevalence of hepatitis C virus in beta-thalassemia major patients at Karbala governorate. *Journal of Babylon University for Pure and Applied Sciences*. 2013;21(8):2801-5.[PMID,doi:
426. Al-Kubaisy WA, Niazi AD, Kubba K. History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women. *Eastern Mediterranean health*

journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2002;8(2-3):239-44.[PMID: 15339110,doi:

427. Chironna M, Germinario C, Lopalco PL, Carrozzini F, Barbuti S, Quarto M. Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey. *Infection*. 2003;31(2):70-4.[PMID: 12682810,doi: 10.1007/s15010-002-3100-3]

428. Al-Kubaisy W. A., Niazi A., Kubba K. Lack of mother-to-newborn transmission of hepatitis C virus in Iraqi women: a prospective study with hepatitis C virus RNA testing. *Journal of the Arab Board of Health Specializations*. 2000;2(2).[PMID,doi:

429. Hussein NR, Mohammed Abdullah I, Mohammed Younus O, Taher AM, Salim AA, Shahab FI. Prevalence of HBV, HCV and HIV infections among Syrian refugees in Kurdistan region, Iraq. *International Journal of Infection*. 2017;4(2).[PMID,doi:

430. Hamoudi W, Ali SA, Abdallat M, Estes CR, Razavi HA. HCV infection prevalence in a population recruited at health centers in Jordan. *Journal of epidemiology and global health*. 2013;3(2):67-71.[PMID: 23856567,doi: 10.1016/j.jegh.2013.02.003]

431. Mansi K, Aburjai T, AlBashtawy M, Abdel-Dayem M. Biochemical factors relevant to kidney functions among Jordanian children with beta-thalassemia major treated with deferoxamine. *International Journal of Medicine and Medical Sciences*. 2013;5(8):374-9.[PMID,doi:

432. Al-Mutairi BSN. Hepatitis B and hepatitis C virus prevalence among sexually transmitted disease patients in farwania region of Kuwait: BMJ Publishing Group; 2013 [Available from: http://0-sti.bmj.com.elibrary.qatar-weill.cornell.edu/content/89/Suppl_1/A198.3.abstract?sid=71ff13af-902c-45de-9450-ae1608b0096d
<http://0-ovidsp.ovid.com.elibrary.qatar-weill.cornell.edu/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=71442653>.

433. Chehadeh W, Kurien SS, Abdella N, Ben-Nakhi A, Al-Arouj M, Almuaili T, et al. Hepatitis C virus infection in a population with high incidence of type 2 diabetes:

impact on diabetes complications. *Journal of infection and public health*. 2011;4(4):200-6.[PMID: 22000848,doi: 10.1016/j.jiph.2011.05.004]

434. Nabulsi MM, Araj GF, Farah AE, Khalil AM. Hepatitis C virus antibodies in pregnant Lebanese women. *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology*. 1997;17(6):548.[PMID: 15511954,doi: 10.1080/01443619768560]

435. Abou Rached A, Abou Kheir S, Saba J, Ammar W. Epidemiology of hepatitis B and hepatitis C in Lebanon. *Arab Journal of Gastroenterology*. 2016;17(1):29-33.[PMID,doi:

436. Baddoura R, Haddad C, Germanos M. Hepatitis B and C seroprevalence in the Lebanese population. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2002;8(1):150-6.[PMID: 15330570,doi:

437. Shabash A, Habas M, Alhajrasi A, Furarah A, Bouzedi A, Daw M. Forecast modelling for prediction of hepatitis B and hepatitis C seropositivity among Libyan population. 2010.[PMID,doi:

438. Elzouki AN, Smeo MN, Sammud M, Elahmer O, Daw M, Furarah A, et al. Prevalence of hepatitis B and C virus infections and their related risk factors in Libya: a national seroepidemiological survey. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2013;19(7):589-99.[PMID: 24975303,doi:

439. Daw MA, Shabash A, El-Bouzedi A, Dau AA. Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya. *PloS one*. 2014;9(6):e98793.[PMID: 24936655,doi: 10.1371/journal.pone.0098793]

440. Cacoub P, Ohayon V, Sekkat S, Dumont B, Sbai A, Lunel F, et al. [Epidemiologic and virologic study of hepatitis C virus infections in Morocco]. *Gastroenterologie clinique et biologique*. 2000;24(2):169-73.[PMID: 12687957,doi:

441. Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. [Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the

- viremia prediction]. *Pathologie-biologie*. 2009;57(5):368-72.[PMID: 18842351,doi: 10.1016/j.patbio.2008.07.006]
442. Masvidal Aliberch RM, Estabanell Buxo A, Miguel Gil B, Cruz Rodriguez C, de Frutos Gallego E, Guzman Molina C, et al. [Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants]. *Gaceta sanitaria / SESPAS*. 2010;24(4):288-92.[PMID: 20053479,doi: 10.1016/j.gaceta.2009.10.013]
443. Doblali T, Hadeif R. [Seroprevalence of hepatitis C at the Military Hospital Mohammed V of Rabat]. *The Pan African medical journal*. 2014;19:182.[PMID: 25815103,doi: 10.11604/pamj.2014.19.182.5347]
444. Akil A, Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, Diagne AG, et al. Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma. *Cancer epidemiology*. 2012;36(5):e300-5.[PMID: 22709982,doi: 10.1016/j.canep.2012.05.011]
445. Tagajdid MR, Belefquih B, Rahoui J, Laidi F, El Annaz H, Doblali T, et al. Seroepidemiology of HIV, hepatitis B and C, herpesviruses, rubella and parvovirus B19 in Moroccan pregnant women.[PMID,doi:
446. Agboatwalla M, Isomura S, Miyake K, Yamashita T, Morishita T, Akram DS. Hepatitis A, B and C seroprevalence in Pakistan. *Indian journal of pediatrics*. 1994;61(5):545-9.[PMID: 125064944,doi:
447. Luby SP, Qamruddin K, Shah AA, Omair A, Pahsa O, Khan AJ, et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. *Epidemiology and infection*. 1997;119(3):349-56.[PMID: 9440439,doi:
448. Khan AJ, Luby SP, Fikree F, Karim A, Obaid S, Dellawala S, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. *Bulletin of the World Health Organization*. 2000;78(8):956-63.[PMID: 30663530,doi:

449. Muhammad N, Jan MA. Frequency of hepatitis "C" in buner, NWFP. Journal of the College of Physicians and Surgeons Pakistan. 2005;15(1):11-4.[PMID: 40347555,doi: 450.
- Idrees M, Lal A, Naseem M, Khalid M. High prevalence of hepatitis C virus infection in the largest province of Pakistan. Journal of digestive diseases. 2008;9(2):95-103.[PMID: 351566631,doi: <http://dx.doi.org/10.1111/j.1751-2980.2008.00329.x>]
451. Aslam M, Aslam J. Seroprevalence of the antibody to hepatitis C in select groups in the Punjab region of Pakistan. Journal of clinical gastroenterology. 2001;33(5):407-11.[PMID: 33026728,doi: <http://dx.doi.org/10.1097/00004836-200111000-00013>]
452. Khokhar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B virus infections in population. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2004;14(9):534-6.[PMID: 15353136,doi: 09.2004/jcpsp.534536]
453. Jaffery T, Tariq N, Ayub R, Yawar A. Frequency of hepatitis C in pregnancy and pregnancy outcome. Journal of the College of Physicians and Surgeons Pakistan. 2005;15(11):716-9.[PMID: 43078880,doi: 454.
- Hakim S, Kazmi S, Bagasra O. Seroprevalence of hepatitis B and C genotypes among young apparently healthy females of Karachi-Pakistan. Libyan Journal of Medicine. 2008;3(2):66-70.[PMID,doi: 455.
- Ali M, Kanwal L, Tassaduqe K, Iqbal R. Prevalence of hepatitis C virus (HCV) in relation to its promotive factors among human urban population of Multan, Pakistan. European Journal of General Medicine. 2009;6(2):41-5.[PMID: 354913988,doi: 456.
- Rifat uz Z. Prevalence of hepatitis B and hepatitis C viruses in human urban population of Bahawalpur district, Pakistan. Journal of Medical Sciences. 2006;6(3):367-73.[PMID: 44010505,doi: <http://dx.doi.org/10.3923/jms.2006.367.373>]
457. Butt T, Amin MS. Seroprevalence of hepatitis B and C infections among young adult males in Pakistan. Eastern Mediterranean Health Journal. 2008;14(4):791-7.[PMID: 352487037,doi: 458.
- Sami S, Korejo R, Bhutta SZ. Prevalence of hepatitis B and C: A Jinnah Postgraduate Medical Centre experience. Journal of Obstetrics and Gynaecology

Research. 2009;35(3):533-8.[PMID: 354905885,doi: <http://dx.doi.org/10.1111/j.1447-0756.2008.00991.x>]

459. Janjua NZ, Hamza HB, Islam M, Tirmizi SFA, Siddiqui A, Jafri W, et al. Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. *Journal of Viral Hepatitis*. 2010;17(5):317-26.[PMID: 358496640,doi: <http://dx.doi.org/10.1111/j.1365-2893.2009.01230.x>]

460. Aziz S, Hossain N, Karim SA, Rajper J, Soomro N, Noorulain W, et al. Vertical transmission of hepatitis C virus in low to middle socio-economic pregnant population of Karachi. *Hepato Int*. 2011;5(2):677-80.[PMID: 21484109,doi: 10.1007/s12072-010-9229-8]

461. Gul N, Sarwar J, Idris M, Farid J, Rizvi F, Suleman M, et al. Seroprevalence of hepatitis C in pregnant females of Hazara division. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2009;21(4):83-6.[PMID: 360248058,doi:

462. Shaikh FH, Ali Abro H, Ali Chhutto M, Abbasi PA, Shaikh AW, Ali Buriro S. Hepatitis C: frequency and risk factors associated with sero-positivity among adults in Larkana City. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2009;21(2):107-9.[PMID: 360289677,doi:

463. Hashmi A, Saleem K, Soomro JA. Prevalence and factors associated with hepatitis C virus seropositivity in female individuals in Islamabad, Pakistan. *International Journal of Preventive Medicine*. 2010;1(4):252-6.[PMID: 361336985,doi:

464. Taseer IU, Ishaq F, Hussain L, Safdar S, Mirbahar AM, Faiz SA. Frequency of anti-HCV, HBsAg and related risk factors in pregnant women at Nishtar Hospital, Multan. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2010;22(1):13-6.[PMID: 361629171,doi:

465. Junejo SA, Khan NA, Lodhi AA. Prevalence of hepatitis B and C infection in patients admitted at tertiary eye care centre: A hospital based study. *Pakistan Journal of Medical Sciences*. 2009;25(4):597-600.[PMID: 355272833,doi:

466. Aziz S, Khanani R, Noorulain W, Rajper J. Frequency of Hepatitis B and C in rural and periurban Sindh. *Journal of the Pakistan Medical Association*. 2010;60(10):853-7.[PMID: 359797018,doi:
467. Hyder O, Ijaz M, Arshad MA, Zahira T. Age-specific frequency of screen-detected hepatitis C virus seropositivity in men from the Punjab province of Pakistan. *Journal of medical screening*. 2010;17(4):214-6.[PMID: 361719013,doi:
468. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in pakistan: Findings of a national survey appealing for effective prevention and control measures. [French]
Prevalence des infections virales de l'hepatite B et de l'hepatite C au Pakistan: Resultats d'une enquete nationale appelant a des mesures de lutte efficaces. *Eastern Mediterranean Health Journal*. 2010;16(SUPPL.):S15-23.[PMID: 359659555,doi:
469. Ahmed F, Irving WL, Anwar M, Myles P, Neal KR. Prevalence and risk factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan: Most infections remain unexplained. A cross-sectional study. *Epidemiology and infection*. 2012;140(4):716-23.[PMID: 364401798,doi:
<http://dx.doi.org/10.1017/S0950268811001087>]
470. Memon AR, Shafique K, Memon A, Draz AU, Rauf MUA, Afsar S. Hepatitis B and C prevalence among the high risk groups of Pakistani population. A cross sectional study. *Archives of Public Health*. 2012;70(1):9-.[PMID: PMC3502333,doi: 10.1186/0778-7367-70-9]
471. Saleem M, Ahmad W, Sarwar J, Jamshed F, Gul N, Idrees M. Frequency of hepatitis C in asymptomatic patients in District Headquarters Hospital Kotli, Azad Kashmir. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2011;23(2):59-62.[PMID: 373389837,doi:
472. Khan MI, Muhammad M. Frequency of hepatitis B and C in patients visiting outpatient department of District Head Quarters Hospital Lakki. *Journal of Postgraduate Medical Institute*. 2012;26(1):55-60.[PMID: 364051307,doi:

473. Ali A, Ahmad H, Ali I, Khan S, Zaidi G, Idrees M. Prevalence of active hepatitis c virus infection in district mansehra pakistan. *Virology journal*. 2010;7 (no pagination)(334).[PMID: 51167480,doi: <http://dx.doi.org/10.1186/1743-422X-7-334>]
474. Rauf A, Nadeem MS, Ali A, Iqbal M, Mustafa M, Latif MM, et al. Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan. *European journal of public health*. 2011;21(5):638-42.[PMID: 560025834,doi:]
475. Hossain N. O316 HEPATITIS E IS AN IMPORTANT CAUSE OF JAUNDICE DURING PREGNANCY IN PAKISTAN. *International Journal of Gynecology & Obstetrics*. 2012;119:S372-S.[PMID,doi:]
476. Muhammad SK, Chandio MA, Soomro MA, Shaikh BA. Hepatitis C virus infection in non-Hodgkin's lymphoma: a case-control study. 2012.[PMID,doi:]
477. Jamil MS, Ali H, Shaheen R, Basit A. Prevalence, knowledge and awareness of hepatitis C among residents of three Union Councils in Mansehra. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2010;22(3):192-6.[PMID: 364571749,doi:]
478. Hafeez ud d, Siddiqui TS, Lahrasab W, Sharif MA. Prevalence of hepatitis B and C in healthy adult males of paramilitary personnel in Punjab. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2012;24(3-4):138-40.[PMID: 373098071,doi:]
479. Khan FS, Lotia-Farrukh I, Khan AJ, Siddiqui ST, Sajun SZ, Malik AA, et al. The Burden of Non-Communicable Disease in Transition Communities in an Asian Megacity: Baseline Findings from a Cohort Study in Karachi, Pakistan. *PloS one*. 2013;8 (2) (no pagination)(e56008).[PMID: 368342594,doi: <http://dx.doi.org/10.1371/journal.pone.0056008>]
480. Seema B. Seroprevalence and risk factors for hepatitis C virus (HCV) infection in pregnant women attending public sector tertiary care hospital in Hyderabad Sindh. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2013;120:172.[PMID: 71136012,doi: <http://dx.doi.org/10.1111/1471-0528.12293>]
481. Bhatti S, Manzoor S. Molecular epidemiology and clinical features of Hepatitis C Virus (HCV) in epidemic areas of Interior Sindh, Pakistan. *Pakistan journal of medical sciences*. 2016;32(5):1279.[PMID,doi:]

482. Nawaz A, Chaudhry A, Nawaz S, Nawaz M, Alvi A, Riaz M, et al. Risk factors for development of chronic hepatitis in the developing world-risk factors and attitudes. *American Journal of Gastroenterology*. 2012;107:S167.[PMID: 70894019,doi: <http://dx.doi.org/10.1038/ajg.2012.271>]
483. Rauf M, Saleem MD, Anwer MO, Ahmed G, Aziz S, Memon MA. HIV, hepatitis B and hepatitis C in garbage scavengers of Karachi. *JPMA The Journal of the Pakistan Medical Association*. 2013;63(6):798-802.[PMID,doi:
484. Kumari K, Seetlani NK, Akhter R. The Emergent Concern of Seropositive Status of Hepatitis-B Virus and Hepatitis-C Virus in the Pregnant Females Attending a Tertiary Care Hospital. *Journal of Ayub Medical College, Abbottabad : JAMC*. 2015;27(1):155-7.[PMID: 605808842,doi:
485. Azhar S, Syed A, Yousaf A, Khan T, Mansoor Z, Haq N. Knowledge, Awareness, And Prevalence Among Community Regarding Hepatitis B And C In Abbottabad, Kpk, Pakistan. *Value in Health*. 2016;19(3):A11.[PMID,doi:
486. Ilyas M, Ahmad I. Chemiluminescent microparticle immunoassay based detection and prevalence of HCV infection in district Peshawar Pakistan. *Virology journal*. 2014;11 (1) (no pagination)(127).[PMID: 53242702,doi: <http://dx.doi.org/10.1186/1743-422X-11-127>]
487. Gohar A. Health status of industrial workforce in district Lahore Pakistan. *International Journal of Infectious Diseases*. 2016;45:225-6.[PMID,doi:
488. Ahmad I. Prevalence of hepatitis b and C viral infection among pregnant women in Peshawar, Pakistan. *Hepatitis monthly*. 2016;16 (6) (no pagination)(e36383).[PMID: 611291318,doi:
489. Khan A, Qazi J. Risk factors and molecular epidemiology of HBV and HCV in internally displaced persons (IDPs) of North Waziristan Agency, Pakistan. *JPMA J Pak Med Assoc*. 2018;68(2):165-9.[PMID,doi:
490. Donchuk D, Rossi G, Bjorklund Y, Zainal HM, Auat R, Mazzeo V. Hepatitis C treatment in a primary care clinic in the high HCV burden setting in Karachi, Pakistan.

Hepatology International. 2016;1):S34.[PMID: 72199986,doi:

<http://dx.doi.org/10.1007/s12072-016-9707-8>]

491. Parveen M, Ismaile M, Masood R. Seroprevalence of Hepatitis B Surface Antigen and Antibodies against Hepatitis C Virus among Pregnant Women Attending Rural Health Centre of South Punjab. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES. 2017;11(3):933-7.[PMID,doi:

492. Parker SP, Khan HI, Cubitt WD. Detection of antibodies to hepatitis C virus in dried blood spot samples from mothers and their offspring in Lahore, Pakistan. Journal of Clinical Microbiology. 1999;37(6):2061-3.[PMID: 29235280,doi:

493. Aslam M, Aslam J, Mitchell BD, Munir KM. Association between smallpox vaccination and hepatitis C antibody positive serology in Pakistani volunteers. Journal of clinical gastroenterology. 2005;39(3):243-6.[PMID: 40283962,doi:

<http://dx.doi.org/10.1097/01.mcg.0000153286.02694.14>]

494. Jafri W, Jafri N, Yakoob J, Islam M, Ali Tirmizi SF, Jafar T, et al. Hepatitis B and C: Prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC infectious diseases. 2006;6 (no pagination)(101).[PMID: 44226580,doi:

<http://dx.doi.org/10.1186/1471-2334-6-101>]

495. Abbas Z, Jeswani NL, Kakepoto GN, Islam M, Mehdi K, Jafri W. Prevalence and mode of spread of hepatitis B and C in rural Sindh, Pakistan. Tropical gastroenterology : official journal of the Digestive Diseases Foundation. 2008;29(4):210-6.[PMID: 354552952,doi:

496. Jalbani A, Ansari IA, Shah AH, MalGurabakhashani K, Chutto M, Jalbani MA. Prevalence of hepatitis-C virus infection in Khairpurnathan Shah and Shahdakot a city based screening program. Medical Forum Monthly. 2009;20(11):15-7.[PMID: 358347786,doi:

497. Abbas M, Hussain MF, Raza S, Shazi L. Frequency and awareness of hepatitis B and C in visitors of Hepatitis Awareness Mela. JPMA The Journal of the Pakistan Medical Association. 2010;60(12):1069-71.[PMID: 21381568,doi:

498. Iqbal A, Akram M, Ali H, Akhtar N, Nazir SUR, Ahmad I, et al. Prevalence of hepatitis C virus (HCV) in gadap town karachi, pakistan. *Journal of Medicinal Plant Research*. 2011;5(25):6102-4.[PMID: 362978760,doi: <http://dx.doi.org/10.5897/JMPR11.307>]
499. Yousaf MZ, Idrees M, Saleem Z, Rehman IU, Ali M. Expression of core antigen of HCV genotype 3a and its evaluation as screening agent for HCV infection in Pakistan. *Virology journal*. 2011;8 (no pagination)(364).[PMID: 51545969,doi: <http://dx.doi.org/10.1186/1743-422X-8-364>]
500. Abbas F, Mengal MA, Hanif M, Ali M, Pirkarni GS, Ahmad Z. Seroprevalence of hepatitis C virus in general population of Balochistan, Pakistan. *Pakistan Journal of Medical and Health Sciences*. 2013;7(1):180-4.[PMID: 369117047,doi:]
501. Ali S, Ahmad A, Khan RS, Khan S, Hamayun M, Khan SA, et al. Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in mardan, pakistan. *Advances in virology*. 2014;2014.[PMID,doi:]
502. Khan S, Ahmed B, Zahid M, editors. Prevalence of HBV and HCV in Sukkar, Pakistan. *VIRCHOWS ARCHIV*; 2016: SPRINGER ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES.
503. Akhtar N, Ilyas M, Muhammad K, Shams S, Saeed K, Asadullah A. Prevalence of Hepatitis C virus infections among the general population of Buner, Khyber Pakhtunkhwa, Pakistan. *Biomedical Research and Therapy*. 2016;3(12):1003-17.[PMID,doi:]
504. Afsheen Z, Ahmad B, Bashir S. Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. *Virology journal*. 2017;14(1):1-6.[PMID,doi:]
505. Sharma M, Matar K, Dweik NA, Kaabi SA, John AK, Mohannadi MA, et al. Early detection of hepatitis C using a one minute visual qualitative based kit system in a community based setting in Doha, Qatar. *Journal of Hepatology*. 2010;52:S260.[PMID: 70131519,doi: <http://dx.doi.org/10.1016/S0168-8278%2810%2960669-1>]

506. Sharma M, Kaabi SA, Dweik NA, John AK, Wani H, Mohannadi MA, et al. Screening for hepatitis c and comparison of disease characteristics and response to treatment with non-screened patients: Elsevier; 2014 [1 SUPPL. 1:[S315]. Available from: <http://0-ovidsp.ovid.com.elibrary.qatar-weill.cornell.edu/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=71444275>.
507. Al-Faleh FZ, Ayoola EA, Al-Jeffry M, Al-Rashed R, Al-Mofarreh M, Arif M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: A community-based study. *Hepatology*. 1991;14(2):215-8.[PMID: 1991281572,doi: <http://dx.doi.org/10.1016/0270-9139%2891%2991405-P>]
508. Al Nasser MN. Intrafamilial transmission of hepatitis C virus (HCV): A major mode of spread in the Saudi Arabia population. *Annals of tropical paediatrics*. 1992;12(2):211-5.[PMID: 1992192876,doi:
509. Al-Sohaibani MO, Al-Sheikh EH, Al-Ballal SJ, Mirghani MAM, Ramia S. Occupational risk of hepatitis B and C infections in Saudi medical staff. *Journal of Hospital Infection*. 1995;31(2):143-7.[PMID: 1995332172,doi: <http://dx.doi.org/10.1016/0195-6701%2895%2990169-8>]
510. Njoh J, Zimmo S. Prevalence of antibodies to hepatitis C virus in drug-dependent patients in Jeddah, Saudi Arabia. *East African medical journal*. 1997;74(2):89-91.[PMID: 1997300211,doi:
511. El-Rifaei AM, Fathalla SE, Al-Sheikh IH, Tinguria MB, Qadry YA. The prevalence of indices of hepatitis C and B infection, and elevated aminotransferase enzymes in patients with oral lichen planus (olp) in eastern saudi arabia. *Journal of family & community medicine*. 1998;5(2):39-43.[PMID: 23008588,doi:
512. Ayoola EA, Gadour MO. Hepatocellular carcinoma in Saudi Arabia: Role of hepatitis B and C infection. *Journal of gastroenterology and hepatology*. 2004;19(6):665-9.[PMID: 2004283547,doi: <http://dx.doi.org/10.1111/j.1440-1746.2003.03334.x>]
513. Alsuhaibani O, Pereira WC, Tareeqanwar M, El Khizzi N, Bakheswain S, Shaker A, et al. Infectious disease screening among stem cell transplant donors: An

Institutional experience in Saudi Arabia. *Annals of neurosciences*.

2015;22(2):81.[PMID,doi:

514. Qasim L, Abed E, Memish Z, AlBasheer A, Aldraihim A, Knawy B, et al. Pattern of viral hepatitis infection in a selected population from Saudi Arabia. *Military Medicine*. 2003;168(7):565-8.[PMID: 2003296385,doi:

515. Tonsi A, Samdani AJ. Association of lichen planus with hepatitis C virus infection. *Annals of Saudi Medicine*. 2005;25(3):243-6.[PMID: 2005308542,doi:

516. Al-Ajlan A. Prevalence of hepatitis B and C among students of health colleges in Saudi Arabia

Prevalence de l'hepatite B et C chez des etudiants en faculte de sante en Arabie Saoudite.

Eastern Mediterranean Health Journal. 2011;17(10):759-62.[PMID: 2011586469,doi:

517. Khalaf H, Jovero R, Al-Sofayan M, Al-Sebayel M. The challenge of finding donors for living donor liver transplantation in Saudi Arabia. *Transplantation proceedings*. 2004;36(8):2222-3.[PMID: 2004504870,doi:

<http://dx.doi.org/10.1016/j.transproceed.2004.08.127>

518. Mansoor AA, Salih AI, Al-Jaroudi DH. Screening of hepatitis B and C and human immunodeficiency virus in infertile couples in Saudi Arabia. *Saudi medical journal*. 2011;32(3):260-4.[PMID: 2011146242,doi:

519. Alswaidi FM, O'Brien SJ. Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors? *Journal of epidemiology and community health*.

2010;64(11):989-97.[PMID: 19822552,doi: 10.1136/jech.2009.093302]

520. Abdel-Moneim AS, Bamaga MS, Shehab GM, Abu-Elsaad AA, Farahat FM. HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. *PloS one*. 2012;7(1):e29781.[PMID: 22253780,doi:

<http://dx.doi.org/10.1371/journal.pone.0029781>

521. Aljarbou AN. Current prevalence of HBV and HCV seropositivity: The initiative for attentiveness and deterrence of viral hepatitis in the Qassim region of Saudi Arabia.

Journal of Antivirals and Antiretrovirals. 2012;4(4):75-9.[PMID: 2013018318,doi:
<http://dx.doi.org/10.4172/jaa.1000049>]

522. Halawani M. Hepatitis C virus genotypes among patients with lichen planus in the Kingdom of Saudi Arabia. *Int J Dermatol.* 2014;53(2):171-7.[PMID: 23675675,doi: 10.1111/j.1365-4632.2012.05685.x]

523. Eisa ZM, Gamil M, Basudan R, Eifan SA, Al-Sum BA. Prevalence of Hepatitis C genotypes in Jazan region, Saudi Arabia *India: Journal of Pure and Applied Microbiology*; 2013 [4:[3231-3]. Available from: <http://0-ovidsp.ovid.com.elibrary.qatar-weill.cornell.edu/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=2014171377>.

524. Al-Mandeel HM, Alansary M, Algawahmed F, Al-Mojally H, Alfaleh KM, Aldakhil LO. Seroprevalence of hepatitis B and C, and human immunodeficiency viruses in Saudi pregnant women and rates of vertical transmission. *KUWAIT MEDICAL JOURNAL.* 2015;47(3):221-4.[PMID,doi:

525. Fakunle YM, Al-Mofarreh M, Al-Ghreimil MS, Idrees YB, El-Drees AZ, Al-Karamany W, et al. Prevalence of antibodies to hepatitis C virus in Saudi and expatriate women in Riyadh, Saudi Arabia. *Annals of Saudi Medicine.* 1991;11(5):494-6.[PMID: 1991287152,doi:

526. Al-Mugeiren M, Al-Faleh FZ, Ramia S, Al-Rasheed S, Mahmoud MA, Al-Nasser M. Seropositivity to hepatitis C virus (HCV) in Saudi children with chronic renal failure maintained on haemodialysis. *Annals of tropical paediatrics.* 1992;12(2):217-9.[PMID: 1992192877,doi:

527. Al-Fawaz I, Ramia S. Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major. *Archives of Disease in Childhood.* 1993;69(5):594-6.[PMID: 1993355872,doi:

528. Al-Faleh FZ, Ramia S, Arif M, Ayoola EA, Al-Rashed RS, Al-Jeffry M, et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the

Gizan area of Saudi Arabia: A community-based study. *Annals of tropical medicine and parasitology*. 1995;89(4):431-7.[PMID: 1995286775,doi:

529. Bakir TMF, Kurbaan KM, Al Fawaz I, Ramia S. Infection with hepatitis viruses (B and C) and human retroviruses (HTLV-1 and HIV) in Saudi children receiving cycled cancer chemotherapy. *Journal of tropical pediatrics*. 1995;41(4):206-9.[PMID: 1995262722,doi:

530. al-Fawaz I, al-Rasheed S, al-Mugeiren M, al-Salloum A, al-Sohaibani M, Ramia S. Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassemia major: possible transmission by blood transfusion. *Journal of Viral Hepatitis*. 1996;3(4):203-5.[PMID: 8871882,doi:

531. Al-Mugeiren M, Al-Rasheed S, Al-Salloum A, El-Zouki A, Al-Sohaibani M, Al-Fawaz I, et al. Hepatitis C virus infection in two groups of paediatric patients: One maintained on haemodialysis and the other on continuous ambulatory peritoneal dialysis. *Annals of tropical paediatrics*. 1996;16(4):335-9.[PMID: 1996377585,doi:

532. Harakati MS, Abualkhair OA, Al-Knawy BA. Hepatitis C Virus infection in Saudi Arab patients with B-cell non-Hodgkin's lymphoma. *Saudi medical journal*. 2000;21(8):755-8.[PMID: 11423889,doi:

533. Shobokshi OA, Serebour FE, Al-Drees AZ, Mitwalli AH, Qahtani A, Skakni LI. Hepatitis C virus seroprevalence rate among Saudis. *Saudi medical journal*. 2003;24(SUPPL. 2):S81-S6.[PMID: 2003384776,doi:

534. Alzahrani AJ, Obeid OE, Al-Ali A, Imamwardi B. Detection of Hepatitis C virus and human immunodeficiency virus in expatriates in Saudi Arabia by antigen-antibody combination assays. *Journal of infection in developing countries*. 2009;3(3):235-8.[PMID: 2009318536,doi:

535. Alqahtani JM, Abu-Eshy SA, Mahfouz AA, El-Mekki AA, Asaad AM. Seroprevalence of hepatitis B and C virus infections among health students and health care workers in the Najran region, southwestern Saudi Arabia: the need for national guidelines for health students. *BMC public health*. 2014;14:577.[PMID: 24912684,doi: 10.1186/1471-2458-14-577]

536. Bile K, Mohamud O, Aden C, Isse A, Norder H, Nilsson L, et al. The risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions. *The American journal of tropical medicine and hygiene*. 1992;47(3):357-64.[PMID: 1524149,doi:
537. Aceti A, Taliani G, Bruni R, Sharif OS, Moallin KA, Celestino D, et al. Hepatitis C virus infection in chronic liver disease in Somalia. *The American journal of tropical medicine and hygiene*. 1993;48(4):581-4.[PMID: 7683179,doi:
538. Bile K, Aden C, Norder H, Magnus L, Lindberg G, Nilsson L. Important role of hepatitis C virus infection as a cause of chronic liver disease in Somalia. *Scandinavian journal of infectious diseases*. 1993;25(5):559-64.[PMID: 7506842,doi:
539. Watts DM, Corwin AL, Omar MA, Hyams KC. Low risk of sexual transmission of hepatitis C virus in Somalia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994;88(1):55-6.[PMID: 8154002,doi:
540. McCarthy MC, el-Tigani A, Khalid IO, Hyams KC. Hepatitis B and C in Juba, southern Sudan: results of a serosurvey. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994;88(5):534-6.[PMID: 7992329,doi:
541. Omer RE, Van't Veer P, Kadaru AM, Kampman E, el Khidir IM, Fedail SS, et al. The role of hepatitis B and hepatitis C viral infections in the incidence of hepatocellular carcinoma in Sudan. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2001;95(5):487-91.[PMID: 11706655,doi:
542. Mudawi HM, Smith HM, Rahoud SA, Fletcher IA, Babikir AM, Saeed OK, et al. Epidemiology of HCV infection in Gezira state of central Sudan. *Journal of medical virology*. 2007;79(4):383-5.[PMID: 17311341,doi: 10.1002/jmv.20780]
543. Elsheikh RM, Daak AA, Elsheikh MA, Karsany MS, Adam I. Hepatitis B virus and hepatitis C virus in pregnant Sudanese women. *Virology journal*. 2007;4:104.[PMID: 17958904,doi: 10.1186/1743-422x-4-104]
544. Osman AMM, Minrghani OA, Gasim GI, Adam I. Hepatitis B Virus, Hepatitis C Virus and Human Immunodeficiency Virus Infection among Pregnant Women in Central Sudan. *Sudanese Journal of Medical Sciences*. 2014;9(2):91-5.[PMID,doi:

545. Mohamedani A. Prevalence of Hepatitis C Virus Antibodies in Patients with Schistosomiasis in Gezira State in Central Sudan. *Endemic and Emerging Viral Diseases of Priority in the Middle East and North Africa (MENA) - A Scientific Workshop to Promote Research Collaboration*; May 2014; Doha, Qatar 2014. p. 86.
546. Karim M, Laham H. Prevalence of viral hepatitis B and C in Syria. *Syrian Epidemiological Bulletin*. 2008;3:10-1.[PMID,doi:
547. Bashour H, Muhjazi G. Hepatitis B and C in the Syrian Arab Republic: a review. *EMHJ-Eastern Mediterranean Health Journal*. 2016;22(4):267-73.[PMID,doi:
548. Angeletti S, Ceccarelli G, Vita S, Dicuonzo G, Lopalco M, Dedej E, et al. Unusual microorganisms and antimicrobial resistances in a group of Syrian migrants: Sentinel surveillance data from an asylum seekers centre in Italy. *Travel medicine and infectious disease*. 2016;14(2):115-22.[PMID,doi:
549. Coursaget P, Bourdil C, Kastally R, Yvonnet B, Rampanarivo Z, Chiron JP, et al. Prevalence of hepatitis C virus infection in Africa: anti-HCV antibodies in the general population and in patients suffering from cirrhosis or primary liver cancer. *Research in virology*. 1990;141(4):449-54.[PMID: 1964239,doi:
550. Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1997;91(1):11-4.[PMID: 9093616,doi:
551. Gorgi Y, Yalaoui S, Ben Nejma HL, Azzouz MM, Hsairi M, Ben Khelifa H, et al. [Detection of hepatitis C virus in the general population of Tunisia]. *Bulletin de la Societe de pathologie exotique (1990)*. 1998;91(2):177.[PMID: 9642480,doi:
552. Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K. Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. *Journal of medical virology*. 2005;76(2):185-93.[PMID: 15834884,doi: 10.1002/jmv.20342]
553. Bizid S, Ben Sassi S, Ben Abdallah H, Doghri A, Tounsi C, Bouali R, et al. Screening of viral hepatitis c in a young tunisian population (more than 175,000 recruits). [French]. *Tunisie Medicale*. 2015;93(12):732-45.[PMID,doi:

554. Kaabia N, Ben Jazia E, Slim I, Fodha I, Hachfi W, Gaha R, et al. Association of hepatitis C virus infection and diabetes in central Tunisia. *World journal of gastroenterology : WJG*. 2009;15(22):2778-81.[PMID: 19522029,doi:
555. Ben Alaya Bouafif N, Triki H, Mejri S, Bahri O, Chlif S, Bettaib J, et al. A case control study to assess risk factors for hepatitis C among a general population in a highly endemic area of northwest Tunisia. *Archives de l'Institut Pasteur de Tunis*. 2007;84(1-4):21-7.[PMID: 19388580,doi:
556. Hannachi N, Hidar S, Harrabi I, Mhalla S, Marzouk M, Ghzel H, et al. [Seroprevalence and risk factors of hepatitis E among pregnant women in central Tunisia]. *Pathologie-biologie*. 2011;59(5):e115-8.[PMID: 19896306,doi: 10.1016/j.patbio.2009.06.004]
557. Langar H, Triki H, Gouider E, Bahri O, Djebbi A, Sadraoui A, et al. [Blood-transmitted viral infections among haemophiliacs in Tunisia]. *Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine*. 2005;12(4):301-5.[PMID: 16099190,doi: 10.1016/j.tracli.2005.07.001]
558. Samoud S, Hannachi N, Boukadida J. High detection of hepatitis c infection RNA in psoriatic sera. 2011.[PMID,doi:
559. Bettaieb J, Chouikha A, Kharroubi G, Khedhiri M, Aissi W, Hajhmida NB, et al., editors. Seroprevalence of Hepatitis C Virus infection among general population in Central-Ouest Tunisia. *TROPICAL MEDICINE & INTERNATIONAL HEALTH*; 2017: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
560. Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. *World J Hepatol*. 2011;3(1):24-30.[PMID: 21307984,doi: 10.4254/wjh.v3.i1.24]
561. Kumar RM. Interspousal and intrafamilial transmission of hepatitis C virus: a myth or a concern? *Obstetrics and gynecology*. 1998;91(3):426-31.[PMID: 9491872,doi:
562. Newson-Smith MS. Importing health conditions of expatriate workers into the United Arab Emirates. *Asia-Pacific journal of public health / Asia-Pacific Academic*

- Consortium for Public Health. 2010;22(3 Suppl):25s-30s.[PMID: 20566530,doi: 10.1177/1010539510373021]
563. Fakhry SM, Al Dawilah TA, Mehta SH. Prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in young adults in United Arab Emirates (UAE). *Hepatology*. 2011;54:607A.[PMID: 70592322,doi: <http://dx.doi.org/10.1002/hep.24666>]
564. Sheek-Hussein M, Hashmey R, Alsuwaidi AR, Al Maskari F, Amiri L, Souid AK. Seroprevalence of measles, mumps, rubella, varicella-zoster and hepatitis A-C in Emirati medical students. *BMC public health*. 2012;12:1047.[PMID: 23217121,doi: 10.1186/1471-2458-12-1047]
565. Denis F, Aussel L, Ranger S, Martin P, Itoua-N'Gaporo A, Frommel D, et al. Prevalence of antibodies to hepatitis C virus among patients with leprosy in several African countries and the Yemen. *Journal of medical virology*. 1994;43(1):1-4.[PMID: 7521898,doi:]
566. Gray GC, Kassira EN, Rodier GR, Myers MC, Calamaio CA, Gregory M, et al. Remote village survey for agents causing hepatosplenic disease in the Republic of Yemen. *Tropical doctor*. 1999;29(4):212-9.[PMID: 10578634,doi:]
567. Salem AK. Prevalence of HCV among Yemeni patients with non-Hodgkin's lymphoma at Al-Thawra teaching hospital. *The Gulf journal of oncology*. 2009(5):22-9.[PMID: 20084782,doi:]
568. Khalil E, Nabehi B, Shamahy H, Saeed W, Musa A, Hassan A. Sero-molecular epidemiology and risk factors of viral hepatitis in urban Yemen. *Int J Virol*. 2015;11(3):133-8.[PMID,doi:]
569. Gacche RN, Kaid AM. Epidemiology of viral hepatitis B and C infections in ibb city, yemen. *Hepatitis monthly*. 2012;12(7):460-2.[PMID: 23008727,doi: 10.5812/hepatmon.6140]
570. Murad EA, Babiker SM, Gasim GI, Rayis DA, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana'a, Yemen. *BMC pregnancy and childbirth*. 2013;13:127.[PMID: 23758990,doi: 10.1186/1471-2393-13-127]

571. Al-Moslih MI, Al-Huraibi MA. Prevalence of hepatitis C virus among patients with liver disease in the Republic of Yemen. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2001;7(4-5):771-8.[PMID: 15332778,doi:
572. Karim F, Nasar A, Alam I, Hassan S, Gul R, Ullah S, et al. Incidence of Active HCV infection amongst Blood Donors of Mardan District, Pakistan. *Asian Pacific journal of cancer prevention : APJCP*. 2016;17(1):235-8.[PMID: 614862348,doi: